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CHAPTER 1 
 
INTRODUCTION 
 
Cell Fate Decisions 
 
Role of cellular fate determination in development and function 
 
All cells of the body, comprising several organs and tissues, arise from a single fertilized zygote. 
The process by which a single, pluripotent cell yields the numerous highly specialized and 
incredibly varied cell types of the body is a complex and tightly regulated process. The process 
is, quite obviously, a very important one, for without the coordinated differentiation of our cells, 
complex multi-cellular organisms could not exist. 
 
The various differentiated cell types of the body, despite all having the same DNA, differ in their 
cell shape, gene expression, and function. Differentiated cell fates are acquired progressively 
over the course of development through a sequence of cell fate decisions that simultaneously 
restrict a cell’s lineage potential and refine a unique and specialized gene expression profile. A 
cell fate decision is the process through which a cell that has the potential to follow two or more 
distinct differentiation paths makes the decision to follow one specific path at the expense of 
other options.  
 
One of the first lineage decisions made by cells comprising an embryo proper is which germ 
layer they will become. This decision is made during gastrulation and defines three germ layers: 
the ectoderm, mesoderm, and endoderm (Loebel et al., 2003). After that decision, cells will 
proceed on through further lineage-refinement decisions. Within the endoderm, cells decide 
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whether to become, for example, liver, lung, thyroid, pancreas, or intestine. Cells that have been 
specified first as endoderm and then as liver are called hepatoblasts, and they can give rise to 
two cell types: hepatocytes and biliary epithelial cells (BECs; also known as cholangiocytes) 
(Figure 1.1). Similar lineage decisions take place in all organs and tissues, and through this 
progressive series of cell fate decisions, an organism obtains a large variety of highly distinct 
cell types comprising unique functional organs and organ systems.  
 
Influence of extrinsic and intrinsic signals in cell fate decisions 
 
Several intrinsic and extrinsic factors, including intercellular signals, intracellular signals, 
mechanical forces, and cell-extracellular matrix (ECM) interactions, contribute to the fate 
decision process of a cell by directly or indirectly influencing gene expression (Discher et al., 
2009; Guilak et al., 2009; Streuli, 2009). 
 
Extrinsic signals, including molecular signals that mediate cell-cell communication, are 
especially important and prominent in the process of cell differentiation. Extrinsic intercellular 
signals can originate from a neighboring cell within the same tissue, a different tissue within an 
organ, or even from a different organ. Cell-cell communication can promote cellular 
differentiation in processes that generate cellular boundaries in organs, ensure proper cell 
ratios, and ensure proper cell spatial relationships. The receipt of extracellular signals can 
change gene expression and can activate or suppress intracellular signaling pathways in a cell 
to change cell behaviors and drive cell fate decisions.  
 
The temporal and spatial coordination of signals is crucial during development in order to have 
proper cell differentiation in all organs of the body. Similarly, some signals are also important for 
homeostasis and function of tissues, and often times certain signaling pathways can be  
3 
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reactivated in the adult state; these signals can either contribute to a beneficial regenerative 
response to injury or can alternatively generate or promote an injury, such as cancer. 
 
Intercellular Communication in Organ Development  
 
Coordination of multiple cell types in organ development and function 
 
Organs consist of multiple cell types that often have different morphologies, functions, and 
locations, but that are all required to work together in order for an organ to function properly. In 
order to generate a properly functioning organ, proper regulation of the number and location of 
all of the involved cells during development is crucial. 
 
The functions of each organ vary, and as such, so do the ways in which cell types must interact 
during development. For all organs, the number and location of blood vessels must be regulated 
so that all cells have access to oxygen and nutrients from the blood stream. The nervous 
system integration into an organ must also be regulated so that all cells that require sensory 
input for function are in contact with a nerve. Several organs have endocrine functions requiring 
that the cells that produce hormones have immediate access to a blood stream into which to 
secrete hormones. Similarly, for organs that generate and excrete products, like the liver, 
pancreas, and kidneys, ductal systems must be established to connect the cells that produce 
and/or modulate an excretion product with the intended destination of that product. Even cells 
that do not directly interact with one another often must still have a precise spatial organization 
in relation to each other; in the eye, the spatial organization of rod and cones cells must be 
precisely regulated to ensure that the eye can detect both light and color from all areas of the 
visual field. As all organs of the body must function in coordination to support a functional 
5 
organism, so must the cells and tissues within each organ interact and work together to form a 
functional organ. 
 
Role of intercellular signaling in defining cellular and morphological organ features 
 
Intercellular signaling during development is important for coordinating organ characteristics 
such as cell type ratios and cellular boundaries within an organ and organ size. There are 
multiple types of signals, distinguished by the range of the signal. Endocrine signals are 
transported in the bloodstream and can access virtually any tissue in the body. Paracrine 
signals can diffuse within a tissue and penetrate several cell layers from the source. Juxtacrine 
signaling occurs between neighboring cells, often as the result of the signaling molecules being 
tethered to the cell membranes. Finally, autocrine signals act on the same cell in which they are 
generated. 
 
During development, paracrine signals are frequently used to set up gradients of morphogens. 
Morphogen gradients are used to differentiate multiple cell fates based on the concentration on 
the morphogen received by each cell (Dessaud et al., 2008). Morphogens can also be used to 
control directional growth of tissues; vascular and nervous tissues, for example, use pathfinding 
led by morphogen gradients to grow directionally into a tissue or towards the source of the 
signal (Eichmann et al., 2005). Juxtacrine signaling is used to set up strict boundaries within a 
tissue (Bolós et al., 2007). Juxtacrine signaling is also used for lateral inhibition during cell fate 
decisions to ensure proper cell type ratios; a cell that adopts a specific fate can signal to its 
neighbors to adopt a different fate, thereby regulating both the ratios and the spacing of different 
cell types during development (Owen et al., 2000). 
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Correct signaling between the different cells and tissues of an organ during development is 
important in order to generate a mature, functional organ. Improper signaling can lead to 
malformed or non-functional organs, and can be a causal factor in the development of cancers. 
 
Liver Architectural Establishment 
 
Early liver development 
 
The liver is specified from the anterior definitive endoderm (Tremblay and Zaret, 2005) at the 5-
6 somite stage, around embryonic day (E)8.0-8.5 in mice (Gualdi et al., 1996). By E9.0-9.5, the 
specified hepatic progenitor cells, called hepatoblasts, activate the expression of liver specific 
genes, such as albumin and !-fetoprotein. The cells begin to proliferate and evaginate into a 
liver bud (Figure 1.2). After the breakdown of extracellular matrix ECM around this bud, the 
hepatoblasts migrate into the septum transversum mesenchyme (STM) that is adjacent to the 
hepatic bud. The continued proliferation and further differentiation of these cells gives rise to the 
adult liver. 
 
Liver architecture and function within the organism 
 
The liver plays crucial functions in nutrient regulation, and its anatomy in relationship to the 
vascular and digestive systems reflect these functions. In one of its roles, the liver produces and 
secretes bile salts into the intestine. The bile produced serves in the predigestive emulsification 
of ingested fats. For this function, the liver maintains a direct connection with both the intestine 
and the gall bladder, which stores bile. The liver also has several metabolic roles and regulates 
the storage and circulation of both lipids and carbohydrates. The location of the liver within the 
vascular system aids in these tasks; the majority of the blood flow into the liver enters via the  
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portal vein (PV), a venous system that collects blood from the other gastrointestinal organs and 
carries it to the liver. As nutrients are absorbed from the digestive organs into the blood stream, 
they are taken directly to the liver for efficient processing and regulation. This vascular anatomy 
is also important for the detoxification functions of the liver. Drugs and pathogens that are orally 
ingested enter the body through the gastrointestinal tract. As they pass through the PV system, 
these agents are metabolized within the liver prior to reaching other tissues. For these 
highlighted functions of the liver, a specific architectural relationship of the liver to the 
gastrointestinal and vascular systems is crucial. 
 
Importance of liver three-dimensional architecture for function 
 
The architecture of the cells and tissues within the liver is also crucial for the liver to perform its 
various functions. The liver includes several tissues that have a specific 3-dimensional 
architecture, including the PV, central vein (CV), and hepatic artery (HA) vascular tissues, the 
intrahepatic bile duct (IHBD), the hepatic nerves, and the hepatocytes. 
 
Proper liver function requires a precise spatial arrangement of the aforementioned tissues. The 
importance of the spatial associations of liver tissues is apparent in the structure and function of 
the hepatic lobule (Figure 1.3). Lobules are proposed to be the smallest functional unit of the 
liver. The architecture of the lobule is defined by the spatial arrangement of several liver tissues, 
including the PV, HA, IHBD, and the CV. Lobules, in two dimensions, have a hexagonal shape 
with a portal vein at each vertex and a CV branch in the middle. The HA and IHBD branches 
also appear at the vertices in close association with PV branches in structures known as portal 
triads. Hepatocytes arranged in cords fill in the space between the PV and the CV (blue shaded 
regions in Figure 1.3). Along the basal sides of the hepatocytes run the sinusoids, specialized 
capillary structures that connect the PV and HA to the CV and supply blood to all hepatocytes. 
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Along the apical sides of the hepatocytes are canaliculi, small structures that transport bile 
produced by hepatocytes into the IHBDs (Figure 1.4). 
 
The spatial organization of the vascular and epithelial tissues within the lobule is required for 
proper liver function. While the precise organization of the PV, HA, and CV are required to 
generate proper blood flow within the liver, the organization of hepatocytes and IHBDs are also 
crucial for the drainage of bile, and the precise layout of all of these structures are required to 
generate the hepatic lobule units. Apart from their relationship in the lobule, each of these 
epithelial and vascular tissues also has its own architecture and spatial organization. 
 
Hepatic vascular development and architecture 
 
The PV and HA both supply blood to the liver and their architecture is important for proper liver 
function. The PV collects nutrient-rich effluent blood from the other peritoneal organs and brings 
it to the liver, where hepatocytes filter the blood and regulate the nutrients in circulation as 
previously described. In humans, the portal vein supplies approximately 75% of the afferent 
hepatic blood flow. The other 25% of hepatic blood flow is supplied by the HA (Lautt, 2009; 
Tygstrup et al., 1962). The PV and HA both empty into the hepatic sinusoids, which line 
hepatocyte cords, forming a specialized capillary network (Figure 1.4). The CV collects the 
blood that has passed through the sinusoids and returns it to the inferior vena cava. 
 
The PV and CV have a unique mechanism of development as extrapolated from the analysis of 
human fetuses (Collardeau-Frachon and Scoazec, 2008; Gouysse et al., 2002; Lassau and 
Bastian, 1983) and mouse embryos (T.J.W. and S.S.H, unpublished)(Crawford et al., 2010). 
Both vessels derive from the fetal vitelline and umbilical veins. At the time of liver bud 
delamination and expansion, the hepatoblasts surround and disrupt the vitelline and umbilical 
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veins. The veins remodel into a modified fetal circulatory network. The pre-hepatic and post-
hepatic portions of the veins remain intact and give rise to the bases of the PV and CV (Figure 
1.5) (Collardeau-Frachon and Scoazec, 2008; Gouysse et al., 2002). The origin of the HA is not 
completely understood, but it appears after birth, after the formation of the PV and CV, and is 
understood to develop as an angiogenic sprout originating from the dorsal aorta (Collardeau-
Frachon and Scoazec, 2008; Gouysse et al., 2002). 
 
The PV, CV, and HA all display hierarchical branching architectures, with progressively smaller 
branches that extend throughout the hepatic parenchyma. The architecture of the HA follows 
that of the PV, indicative of functional relationship between the two structures, as both supply 
blood to the hepatic sinusoids. (Please see Figure 1.6 for a representative image of the 3-
dimensional structure of the left lobe PV and Appendix D for further information on the 3-
dimensional relationship between the PV and IHBD).  
 
There is also a presumed developmental relationship between the HA and the IHBD. HAs form 
after birth and after the remodeling and maturation of the IHBDs (Collardeau-Frachon and 
Scoazec, 2008; Gouysse et al., 2002). Anatomically, HAs follow the architectural pattern of the 
IHBDs, being spatially associated with IHBDs through their structure. It is proposed that signals 
derived from the IHBD direct the development of the HA. This is supported by a failure to 
generate mature HAs in a genetic mouse model where IHBD morphogenesis is genetically 
impaired (Fabris et al., 2008). 
 
The sinusoids, lined by liver sinusoidal endothelial cells (LSECs), traverse the lobule, bridging 
the PV and the CV. The origin of LSECs in the liver is not known, but they are presumed to 
arise from endothelial cells (ECs) resident in the septum transversum mesenchyme (STM), 
including the ECs that surround that hepatic bud at the time of evagination and delamination.  
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LSECs provide a lenient selective barrier between the sinusoidal blood and the hepatocytes, 
allowing for particles to pass through them to the hepatocytes. The scavenging functions of 
LSECs, allowing them to take up particles from the blood and transmit them to hepatocytes, are 
aided by several key features, including: 1. the presence of multiple fenestrae, arranged into 
sieve plates, on the LSECs; 2. The absence of a basal lamina; 3. The discontinuous 
organization of LSECs and corresponding absence of cell-junction proteins (Aird, 2007; Wisse 
et al., 1985). The maintenance of these LSEC characteristics has been shown to require VEGF 
signaling (DeLeve et al., 2004). In experiments with cultured primary LSECs, the loss of 
fenestrae and upregulation of the platelet-derived endothelial cell adhesion molecule (PECAM) 
expression occur within days after isolation unless the cells are either treated with exogenous 
VEGF or co-cultured with a VEGF-producing cell type, including either hepatocytes or stellate 
cells (DeLeve et al., 2004). Due to the close spatial relationship between LSECs and 
hepatocytes, it is likely that the hepatocytes are a source of VEGF that maintains LSEC identity 
in vivo. 
 
One interesting feature of the hepatic lobule, generated by the arrangement of the blood 
vessels, is the gradient of oxygen across the lobule. The blood oxygen tension in the sinusoid 
ranges from approximately 65 mm Hg in the periportal zone to approximately 30-35 mm Hg in 
the pericentral zone in rats and humans (Figure 1.7) (Jungermann and Keitzmann, 1996; Lautt, 
2009). The oxygen gradient within the sinusoid also generates a gradient in intracellular oxygen 
tension in hepatocytes. The hepatocyte oxygen tensions are considered to range from 45-50 
mm Hg in the periportal hepatocytes to 15-20 mm Hg in the pericentral hepatocytes 
(Jungermann and Kietzmann, 2000).  
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IHBD development and architecture 
 
The IHBD also has a hierarchical branching architecture that follows the branching pattern of 
the PV. This architectural relationship results from a developmental connection. The IHBD 
develops through a process called ductal plate morphogenesis. During mid-gestational liver 
development, the liver is comprised of bipotential hepatic progenitor cells, called hepatoblasts, 
which give rise to both hepatocytes and BECs. In the first step of IHBD morphogenesis, a single 
cell layer of hepatoblasts adjacent to the portal vein mesenchyme activate expression of BEC 
marker genes such as Sry-related HMG box 9 (Sox9) and wide spectrum cytokeratins (wsCK). 
After this, a second cell layer of hepatoblasts activates Sox9 and wsCK expression in the areas 
where IHBDs will form. The specified BECs then undergo a remodeling event during which the 
double cell layers become polarized and generate a lumen; the ductal plate cells that do not 
become incorporated into IHBDs regress, turning off the BEC markers, and become periportal 
hepatocytes (Figure 1.8) (Antoniou et al., 2009; Carpentier et al., 2011; Si-Tayeb et al., 2010). 
Due to this developmental connection, the architecture of the IHBD follows the pattern of the 
PV. 
 
The smallest branches of the IHBD, called canaliculi, collect bile as is it secreted from 
hepatocytes and transport it into the peripheral branches of the IHBDs. The small peripheral 
IHBD branches merge into fewer, larger branches, until finally one single branch carries the bile 
out of the liver and transports it into the gallbladder for storage and ultimately into the intestine 
to aid in digestion. The IHBD relies on its highly regulated 3-dimensional structure to access all 
of the hepatocytes and effectively clear bile out of the liver. The process of IHBD architectural 
formation is a highly complex and regulated one, process of IHBD maturation and ductal plate  
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regression has to occur in a coordinated fashion along the 3-dimensional PV network to form a 
IHBD network that connects with the canaliculi supporting every hepatocyte within the liver.  
 
Hepatocyte zonal organization 
 
Approximately 15-25 hepatocytes span the distance between the portal and central veins in the 
rat liver, forming a series of hepatocyte plates that radiate between the central vein and the 
portal vein vertices (Colnot and Perret, 2011). Within the lobule, there is spatial organization of 
hepatocytes that is important for function. The hepatocytes collectively perform a wide variety of 
tasks, including gluconeogenesis, urea genesis, "-oxidation, and liponeogenesis (Bhatia et al., 
1996). These functions are segregated between different subpopulations of hepatocytes that 
are organized into three spatial zones within the lobule: zone 1 is the periportal zone, zone 2 is 
the intermediate zone, and zone 3 is the pericentral zone (Figure 1.9).  
 
Hepatocytes exhibit zonal heterogeneity in several ways, including gene expression and 
metabolic function, cell size, and oxygen pressure. Zone 1 hepatocytes specialize in 
gluconeogenesis and urea formation, while zone 3 hepatocytes specialize in liponeogenesis, 
glutamine synthesis, and glycolysis (Colnot and Perret, 2011). Accordingly, the expression of 
metabolic genes varies between the zones. For example, in rats and mice, one enzyme 
involved in urea synthesis, glutamine synthetase, is only expressed in the 1-2 cell layers of 
hepatocytes that immediately juxtapose the central veins. Cell morphologies also change 
zonally in the rat liver; periportal hepatocytes are smaller, approximately 7-15 µm in diameter, 
than pericentral hepatocytes, measuring approximately 30-40 µm (Bhatia et al., 1996). 
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Signaling in Hepatic Development and Cell Fate Decisions 
 
Signaling pathways that drive hepatic specification and early development 
 
At the first stage of hepatic specification, a combination of Fgf1 and Fgf2 signaling from the 
cardiac mesoderm and Bmp4 signaling from the STM, starting at E8.0-8.5, are crucial for the 
activation of liver specific gene expression in the pre-hepatic endoderm. (Gualdi et al., 1996; 
Jung et al., 1999; Rossi et al., 2001). After specification, the hepatic endoderm begins to 
express several important transcription factors, including Hepatocyte nuclear factor (Hnf)1! and 
", Hnf4!, Hnf6, Forkhead homeobox (Fox)a1, Foxa2, Foxa3, Hex, Prox1, Gata4, and Gata6 
(Kaestner, 2005). The Foxa gene group is redundantly required for liver specification; knocking 
out Foxa1 and Foxa2 together in the endoderm results in the inability to specify the liver 
primordium (Lee et al., 2005). Mutations in the transcription factors Hex, Hnf4!, Hnf1", Hnf6, 
Prox1, Gata4, and Gata6 result in liver developmental abnormalities that occur after liver 
specification (Bort et al., 2006; Clotman et al., 2002; Coffinier et al., 2002; Kaestner, 2005; 
Parviz et al., 2003; Sosa-Pineda et al., 2000; Watt et al., 2007; Zhao et al., 2005). The 
abnormalities occur at different stages in hepatic development. Alterations in Gata6 or Hex 
result in abnormalities early in liver bud specification; Gata6 mutants fail to express the liver 
gene Albumin and Hex mutant liver buds fail to transition from a columnar epithelium to a 
pseudostratified epithelium. Gata4 and Prox1 mutants have abnormalities slightly later in 
development, as they activate expression of liver bud genes and transition to a pseudostratified 
epithelium, but do not invade the STM. Mutations in Hnf4!, Hnf1", and Hnf6 occur later in liver 
development and affect liver cell maturation and architecture. Hnf4! mutants display problems 
in hepatocyte maturation and epithelium formation, while Hnf6 and Hnf1" mutants fail to 
organize IHBD structures.  Together, these genetic manipulations reveal several crucial steps in 
hepatogenesis where precise signaling and gene expression is required for development. 
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Signaling pathways driving IHBD morphogenesis 
 
The primary pathway that has been implicated in IHBD morphogenesis is Notch signaling. 
Notch is a conserved signaling pathway that plays a role in cell fate decisions in several organs 
and timepoints during development. Notch signaling has known roles in stem cell maintenance, 
cell fate decisions, proliferation, and tissue patterning (Andersson et al., 2011). In mammals, 
there are five canonical Notch ligands across two families (Delta1, 3, and 4, and Jagged1 and 2) 
and four Notch receptors (Notch1, 2, 3, and 4). Notch ligands and receptors are both membrane 
bound and participate in juxtacrine signaling between adjacent cells. Upon binding between a 
Notch ligand and receptor, a conformational change in Notch allows a proteolytic cleavage by #-
secretase, releasing the Notch intracellular domain (NICD) from the cell membrane. NICD 
translocates to the nucleus, where it interacts with the DNA-binding co-factor Rbpj (also known 
as CSL) and initiates the transcription of Notch-responsive genes (Andersson et al., 2011). Rbpj 
is required for canonical Notch signaling via all four Notch receptors.  
 
Ductal plate morphogenesis begins at E13.5, at which time the mesenchymal cells surrounding 
the PV express the Notch ligand Jagged1. Jagged1 interacts with the fundamental Notch2 
receptor expressed on bipotential hepatoblasts surrounding the portal vein to activate Notch 
signaling (Hofmann et al., 2010). Notch signaling is required for remodeling of the specified 
BECs into mature, lumenal IHBDs and the expression of a constitutively activated form of 
Notch2 or Notch1 is sufficient to promote BEC differentiation (Geisler et al., 2008; Hofmann et 
al., 2010; Jeliazkova et al., 2013; Lozier et al., 2008a; McCright et al., 2002; Sparks et al., 2010; 
Tanimizu and Miyajima, 2004). Ductal plates are first observed in the proximal hilar regions of 
the liver and appear in the more distal regions progressively following the PV during embryonic 
and early postnatal development. 
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In addition to Notch signaling, the transcription factors Sox9, Hnf1", and Hnf6 are important for 
biliary morphogenesis; without each of these genes, delays or disruptions in biliary development 
are observed in mice (Antoniou et al., 2009; Clotman et al., 2002; Coffinier et al., 2002). It is 
likely that Notch acts upstream of Sox9 during biliary morphogenesis, as Sox9 is a known target 
of Notch signaling in several organs (Chen et al., 2012; Haller et al., 2012; Muto et al., 2009). 
Sox9 has also been found to be regulated by HIF signaling; however, this association not been 
examined in the liver (Zhang et al., 2011). Additionally, Hnf6 and Hnf1" are known to function in 
the same pathway, as Hnf6 can regulate the expression of Hnf1" (Clotman et al., 2002). 
 
Signaling pathways controlling vascular morphogenesis 
 
The main pathway implicated in regulating vascular morphogenesis is vascular endothelial 
growth factor (VEGF) signaling. VEGF is a crucial signaling pathway governing vascular 
development and behavior throughout the body. In mammals, there is one principal VEGF 
ligand and two principal receptors, VEGF receptor 1 (VEGFR1, also known as Flt1) and 
VEGFR2 (also known as KDR and Flk1) (Ferrara and Davis-Smyth, 1997). Related molecules 
include the ligands VEGF-B, VEGF-C, and placental growth factor and the receptor VEGFR3 
(also known as Flt4) (Ferrara and Davis-Smyth, 1997). The VEGF signaling pathway is 
essential during development, as mice with a homozygous gene deletion for either VEGFR1 or 
VEGFR2, as well as mice with either a homozygous or heterozygous deletion for VEGF, are 
embryonic lethal due to impaired or altered vascular development and failed blood-island 
formation (Carmeliet et al., 1996; Ferrara et al., 1996; Fong et al., 1995; Shalaby et al., 1995).  
 
VEGF has several known functions in vascular development and homeostasis, including in 
angiogenic directional growth and branching behavior, vascular permeability, endothelial 
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fenestration, endothelial proliferation, and endothelial cell survival (Carpenter et al., 2005; 
Connolly et al., 1989; Gerber et al., 2002; Gerhardt et al., 2003; Krueger et al., 2011; Lee et al., 
2007; Leung et al., 2013). 
 
Angiogenesis is the process of vascular development by which new vessels are generated and 
grow by sprouting off of an existing vessel and extending directionally. The directionality of the 
angiogenic growth is directed by the graded concentration of VEGF protein. During 
angiogenesis ECs in the growing vessel can take on one of two identities: tip or stalk (Phng and 
Gerhardt, 2009). Tip cells are located at the tips of growing blood vessels and display filopodial 
extensions. Tip cells are responsible for pathfinding and directionality. Stalk cells are all cells of 
the new vessel that trail behind the tip cell. These cells form a luminal structure and perform the 
proliferation required for vessel extension and growth.  
 
Tip and stalk cells engage in lateral inhibition through VEGF and Notch signaling. Both tip and 
stalk cells express VEGFR2. Upon exposure to VEGF protein, VEGFR2 is activated, leading to 
the upreguation of the Notch ligand Delta-like4 (Dll4) and, in a positive feedback loop, VEGFR2 
(Phng and Gerhardt, 2009). Dll4 interacts with and activates Notch receptors expressed on 
surrounding cells. The activation of Notch inhibits the expression of VEGFR2 and upregulates 
VEGFR1, making the Notch-activated cell less sensitive to VEGF protein (Figure 1.10) (Phng 
and Gerhardt, 2009). Through these feedback loops, one cell adopts the tip cell identity while 
the surrounding cells are designated as stalk cells. The functions of Notch and VEGF in the 
tip/stalk designation have recently been defined in detail in several papers, mainly using the 
cultured mouse retina as a model system (Benedito et al., 2009; Gerhardt et al., 2003; Hellström 
et al., 2007; Lobov et al., 2007; Suchting et al., 2007; Trindade et al., 2008). 
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VEGF expression and consequent angiogenesis is often promoted by hypoxia. Under hypoxic 
conditions, cells stabilize the hypoxia inducible factor1! (HIF1!) protein, and the HIF1!/" 
heterodimer binds enhancer sequences of the Vegf gene, stimulating the production of VEGF 
protein (Hoeben et al., 2004). Secretion of VEGF protein from a region of hypoxic tissue directs 
angiogenesis towards that area, ultimately increasing blood flow to alleviate the hypoxic 
condition. 
 
There is relatively little known about the signaling pathways that regulate the development of 
vasculature in the liver. A limited number of studies have confirmed that VEGF and Notch 
signaling do influence liver vasculature (Carlson et al., 2005; Carpenter et al., 2005; Gerber et 
al., 2002). However, these studies to date have been unable, due to their experimental systems, 
to address the question of whether the different vascular tissues in the liver form through 
angiogenesis and whether Notch and VEGF are involved in liver vascular development in the 
same way as they are in other organs. 
 
Several studies have analyzed the role of VEGF signaling in the maintenance of LSECs. These 
studies have consistently found that LSECs require VEGF signaling in order to maintain several 
unique LSEC features, including fenestration, scavenger function, lack of platelet cell-derived 
endothelial cell adhesion molecule (PECAM) expression, and lack of an organized basement 
membrane (DeLeve et al., 2004). The majority of these studies were performed on cultured 
primary LSECs. Primary LSECs lose their identity and unique features within a few days in 
culture unless they are either treated with exogenous VEGF or co-cultured with another liver cell 
type, including either hepatocytes or stellate cells, that produces VEGF (DeLeve et al., 2004). 
Another known role of VEGF in the liver is to regulate the expression of erythropoietin in 
hepatocytes (Tam et al., 2006). 
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Signals controlling lobular hepatocyte zonation 
 
Within the liver, the main factor implicated in the establishment and maintenance of hepatocyte 
zonation is Wnt/"-catenin signaling. "-catenin stabilization is both necessary and sufficient for 
expression of the pericentral enzyme glutamine synthetase (GS) in vivo in the mouse liver 
(Colnot and Perret, 2011). In a normal liver, stabilized "-catenin is observed only in the 
pericentral hepatocytes. In a liver-specific "-catenin knockout mouse model, the expression of 
GS is completely absent from the liver. Contrastingly, the liver-specific knockout of Apc, a 
negative regulator of "-catenin stabilization, activates the expression of GS in all hepatocytes in 
the liver (Benhamouche et al., 2006; Colnot and Perret, 2011). "-catenin expression in 
pericentral hepatocytes is dependent on Wnt signaling (Benhamouche et al., 2006). The 
expression of Wnt liagands has been found in several liver cell types, including: hepatocytes, 
BECs, LSECs, stellate cells (pericytes in the liver sinusoids), and Kupffer cells (resident 
macrophages in the liver) (Zeng et al., 2007). At this time, it remains unknown which Wnt 
proteins, secreted from which cells in the liver, are responsible for establishing and maintaining 
hepatocyte zonation. It has been hypothesized, although without any concrete evidence, that 
Wnt signaling in the pericentral zone is directed by LSECs (Colnot and Perret, 2011).  
 
Another key molecule mediating hepatic zonation is Hnf4!. Hnf4! opposes Wnt signaling to 
promote the expression of periportal hepatocyte genes and inhibit the expression of pericentral 
hepatocyte genes (Colletti et al., 2009). In the liver deficient for Hnf4!, the expression of 
pericentral hepatocyte genes, including GS, is expanded into the periportal zone (Stanulovi$ et 
al., 2007). There is evidence that Hnf4! and "-catenin, along with its DNA-binding co-factors 
Tcf/Lef, directly compete for binding on the same consensus motifs on the enhancer regions of 
zonal hepatocyte genes (Colletti et al., 2009; Colnot and Perret, 2011). 
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Finally, the last recognized factor in regulating hepatic zonation is oxygen pressure. As 
previously described, the oxygen pressure both in the sinusoids and in the hepatocytes is 
graded along the axis of the hepatic lobule between the PV and the CV. There is evidence that 
hepatocytes are able to sense oxygen tension through a non-respiratory chain ferro-heme 
protein, which reveals a potential pathway for oxygen to regulate hepatocyte zonal gene 
expression (Kietzmann et al., 1992; Kietzmann et al., 1993). In cultured primary rat hepatocytes, 
oxygen tensions influence the gene expression of some zonal genes, including the periportal 
gene phosphoenolpyruvate carboxykinase (PEPCK, involved in gluconeogenesis) and the 
pericentral gene glucokinase (GK, involved in glycolysis) (Jungermann and Keitzmann, 1996; 
WÖLfle and Jungermann, 1985). However, it appears that only certain classes of zonal 
hepatocyte genes are sensitive to oxygen tension. Genes involved in glucose and drug 
metabolism are more readily influenced by blood flow and oxygen tension, while genes involved 
in ammonia detoxification and glutamine synthesis have a more stable and defined expression 
pattern in the face of oxygenation manipulations (Allen and Bhatia, 2003; Bhatia et al., 1996; 
Colnot and Perret, 2011; Jungermann and Kietzmann, 1997; Wagenaar et al., 1993; Wagenaar 
et al., 1994). While it appears clear that oxygen pressure can influence hepatocyte zonation, in 
in vivo mechanism through which the regulation occurs and the importance of oxygen pressure 
during developmental zone establishment and homeostasis remain unknown. 
 
Cell Plasticity in Injury 
 
Reactivation of developmental pathways in regeneration  
 
Often times, the signaling pathways and mechanisms that control embryonic cell fates and 
tissue architecture retain function during adult homeostasis and are re-activated during organ 
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regeneration. In the liver, several signaling pathways with known roles during hepatogenesis, 
including VEGF, Notch, Wnt, and Sox9, have roles during injury and regeneration as well.  
 
Very recently, Sox9 has been under investigation for its role in marking liver progenitor cells. 
This examination began in large part with a publication claiming that Sox9-expressing cells 
constitute a bipotential liver progenitor, giving rise to both hepatocytes and cholangiocytes 
under injury and regeneration conditions as well as over time during the normal homeostatic 
process (Furuyama et al., 2010). This paper was widely recognized in the liver field, where the 
identity of the “hepatic stem cell” has been an elusive object of investigation and controversy. A 
following study refuted some of the findings presented by Furuyama et al. (2010), but added 
evidence that a Sox9-expressing progenitor present during embryonic development did give rise 
to a bipotential liver progenitor cell that had potential to differentiate into both hepatoctyes and 
BECs during regeneration (Carpentier et al., 2011). 
 
Sox9 has also gained the interest of many researchers due to recent findings that Sox9 is highly 
expressed in a population of liver cells that have bipotential differentiation capability in vitro 
(Dorrell et al., 2011). The implications of Sox9 playing a role in, or at least marking cells that are 
capable of, multi-lineage differentiation is of interest because Sox9-expressing “hepatobiliary 
intermediate cells,” expressing lineage markers of both hepatocytes and BECs, have been 
found in human liver disease (Yanger et al., 2013). Also of interest, Sox9 has been implicated 
as a marker of hepatocyte-to-BEC conversion during liver injury in mice, suggesting that some 
components of the ductal plate differentiation program may be utilized for the generation of new 
BECs in injured livers of adult mice (Yanger et al., 2013). If Sox9 does denote a hepatic 
progenitor population or play a role in hepatic cell plasticity, the protein would be of high interest 
for future studies on in vivo cell-based therapies for liver disease. 
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In many organs, Sox9 is regulated downstream of Notch signaling (Chen et al., 2012; Haller et 
al., 2012; Hardingham et al., 2006; Muto et al., 2009). In the liver, Sox9 it is a direct target of 
Notch signaling in the ductal plate (Zong et al., 2009). During liver injury in adult mice, disrupting 
Notch signaling is demonstrated to reduce the expression of Sox9 in hepatocytes and to 
consequently restrict the process of hepatocyte-to-BEC conversion, confirming the link between 
Notch signaling and Sox9 in cell lineage decisions and plasticity in both the embryonic and adult 
liver (Yanger et al., 2013). 
 
Endothelial-epithelial interactions in disease and regeneration 
 
Several epithelial-endothelial interactions have been observed during injury and regeneration in 
the liver. The connection between epithelial and endothelial tissues in disease is elucidated by 
the vascular phenotypes observed in human liver diseases of malformed IHBDs. In diseases 
where the ductal plate does not remodel, resulting in IHBD abnormalities (such as autosomal 
dominant polycystic kidney disease and Caroli’s disease), BECs express abnormally high VEGF 
and the microvasculature around the IHBD is expanded and very dense (Fabris et al., 2006). In 
some patients with IHBD malformations, unremodeled ductal plates are frequently associated 
with abnormal “Pollard willow” branching patterns of the portal vein, in which the portal veins 
develop too many branches that are too small and too densely spaced (Desmet, 1992). These 
human studies provide evidence that the epithelial and endothelial tissues can affect each other 
in a disease circumstance. In addition to being altered in genetic diseases, VEGF also appears 
to mediate epithelial-endothelial interactions in situations of acute liver injury and regeneration. 
VEGF expression from both hepatocytes and non-parenchymal cells is upregulated after 
necrosis in the rat liver. In this case, it is proposed that this VEGF promotes liver regeneration 
by promoting vascular endothelial cell and LSEC proliferation (Ishikawa et al., 1999). A 
hepatocyte-endothelial signaling loop is also proposed to enhance regeneration after partial 
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hepatectomy; VEGF secreted by the hepatocytes promotes the proliferation of ECs and the 
revascularization of the growing liver tissues, while the ECs in turn produce hepatocyte growth 
factor (HGF), which stimulates hepatocyte proliferation and demonstrate the VEGF is an 
important mediator of epithelial-endothelial interactions (Bockhorn et al., 2007; Ding et al., 2010; 
Oe et al., 2004; Shimizu et al., 2005; Shimizu et al., 2001; Taniguchi et al., 2001; Yamamoto et 
al., 2010).  
 
Increases in VEGF signaling are also observed in rodent experimental models of 
acetaminophen hepatotoxicity, bile duct ligation, polycystic kidney disease, and biliary cirrhosis 
(Gaudio et al., 2006; Kato et al., 2011; Ren et al., 2011; Rosmorduc et al., 1999; Tanaka et al., 
2007). In these studies, VEGF expression was found in the hepatocytes and BECs. Together, 
these studies indicate a characteristic collaboration between epithelial and endothelial lineage 
during regeneration. 
 
Ductular reactions in liver injury 
 
A frequent manifestation of liver disease is the presence of a ductular reaction (Desmet, 2011; 
Desmet et al., 1995; Gouw et al., 2011). Ductular reactions are comprised of semi-polarized 
proliferative BECs that expand outside of the portal triad into the hepatic parenchyma. Ductular 
reactions are seen both in human liver disease and in rodent models of liver injury. The BECs 
that comprise the ductual reaction are sometimes referred to as “oval cells” due to their cell 
shape. It remains unclear if the ductular reaction is merely a byproduct of liver injury or if the 
structure serves some function, either negative or positive, during the injury and regeneration 
process.  
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Studies have demonstrated that Notch signaling plays a role in the generation of the ductular 
reaction in rats and in mice, as inhibiting Notch signaling can reduce or delay the formation of 
the ductular reaction (Darwiche et al., 2011; Fiorotto et al., 2013).  Notch2 is also sufficient to 
direct biliary differentiation in adult hepatocytes and generating ductual reactions (Jeliazkova et 
al., 2013).  
 
In addition to Notch, Wnt signaling has also been examined for its role in directing cell fate 
decisions in the regenerating adult rodent liver. Current thinking suggests that Notch and Wnt 
may have opposing roles in directing cell fate decisions during liver regeneration, with Notch 
promoting BEC specification and Wnt promoting hepatocyte fates (Boulter et al., 2012; 
Strazzabosco and Fabris, 2013). These data suggest that Notch signaling retains its ability to 
direct BEC specification in the adult liver, and that Notch is involved in the response to injury 
and generation of reactive ductules. 
 
In an interesting study, the hepatic progenitor cells (HPCs, referring to the BECs of the reactive 
ductules) in a variety of acute and chronic human liver diseases were analyzed to see whether 
they had activated Notch and/or Wnt signaling (Spee et al., 2010). The diseases analyzed were 
classified as either parenchymal (injuring the hepatocytes) or biliary diseases. This study found 
a strong activation of Wnt signaling in the HPCs arising in acute necrotizing hepatitis, a 
parenchymal disease, but a high activation of Notch in the HPCs present in the biliary disease 
primary biliary cirrhosis (PBC). These data support the idea that Notch and Wnt oppose each 
other to promote biliary and hepatic cell fates, respectively, and also supports the idea that 
different regenerative responses occur in the liver depending on the mechanism (including 
which cells and tissues are affected) and extent of injury. Together, the findings in humans and 
mice indicate that cell therapies targeting cell populations and signaling pathways may be 
differentially effective in the context of different liver diseases. 
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Hepatocyte and BEC inter-lineage conversion 
 
The study of signaling pathways during liver regeneration is aimed at answering the base 
questions: what progenitor populations exist in the liver, and how can we activate them to 
promote liver regeneration? As previously described, recent studies have discovered that there 
is a high degree of cell plasticity in the adult liver and that Notch signaling plays a role in the 
ability of seemingly differentiated cell types to adopt a different cell fate (Jeliazkova et al., 2013; 
Yanger et al., 2013). The concept of hepatocyte-to-BEC conversion had previously been 
suggested by expression studies and demonstrated by transplantation experiments to occur 
during liver injury in a rat model (Limaye et al., 2010; Limaye et al., 2008b; Michalopoulos et al., 
2005; Michalopoulos et al., 2002).  
 
To further explore the potential of differentiated hepatocytes and BECs to undergo lineage 
conversion, several groups have recently performed lineage tracing studies whereby they 
indelibly label either hepatocytes or BECs in mice and then injure the liver through several 
common chemical and surgical liver injury models. These studies are intended to demonstrate 
whether a cell with bipotential progenitor or interlineage conversion capacities reside within 
either the hepatocyte or BEC lineage and is activated by the injury model. 
 
Thus far, some of these lineage tracing studies have yielded conflicting results (Español-Suñer 
et al., 2012; Malato et al., 2011; Yanger et al., 2013). Despite the specific discords between the 
studies (Table 1.1), it appears as though there is at least the potential that interlineage 
conversion from hepatocyte-to-BEC and BEC-to-hepatocyte can occur in specific injury 
situations.  
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Oncogenic implications of cell plasticity and intercellular signaling 
 
While cell plasticity has an obvious therapeutic importance for liver regeneration, the flexibility in 
cell lineages and the retained proliferative ability of hepatocytes and cholangiocytes can also 
yield negative consequences in disease situations, most notably cancer. The signaling 
pathways Notch and Wnt, as previously explained, contribute to cell fate decisions, but both 
pathways also have roles in cancer progression in the liver.  
 
Recent findings have demonstrated that the overexpression of Notch signaling in hepatocytes 
can promote to both hepatocyte-to-BEC conversion and to cellular proliferation, ultimately 
contributing to the development of cholangiocarcinoma in a mouse model (Fan et al., 2012; 
Sekiya and Suzuki, 2012). In mice, overexpression of Notch2 increases proliferation and 
promotes tumor progression in both hepatocytes and BECs (Dill et al., 2013). Studies analyzing 
the expression of Notch in human hepatocellular carcinoma (HCC) have found conflicting 
results on the role of Notch in HCC; while some studies suggest that Notch signaling can 
actually play a pro-differentiation role in hepatocellular carcinoma and function to suppress 
hepatocellular carcinoma (Wang et al., 2009; Yao and Mishra, 2009), others find correlations 
between Notch expression and tumor size, tumor grade, and poor prognosis (Ahn S, 2013; 
Zhou et al., 2013). 
 
In addition to Notch, Wnt/"-catenin signaling also has oncogenic potential in the liver (Moeini et 
al., 2012). Nuclear "-catenin is frequently found in hepatocellular carcinoma and correlates with 
tumor grade (Wang et al., 2009). Interestingly, one study analyzing human hepatocellular 
carcinomas found a negative correlation between "-catenin expression and Notch1/Jagged1 
expression, where tumor grade was positively correlated with "-catenin expression but 
36 
negatively correlated with Jagged1/Notch1 expression (Wang et al., 2009). This finding may 
indicate that the Wnt/Notch duality that governs cell fates during liver regeneration may also 
dictate hepatocellular carcinoma tumor types and differentiation status, ultimately influencing 
tumor progression. These findings indicate that a very careful control of Notch and Wnt is 
required within the liver to balance the potential positive effects in regeneration and avoid 
oncogenic effects. 
 
Like Notch, the misregulation of VEGF signaling can also be pathogenic in the context of liver 
injury, especially cancer. VEGF expression is upregulated in hepatocellular carcinoma and is 
correlated with tumor size (Kwon et al., 2012; Marschall et al., 2001; Moon et al., 2003). The 
VEGF-mediated neovascularization of hepatocellular carcinoma may reflect a negative 
manifestation of a developmental epithelial-endothelial signaling interaction. In another example 
of a signaling pathway that can both promote regeneration and fuel tumor growth, we see that a 
precise understanding of signaling between tissues, specifically mediated by VEGF, will be 
important for the understanding of liver homeostasis and regeneration and for the future 
exploration of in vivo therapies for liver disease. 
 
Cell plasticity and the associated signaling pathways that influence cell fate changes have both 
an exciting potential for therapeutic applications and potential negative consequences in 
disrupting normal organ behavior and promoting disease. A thorough understanding of the 
process of cell fate regulation and the involvement of pathways such as Notch and VEGF will be 
important in order to understand normal development and physiology, disease, and 
regeneration. 
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Aims of the Dissertation 
 
It is clear that the regulation of cell fates and architecture in the liver are crucial for proper liver 
development, function, and regeneration. 
 
This dissertation intends to focus on the role of inter- and intracellular signaling in directing cell 
fate decisions and architectural establishment during hepatic development and regeneration in 
response to injury.  
 
First, I will investigate the requirement for Notch signaling in the regeneration of the three-
dimensional IHBD network in a genetic model of IHBD paucity and the rule of Sox9 in the 
regenerative process (Please refer to Chapter 3). Next, I will explore the mechanism of 
regeneration in regard to Sox9 expression in a variety of liver injuries and diseases, both human 
and rodent models (Please refer to Chapter 4). Finally, I will examine the role of epithelial VEGF 
signaling in directing vascular cell identities and architecture during liver development and the 
effects of vascular manipulation on hepatocyte zonal identity. 
 
In summary, this dissertation will address the role of Notch signaling, VEGF signaling, and Sox9 
in directing the architecture of the IHBD, vasculature, and hepatic lobule, and in directing the 
cell fates and identities of vascular and epithelial cells during development and regeneration. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
Mouse Lines 
 
Double Knockout (DKO) Mice 
 
DKO mice were generated by crossing Tg(Alb-cre)21Mgn (Albumin-Cre )(Postic and Magnuson, 
2000), Rbpjtm1Hon (Rbpflox) (Han et al., 2002), and Onecut1tm1.1Mga (Hnf6flox) (Zhang et al., 2009) 
mouse lines.  
 
VEGF Knockout (VKO) Mice 
 
VEGF-knockout (VKO) mice were generated by crossing Albumin-Cre (Postic et al., 2000)  and 
Vegfatm2Gne (Gerber et al., 1999) mouse lines to generate Albumin-Cre;VEGFflox/flox mice. 
 
Genotyping 
 
Mouse genotypes were confirmed by polymerase chain reaction using previously established 
primer pairs.  
 
Animal Care and Use 
 
All breeding and experimental procedures were performed with approval from the Institutional 
Animal Care and Use Committees at Vanderbilt University Medical Center, Cincinnati Children’s 
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Hospital, University of Pittsburgh Medical Center, and Washington University School of 
Medicine. 
 
Livery Injury Models 
 
DDC Feeding 
 
Adult mice were fed a diet of chow supplemented with 0.1% 3,5-diethoxycarbonyl-1,4-
dihydrocollidine (DDC) (Bio-Serve, Frenchtown, NJ) for a maximum of 4 weeks. Control 
littermate mice were kept on normal chow without DDC. 
 
Partial Hepatectomy (PHx) 
 
Adult 8-12 week old male mice on a mixed genetic background (C57Bl/6-6x129) were subjected 
to 2/3 partial hepatectomy (PHx) and allowed to recover for 12 hours, 24 hours, 36 hours, 3 
days, 7 days, or 14 days. Control mice were subjected to a sham surgery. Surgeries were 
performed as previously described(Shteyer et al., 2004). 
 
2-AAF/PHx 
 
Male Fisher rats were received an intraperitoneal implantation of a 70mg (28-day slow release) 
2-acetylaminofluorene (2-AAF) tablet. 7 days after tablet implantation, rats were subjected to 2/3 
PHx. Control rats received a sham surgery. Implantations and surgeries were performed as 
previously described(Apte et al., 2008; Petersen et al., 1998). 
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Bile Duct Ligation (BDL) 
 
Adult 4-6 week old female mice on a mixed genetic background (C57Bl/6-6-SJL-Swiss Black) 
were subjected to bile duct ligation (BDL) and allowed to recover for 1, 7, 14, or 21 days. 
Control mice were subjected to a sham surgery. Surgeries were performed as previously 
described(Campbell et al., 2004). 
 
Rhesus Rotavirus (RRV) Injection 
 
Postnatal day 1 (P1) Balb/c mice were injected with Rhesus rotavirus (RRV). Mice were 
analyzed 14 days after injection. Control littermate mice were injected with saline. Injections 
were performed as previously described(Mohanty et al., 2006). 
 
Human Tissue Samples 
 
De-identified formalin-fixed, paraffin-embedded human tissue samples from patients with 
Alagille syndrome (ALGS), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), 
or biliary atresia (BA) were obtained from the pathology archives of Vanderbilt University 
Medical Center by Dr. Kay Washington (IRB protocol 010294, Tennessee Valley Cooperative 
Human Tissue Network). Research on human tissue samples was performed at Vanderbilt in 
accordance with Vanderbilt University Institutional Review Board (120649-SSH; 120047-ALM) 
and conforms to the ethical guidelines of the 1975 Declaration of Helsinki. 
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Serum Chemistry 
 
Blood was collected from postmortem mice and tested for serum total bilirubin 
(TecoDiagnostics, Anaheim, CA), total bile acids (Diazyme, Poway, CA), and alanine 
aminotransferase (TecoDiagnostics, Anaheim, CA). 
 
Immunohistochemistry and Immunofluorescence 
 
Paraffin-Embedded Tissue 
 
Murine liver tissue was fixed overnight at 4°C in 4% paraformaldehyde, processed and 
embedded in paraffin. Sodium citrate pH6 antigen retrieval was performed in heat and high 
pressure for 15 minutes. Sections were incubated in 1° antibody overnight at 4°C and 2° 
antibody for 2 hours at room temperature in 1% bovine serum albumin in phosphate-buffered 
saline. Sections were cut at 6 µm. Antibodies and reagents are listed in Table 2.1. Mayer’s 
hematoxylin or bisbenzimide were used as counterstains. 
 
Frozen-Embedded Tissue 
 
Murine liver tissue was either fixed overnight at 4°C in 4% paraformaldehyde, washed in PBS, 
and equilibrated in sucrose, or was put directly into sucrose without fixation. Equilibrated tissues 
were embedded in OCT (Tissue-Tek, Torrence, CA). Sections were cut at 10 µm. Unfixed 
frozen tissue was fixed for 5 minutes in acetone after sectioning. Sections were incubated in 1° 
antibody overnight at 4°C and 2° antibody for 2 hours at room temperature in 1% bovine serum 
albumin in phosphate-buffered saline. Sections were cute at 6 µm. Antibodies and reagents are 
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Table 2.1: Antibodies and reagents used for immunohistochemistry 
 
A. 
Primary antibodies used for IHC 
Antigen Retrieval Dilution Host Company Amplification 
CK19 (TromaIII) Na citrate 1:200 rat DSHB 
ABC; DAB 
(chromogenic) 
CK19 Na citrate 1:200 mouse Dako 
ABC; TSA-
FITC 
CPS1 Na citrate 1:500 rabbit Abcam  
Cytokeratin, 
wide spectrum Na citrate 1:300 rabbit Dako  
DBA-biotin Na citrate 1:500  Vector  
EYFP (GFP) Na citrate 1:500 rabbit Novus  
Endomucin Na citrate 1:200 goat R&D  
Glutamine 
synthetase Na citrate 1:1000 mouse BD Transduction  
HepPar1 Na citrate 1:500 mouse Dako 
ABC; TSA-
FITC 
Hnf1 Na citrate 1:500 rabbit 
From Joo-Seop 
Park  
HNF1" Na citrate 1:2000 goat Santa Cruz 
ABC; TSA-
FITC 
HNF4! Na citrate 1:1000 goat Santa Cruz 
ABC; TSA-
FITC 
HNF6 Na citrate 1:200 rabbit Santa Cruz 
ABC; TSA-
FITC 
Hypoxyprobe Na citrate 1:100 mouse NPI Vector Blue 
IsolectinB4-
biotin Na citrate 1:100  Sigma ABC; DAB 
Ki67 Na citrate 1:200 mouse BD Pharmingen  
Ki67 Na citrate 1:200 rabbit 
Thermo 
Neomarkers  
PECAM (CD31) Na citrate 1:100 rat BD Pharmingen  
RBPJ-% (T6709) 
AUS 
H3300 1:100 rat CosmoBio 
ABC; TSA-
Biotin; TSA-
FITC 
Sox9 Na citrate 1:500 rabbit Millipore  
VEGF Na citrate 1:100 rabbit Abcam  
B.      
Secondary Antibodies used for IHC 
Antibody  Dilution Host Company  
! rabbit-biotin  1:500 donkey 
Jackson 
ImmunoResearch  
! rabbit-cy3  1:300 donkey 
Jackson 
ImmunoResearch  
! rat-Alexa488  1:300 donkey 
Jackson 
ImmunoResearch  
! rat-biotin  1:1000 goat Jackson  
43 
ImmunoResearch 
! goat-biotin  1:500 donkey 
Jackson 
ImmunoResearch  
! mouse-biotin  1:500 goat 
Jackson 
ImmunoResearch  
! mouse-
alkaline 
phosphatase 
(AP)  1:1000  
Jackson 
ImmunoResearch  
streptavidin-cy2  1:300  
Jackson 
ImmunoResearch  
streptavidin-
HRP  1:500  Vector  
C.      
Reagents 
Reagent Company     
ABC Vector     
Apoptag kit Millipore     
AUS H3300 Vector     
TSA-Biotin 
PerkinElme
r 
    
TSA Plus-FITC 
PerkinElme
r 
    
Vector Blue Vector     
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listed in Table 2.1. Bisbenzimide was used as a counterstain. 
 
Imaging 
 
Images were acquired using either an Axioplan2 microscope and QImaging RETIGA EXi 
camera or an Olympus BX51 scope and Olympus DP71 camera. Post-capture image 
processing was performed with Adobe Photoshop. 
 
Histology 
 
For H&E stains, paraffin-embedded tissues sections were stained with Harris Hematoxylin 
(PolyScientific, Bay Shore, NY) and eosin Y alcoholic (Sigma Aldrich, St. Louis, MO). 
 
Cell and Structure Counts 
 
Hilar and peripheral bile duct counts 
 
Paraffin sections of the left liver lobe were stained for CK19 and DBA. The number of peripheral 
(DBA-) and hilar (DBA+) IHBDs per section were counted. Counts from multiple tissue sections, 
including sections from proximal, intermediate, and distal liver segments, were added and 
divided by the total area of liver tissue in section analyzed to provide numbers of IHBDs/mm2 
liver tissue. 
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Portal vein counts 
 
Paraffin sections of the left liver lobe were stained for DBA and GS to count portal veins. Portal 
veins were determined as any vein not surrounded by GS+ hepatocytes and were characterized 
as hilar or non-hilar by the presence of absence, respectively, of an associated DBA+ IHBD. The 
numbers of portal veins were counted on multiple tissue sections, including sections from 
proximal, intermediate, and distal liver segments, were added and divided by the total area of 
liver tissue in section analyzed to provide numbers of vessels/mm2 liver tissue. 
 
Hepatic artery counts 
 
Paraffin sections of the left liver lobe were stained for smooth muscle actin (SMA) to count 
hepatic arteries. Hepatic arteries were determined as any vessel with a thick SMA+ muscle layer 
and associated with a portal vein. The numbers of hepatic arteries were counted on multiple 
tissue sections, including sections from proximal, intermediate, and distal liver segments, were 
added and divided by the total area of liver tissue in section analyzed to provide numbers of 
vessels/mm2 liver tissue. 
 
Sox9+ cell counts 
 
Paraffin section of the left liver lobe were stained for Sox9 and Hnf4!. Random fields of the liver 
were imaged and counted for Sox9+ single-positive and Sox9+Hnf4!+ double-positive cells. 
The numbers of cells were added and divided by the total area of the liver tissue analyzed to 
provide numbers of cells/mm2 liver tissue. 
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Resin Casting and Tissue Clearance 
 
Retrograde resin injection of the common bile duct and tissue clearance were performed as 
previously described (Walter et al., 2012). See Appendix D for further details. The left liver lobes 
were photographed using a Leica MZ 16 FA stereoscope and QImaging RETIGA 4000R 
camera for IHBD casts and were photographed using an Olympus SZX12 stereoscope and a 
Diagnostic Instruments Spot Insight Color 3.2.0 camera for PV casts. 
 
Visualization of Hypoxia 
 
Hypoxyprobe (NPI, Inc., Bulington, MA) was used as directed. Approximately 0.6mg/g 
Hypoxyprobe was injected into mice. Mice were sacrificed 90 minutes after injection. 
Immunohistochemistry for Hypoxyprobe was performed on paraffin-embedded tissue. 
 
Quantification of VEGF Protein in Liver Tissue and Serum 
 
Liver tissue (caudate lobes at P30; caudate, right, and medial lobes at P15 and P3; whole liver 
at E16.5) was digested with Complete protease inhibitor cocktail (Roche, Mannheim, Germany). 
Serum was isolated from mouse blood at the time of harvest. VEGF protein was measured with 
using ELISA as directed (R&D, Minneapolis, MN). Total protein for normalization was measured 
with a Pierce BCA Protein Assay Kit as directing (Thermo Scientific, Rockford, IL).     
 
Circulating Blood Cell Analysis 
 
Blood samples were collected from the inferior vena cava in Microvette EDTA tubes at the time 
of sacrifice. Blood was analyzed with a Hemavet machine.  
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Statistical Analysis 
 
One-tailed unpaired Student’s t-tests were used to analyze statistical differences. 
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CHAPTER 3 
 
INTRAHEPATIC BILE DUCT REGENERATION IN MICE DOES NOT REQUIRE HNF6 OR 
NOTCH SIGNALING VIA RBPJ. 
 
Introduction 
 
Studies have demonstrated that bipotential progenitors may be present in the liver that are 
capable of giving rise to both hepatocytes and biliary epithelial cells (BECs) (Carpentier et al., 
2011; Dorrell et al., 2011; Sackett et al., 2009; Shin et al., 2011). It remains unknown, however, 
what degree of in vivo capacity specific stem, progenitor, or liver epithelial cells have to 
regenerate a functional IHBD system, and whether endogenous hepatic cells hold potential 
therapeutic benefit to treat bile duct insufficiency or ductopenic liver diseases. 
 
In addition to human studies of Alagille syndrome (ALGS) etiology, mouse models have 
elucidated the importance of Notch signaling in IHBD morphogenesis (Geisler et al., 2008; 
Hofmann et al., 2010; Lozier et al., 2008a; Sparks et al., 2010; Zong et al., 2009). The Jagged1 
ligand, expressed in portal vein (PV) mesenchyme, activates Notch receptors on bipotential 
hepatoblasts to promote intrahepatic bile duct (IHBD) formation (Hofmann et al., 2010). The 
DNA-binding co-factor recombination signaling binding protein immunoglobulin kappa J (Rbpj) is 
required for canonical Notch signaling within hepatoblasts. Along with Notch signaling, 
Hepatocyte nuclear factor 6 (Hnf6) is also important for BEC specification of bipotential 
hepatoblasts during embryonic development (Clotman et al., 2002). 
 
Rbpj/Notch signaling and Hnf6 are central mediators of the known differentiation pathway for 
BECs (Si-Tayeb et al., 2010). In the current model of BEC specification, inhibiting both 
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Notch/Rbpj and Hnf6 blocks all known arms of the BEC specification signaling cascade, and 
would be hypothesized to cause a blockade in IHBD morphogenesis (Si-Tayeb et al., 2010). 
Previous work in our laboratory has demonstrated that the Albumin-Cre-mediated (Postic and 
Magnuson, 2000) hepatoblast-specific deletion of both Rbpj (Han et al., 2002) and Hnf6 (Zhang 
et al., 2009) produces a synergistic defect whereby Rbpj and Hnf6 double-knockout (DKO) mice 
are developmentally unable to form peripheral IHBDs (Vanderpool et al., 2012). Early in life 
IHBD paucity causes severe cholestasis, hepatic necrosis, and fibrosis in these mice. However, 
DKO mice eventually generate BECs in reactive ductules (Vanderpool et al., 2012). The DKO 
mouse provides a unique and unprecedented model in which to study regeneration from a true 
IHBD paucity model. 
 
In this study, we demonstrate that DKO mice are indeed capable of forming communicating 
peripheral IHBDs subsequent to the emergence of a ductular reaction. This indicates that Notch 
and Hnf6 are together dispensable for IHBD regeneration in adult mice. This is a surprising 
result that demonstrates that alternate mechanisms for IHBD morphogenesis exist that are 
different than the mechanism of embryonic ductal plate morphogenesis. This finding may 
explain the recovery of cholestasis that occurs in some ALGS patients while providing a new 
concept for investigation of potential Notch-independent IHBD regenerative therapies. 
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Results 
 
Adult peripheral IHBDs form in the absence of Rbpj and Hnf6. 
 
To examine IHBD regeneration, we utilized the bile duct insufficiency Albumin-Cre Rbpjflox/flox 
Hnf6flox/flox (DKO) mouse model (Vanderpool et al., 2012). At postnatal day (P)15, DKO mice lack 
peripheral IHBDs, but have normal appearing hilar and extrahepatic bile ducts. DKO mice also 
demonstrate extensive hepatocyte necrosis at P15 (Figure 3.1B). However, by P60, DKO mice 
display a cytokeratin 19 (CK19)+ ductular reaction (Figure 3.1D). At P120, DKO mice exhibit a 
reduction in reactive ductules and display patent regenerated peripheral IHBDs (Figure 3.1F).  
  
To quantify the extent of IHBD paucity and regeneration, hilar and peripheral IHBD branches in 
DKO and control mice were counted in tissue section at P15 and P120. Among the CK19+ cells, 
localization of the lectin Dolichos Biflorus Agglutinin (DBA) was used to define and distinguish 
hilar from peripheral IHBDs. At P15, DKO mice display no difference in the number of hilar IHBD 
branches (Figure 3.2A). However, there is a dramatic and significant decrease in peripheral 
IHBD branches in DKO mice as compared to controls. At P120, there remained no difference in 
hilar IHBD branches between control and DKO mice (Figure 3.2B). At P120, some DKO mice 
displayed a complete recovery in peripheral IHBD branches to control levels; however, some 
DKO mice still exhibited a reduction in the number of peripheral IHBD branches as compared to 
control (Figure 3.2B). 
 
We performed IHBD resin casting (Walter et al., 2012) to determine if the peripheral IHBDs 
observed in section contributed to the 3-dimensional communicating IHBD  
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architecture. At P60 in DKO mice, only the hilar branches of the IHBD are communicating with 
the extrahepatic bile duct system (Figure 3.3C). However, DKO mice at P120 display 
regenerated peripheral IHBD branches (Figure 3.3D). P120 DKO mice also demonstrate 
recovery from cholestasis, as measured by total bilirubin levels in serum (Table 3.1). There was 
some variation within the DKO mice in terms of extent of IHBD paucity in casts and in total 
bilirubin levels (Table 3.1). Representative cast images with the corresponding total bilirubin are 
shown at each timepoint: for P60 DKOs, the most common phenotype is “only hilum” cast and 
for P120 DKOs, the most common phenotype is “moderate”. 
 
BECs in ductular reactions and regenerated peripheral IHBDs do not express Rbpj or Hnf6 
 
To determine whether the ductular reaction and regeneration of peripheral IHBDs can truly 
occur without Rbpj and Hnf6, we examined the expression of each protein in BECs. If the 
recovery is due to either (1) an expansion of BECs that retain Rbpj and/or Hnf6 expression, or 
(2) a conversion of cells from a non-Albumin-Cre expressing cell lineage into BECs, we would 
expect to find that all or most BECs at P60 and P120 will retain expression of one or both of 
these proteins. 
 
We performed immunohistochemistry for Hnf6 in P60 and P120 DKO and control mice. Hnf6 is 
present throughout the tissue in hepatocytes and BECs at both P60 and P120 (Figure 3.4A,C). 
In DKO mice, however, hepatocytes and BECs express no detectable Hnf6 at P60 or P120, 
demonstrating that the BECs constituting both reactive ductules and regenerated peripheral 
IHBDs are formed in the absence of Hnf6 protein (Figure 3.4B,D). 
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To determine whether Rbpj is present in reactive and regenerated peripheral BECs, we 
performed immunostaining for Rbpj protein. Rbpj is expressed not only in cells with activated 
Notch signaling, but is ubiquitously expressed in all cell types (Hamaguchi et al., 1992). The 
levels of Rbpj protein are normally very low in liver epithelial cells, and the protein can only be 
detected with multiple steps of amplification for immunostaining performed on paraffin 
embedded tissue. In control mice at P15, P60, and P120, Rbpj is consistently observed in both 
wide spectrum cytokeratin (wsCK)+ BECs and in the surrounding stromal cells (Figure 
3.5A,C,E, white arrowheads). In P15 DKO mice, the majority of BECs in hilar IHBDs express no 
detectable Rbpj protein; however, a small number of rare BECs do still express Rbpj (Figure 
3.5B, white arrowhead). The presence of some Rbpj-expressing cells in the hilar IHBDs may 
indicate that these cells underwent BEC-specification prior to Albumin-Cre transgene 
expression, thus avoiding Albumin-Cre mediated recombination and deletion of Rbpj. At P60 
and P120, the vast majority of BECs present in either reactive ductules or regenerated IHBDs 
express no detectable Rbpj protein. Only very rare BECs that express Rbpj are present in the 
liver at P60 and P120 (Figure 3.5D,F, white arrowheads). We detect no indication that 
undeleted populations of BECs are preferentially expanding and contributing to regenerated 
IHBDs in the DKO mice. 
  
Ductular reactions occur surrounding all peripheral portal veins and not in isolated locations. 
 
To assess the extent of the ductular reaction and IHBD regeneration over time within the 
hepatic architecture context, we immunostained for CK19 to mark BECs and glutamine 
synthetase (GS) to marks pericentral hepatocytes. This allows us to discriminate between portal 
veins, where IHBDs are normally associated, and central veins (Figure  
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3.6A,C,E,G). If new BECs arise from rare cells in the liver, for example, a small number of cells 
that retain Rbpj and/or Hnf6 expression, we would expect to see localized expansions of CK19+ 
cells. Instead, we see that at P60, the CK19+ ductular reaction extends throughout the liver, with 
reactive ductules surrounding all peripheral portal vein branches (Figure 3.6B,D). At P120, the 
CK19+ reactive ductules have resolved and patent IHBDs are present in regions of GS- 
hepatocyte-associated portal veins (Figure 3.6F,H).   
 
Reactive BECs are not derived from hilar DBA+ IHBDs. 
 
To explore the hypothesis that cells contributing to pre-existing IHBDs give rise to ductular 
reactions and peripheral IHBDs, we analyzed the relationship between CK19 expressing cells 
and DBA+ hilar ducts. We looked at a timepoint between P15, when no peripheral BECs are 
present and P60 when a full ductular reaction has developed; at P30, reactive CK19+ BECs are 
just beginning to appear (Figure 3.7B-F, white arrowheads compared to Figure 3.6). To 
determine whether these emerging CK19+ reactive BECs are coming from differentiated hilar 
BECs, we assessed the expression of CK19 and DBA in three dimensions on serial liver 
sections. We examined serial sections of the P30 DKO mouse liver in areas where CK19+ 
reactive BECs were found. These cells exist in small clusters that extend in three-dimensions 
but do not juxtapose DBA+ hilar IHBDs on any spatial axis, as visible in the Figure 3.7A image 
captured from a hilar region. These results suggest that the initial CK19+ reactive BECs are not 
emerging directly from formed hilar IHBDs.  
 
Next, we examined the expression of the BEC marker Sex determining region Y-related HMG 
box transcription factor 9 (Sox9). Normally, Sox9 expression is activated during  
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ductal plate differentiation of BECs (Antoniou et al., 2009), expressed in mature BECs, enriched 
in adult mouse hepatic progenitor cell (HPC) populations (Dorrell et al., 2011), and has been 
demonstrated to be a marker of hepatocyte-to-BEC conversion (Yanger et al., 2013). To 
examine the spatial relationship between the Sox9+ cells, emerging CK19+ reactive BECs, and 
DBA+ IHBDs, we performed immunostaining for Sox9 and CK19 on serial liver sections in P30 
DKO mice (Figure 3.7A’-F’). Sox9 is expressed widely throughout the hepatic tissue of DKO 
mice. Sox9+ cells (Figure 3.7A’-F’, red arrowheads) are present outside of CK19+DBA+ hilar 
IHBDs (Figure 3.7A’, green arrowhead) and CK19+DBA- peripheral BECs (Figure 3.7B’-F’, white 
arrowheads). CK19+DBA- peripheral BECs are consistently found in close spatial association 
with Sox9+CK19- cells. While small clusters of Sox9+ cells do exist in close proximity to DBA+ 
IHBDs, they are already widespread in the peripheral tissue by P30. 
 
To further assess whether these Sox9+ cells may be arising from hilar IHBDs, we also analyzed 
the spatial relationship between Sox9+ cells and DBA+ hilar IHBDs through immunofluorescence 
on serial liver sections at P15 (Figure 3.8). Sox9+ cells are found surrounding necrotic patches 
(Figure 3.8B-F, dashed outline). At P15, Sox9+ cells extend in three-dimensions surrounding 
areas of focal necrosis. The areas of focal necrosis are apparent by cell morphology and the 
sticking of the lectin DBA. Importantly, we find that these areas of Sox9+ cells do not juxtapose 
hilar IHBDs in any area examined. Although this analysis does not definitively determine that the 
Sox9+ cells do not arise from DBA+ IHBDs, our data strongly support this conclusion. 
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DKO mice exhibit Sox9+ “intermediate” cells. 
 
To assess the cellular identity of the observed Sox9+ cells in DKO mice, we performed 
immunohistochemistry for Sox9. Sox9 expression is observed in cells that histologically appear 
as BECs in P15 and P60 control livers (Figure 3.9A,C). In P15 DKO mice, Sox9 is seen not only 
in IHBDs (Figure 3.9B”), but also in non-IHBD cells surrounding necrotic patches throughout the 
liver (Figure 3.9B’). These cells morphologically resemble hepatocytes. Although they are found 
near necrotic patches, these Sox9+ cells are not undergoing apoptosis (Figure 3.10). In P60 
DKO mice, Sox9 expression is found both in IHBDs (Figure 3.9D”) and within the liver 
parenchyma in cells that morphologically resemble hepatocytes (Figure 3.9D’). 
 
We further characterized the identity of Sox9+ cells by performing co-immunostaining with 
markers of BECs or hepatocytes. In DKO mice at P15, Sox9+ cells surrounding necrotic areas 
co-express the hepatocyte marker Hnf4! (Figure 3.11A) and do not express the BEC markers 
Hnf1" (Figure 3.11B) or CK19 (Figure 3.11C). The Sox9+ cells display cell fate markers of both 
the hepatocyte marker Hnf4! and the BEC marker Sox9 and therefore represent a population of 
“intermediate” cells. In DKO mice at P60, Sox9 was again found in intermediate cells co-
expressing Hnf4! (Figure 3.11D) as well as in Hnf1ß+ and CK19+ reactive BECs (Figure 3.11F, 
red arrowheads). The Sox9+ intermediate cells that juxtapose central veins co-express 
glutamine synthetase (GS), an enzyme expressed in pericentral hepatocytes, supporting the 
hypothesis that these cells originate from hepatocytes and active the expression of BEC 
markers (Figure 3.12). The number of Sox9+ intermediate cells is significantly higher in DKO 
mice than in controls at P15, P60 and P120, but decreases over time (Figure 3.13A).  
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We examined proliferation to determine whether Sox9+ intermediate cells represent an 
expanding progenitor population. In DKO mice at P15, Sox9+ intermediate cells did not express 
the proliferation marker Ki67, despite high amounts of proliferation in surrounding hepatocytes 
(Figure 3.14B). Sox9+ intermediate cells were also non-proliferative at P60 in DKO mouse livers 
(Figure 3.14D). This suggests that these cells do not represent a proliferative progenitor 
population. 
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Conclusion 
 
Sox9+ BECs and a communicating IHBD are able to form without Notch/Rbpj signaling and 
Hnf6. 
 
The involvement of Notch and Hnf6 in ductal plate IHBD development has been well-
characterized (Antoniou et al., 2009; Clotman et al., 2002; Hofmann et al., 2010; Lozier et al., 
2008a). During ductal plate morphogenesis, hepatoblasts surrounding the portal vein are 
specified as BECs, become polarized, and remodel into a luminal IHBD structure (Antoniou et 
al., 2009). The initial peripheral IHBD paucity observed in DKO mice indicates that ductal plate 
IHBD morphogenesis cannot occur without Notch signaling and Hnf6 (Figure 3.1). However, the 
regeneration of peripheral IHBDs in DKO mice (Figures 3.2, 3.3) despite the absence of Rbpj 
and Hnf6 protein from nearly all BECs and hepatocytes (Figures 3.4, 3.5) (Vanderpool et al., 
2012) excludes an absolute cell-autonomous requirement of these genes for BEC differentiation 
during injury.  
  
Recent studies have demonstrated that the cell autonomous over-activation of Notch signaling 
is capable of driving hepatocyte-to-BEC conversion and that deleting Rbpj impairs efficient 
hepatocyte-to-BEC conversion in liver injury models (Jeliazkova et al., 2013; Yanger et al., 
2013). For example, Yanger et al. (2013) demonstrate that deleting Rbpj decreases the number 
of Sox9+ lineage-labeled hepatocytes arising during liver injury, but does not completely block 
the response. Similarly, inhibiting Notch signaling reduced the extent of the ductular reaction 
mounted in response to injury (Fiorotto et al., 2013). Our data add to this story through the 
indication that Rbpj, and canonical Notch signaling, is not absolutely required. In a Notch loss 
model, it may take longer to reach intracellular thresholds to activate Sox9 expression. We 
hypothesize that one or more signaling pathways may converge to activate Sox9 expression 
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and, in coordination with Sox9, overcome the loss of Notch signaling in the DKO model. 
Contributing signaling molecules may originate from infiltrating immune cells to initiate 
expression of Sox9 localized around necrotic lesions. There is precedent for immune and 
endothelial cells communicating with the liver epithelium during injury (Boulter et al., 2012; 
Wang et al., 2012) to promote liver regeneration. Previous studies investigating hepatocyte-to-
BEC conversion in mice and rats have identified Akt, HGF, EGF, and PI3K as potential 
mediators of the transdifferentiation process (Fan et al., 2012; Limaye et al., 2008b) in a Notch 
signaling-capable background. Further studies are required to determine which extra- and 
intracellular signaling pathways are driving the Notch-independent alternate BEC differentiation 
mechanism observed in DKO mice. 
 
Interestingly, although Sox9+ intermediate cells are observed in both Notch loss and Notch over-
activation models, the molecular regulation may be different. In Notch over-activation, the biliary 
cell marker Hnf1" becomes activated in hepatocytes co-expressing Hnf4! (Yanger et al., 2013); 
however, the co-expression of these markers is not observed in the DKO mouse model, where 
Hnf1" is expressed in Sox9+ cells that have already downregulated Hnf4! (Figure 3.11). This 
suggests that the regulation of Sox9 expression may be quite different in the presence or 
absence of Notch signaling. The two different models may have complementary clinical 
implications, with Notch over-activation modeling carcinogenesis and the Notch loss more 
closely resembling a chronic cholestatic disease injury. 
 
Reactive BECs that arise in peripheral regions originate from liver epithelium but not from hilar 
IHBDs.  
 
There are several possible origins of the peripheral reactive BECs and regenerated IHBDs in 
the DKO mouse models, including: differentiated DBA+ hilar IHBDs, extrahepatic bile ducts 
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(EHBDs), EHBD associated peribiliary glands (Carpino et al., 2012), hepatocytes (Fan et al., 
2012; Michalopoulos et al., 2005; Yanger et al., 2013), mesenchymal/stellate cells (Tao et al., 
2009; Yang et al., 2008), endothelial cells (Goldman et al., 2013), or hematopoietic cells 
(Petersen et al., 1999). As we are not able to perform Cre-mediated lineage tracing in this Cre-
generated genetic deficiency model, we cannot definitively rule out any of these possibilities. 
However, based on the finding that almost every BEC observed in P60 and P120 DKO mice are 
deleted for both Rbpj and Hnf6 strongly indicates that new BECs come from an Albumin-Cre-
derived intrahepatic cell and not from a non-hepatic source (Figures 3.4, 3.5). This makes it 
highly unlikely that the new BECs would originate from the EHBDs, peribiliary glands, 
mesenchymal cells, endothelial cells, or hematopoietic cells. While the existing hilar IHBDs at 
P15 are restricted to the proximal base of the liver, the reactive BECs are present throughout 
the liver periphery. It is difficult to imagine how cells from either the hilar IHBD would distribute 
throughout the liver periphery, either by cell migration or proliferation, in the time it takes before 
reactive BECs are seen throughout the tissue (Figure 3.6). This dissuades the idea that the new 
BECs are arising from the existing Albumin-Cre derived IHBDs. Similarly, the observation that 
the first peripheral appearing Sox9+ CK19+ BECs that form reactive ductules emerge within the 
parenchyma, not juxtaposing differentiated DBA+ hilar IHBDs, strongly indicates that the BECs 
of the ductular reaction are arising through a de novo differentiation process and not originating 
from pre-existing formed hilar IHBDs (Figures 3.7, 3.8). 
 
A remaining possibility is that the new BECs arise from Albumin-Cre derived hepatocytes. This 
idea is supported by two observations.  First, the BECs contributing to the ductular reaction and 
the regenerated peripheral IHBDs do not express Rbpj and Hnf6 protein. Second, we observe 
expression of Sox9, a biliary and progenitor cell marker, in intermediate Hnf4!+ cells of the DKO 
liver (Figure 3.11). Sox9 has previously been shown to be an early marker of interlineage 
conversion (Yanger et al., 2013) and may mark cells beginning a conversion process in the 
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DKO model as well. Indeed, new peripherally localized BECs are found in areas dense with 
Sox9+ cells that do not express CK19 (Figure 3.7, white arrowheads). Therefore, it remains 
formally possible that the Sox9+ intermediate cells give rise to the new CK19+ BECs. 
 
The combined loss of Rbpj and Hnf6 has a synergistic effect on the injury condition that may be 
crucial for the observed regenerative response. 
 
The liver-specific single deletion of Rbpj (Rbpj KO) decreases the number of IHBD branches, 
and no recovery in IHBD branch number was found to occur with age in that model (Sparks et 
al., 2011). We propose three explanations for the difference in regenerative capacity between 
Rbpj KO and DKO mice: 1. The more severe degree of hepatic injury observed in DKO mice is 
required to induce the proper stimulus or signal to drive adult IHBD regeneration; 2. The Rbpj 
KO mice undergo a low level of IHBD regeneration and replenishment that is below the 
resolution of our previous resin cast microCT analysis (20&m limitation) (Sparks et al., 2011); or 
3. The absence of Hnf6 in a Notch deficient background is required for adult IHBD regeneration. 
The presence of Sox9+ intermediate cells in Rbpj KO mice (Jeliazkova et al., 2013) (T.J.W. and 
S.S.H., unpublished) indicates that the absence of Hnf6 is not required for the emergence of 
intermediate cells, but it remains possible that Hnf6 functions to inhibit later stages of IHBD 
regeneration. Interestingly, hepatic Hnf6 levels have been found to decrease after bile duct 
ligation in mouse, and forced overexpression of Hnf6 inhibits IHBD regeneration through 
decreasing BEC proliferation (Holterman et al., 2002). Thus, Hnf6 may potentially play an active 
role in mediating IHBD regeneration. This is an active area of investigation in our laboratory. At 
this time, we cannot rule out any of these explanations with certainty. 
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De novo BEC differentiation may be a common and targetable phenomenon in human liver 
disease and regeneration. 
 
The occurrence of Sox9+ intermediate cells in human liver disease samples has previously been 
observed in cases of hepatocellular injury and fibrosis (Yanger et al., 2013). These findings 
indicate that the intermediate cells seen in the DKO mouse model may be a common feature of 
cholestatic liver diseases (Figure 3.1), situations of IHBD regeneration, and are especially 
relevant to the Notch-associated disease ALGS (Oda et al., 1997). Histopathological studies 
have shown that ALGS patients display large accumulations of intermediate “hepatobiliary” cells 
which co-express hepatocyte and BEC markers (Desmet, 2011; Fabris et al., 2007; Roskams et 
al., 2003). Additional studies will be required to determine whether Sox9+ intermediate cells 
correlate with ALGS disease severity or outcome.  
 
To date, Hnf6 mutations have not been found to contribute to ALGS. However, the loss of Hnf6 
greatly increases the severity of injury caused by Rbpj deletion in mouse liver (Vanderpool et 
al., 2012). This finding may reflect how epigenetic changes of Hnf6, and/or genetic or epigenetic 
changes of other liver genes, could modulate Notch loss in ALGS patients and influence 
disease severity between patients. Further detailed analysis will be required to characterize the 
role of other genes in modulating the varied disease severity and recovery in ALGS patients. 
 
Our findings in DKO mice demonstrate that new BECs may be able to alleviate cholestasis in 
patients with ALGS despite the persistent Notch impairment. Hopefully, further investigation on 
the potential of intermediate cells in mice and more in depth studies analyzing human tissues 
will identify alternate signaling mechanisms that may be utilized therapeutically to drive Notch-
independent IHBD regeneration in patients, especially given the potential cholangiocellular 
carcinogenic outcome of Notch over-activation (Fan et al., 2012; Sekiya and Suzuki, 2012). 
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CHAPTER 4 
 
HEPATOCYTE IDENTITY RESPONSE IS BASED ON THE NATURE OF THE LIVER INJURY 
 
Introduction 
 
The liver has an incredible capacity for regeneration; in rats, 2/3 of the liver can be removed and 
within 5 to 7 days, it will return to its original mass (Michalopoulos and DeFrances, 1997). In this 
model of acute liver injury, “regeneration” occurs through the compensatory growth of the 
remaining liver tissue and involves the proliferation of all existing mature cell types in the liver 
(Michalopoulos and DeFrances, 1997). However, the innate ability of the liver to regenerate is 
frequently compromised in situations of chronic liver disease. The use of cell-based therapies to 
aid liver regeneration and avoid transplantation would be an important therapeutic advance in 
the treatment of liver disease.  
 
Different liver injuries and diseases can be highly variable in the pathological manifestation and 
course of progression and/or regeneration. Before we can explore and utilize cell-based 
therapies for treatment of hepatobiliary diseases, we must classify the different and temporal 
cellular responses inherent to specific liver disease types. This will provide a foundation for 
using cell markers for diagnostic and prognostic purposes and also allow for the identification of 
the most appropriate in vivo models for studying human liver disease progression. 
 
Several groups have previously demonstrated the differential cellular response in different 
rodent liver injury models (Español-Suñer et al., 2012; Malato et al., 2011; Yanger et al., 2013). 
Lineage-tracing studies have demonstrated that biliary epithelial cell (BEC)-to-hepatocyte 
conversion occurs in response to a choline-deficient diet supplemented with ethionine (CDE), 
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but not in response to 2/3 partial hepatectomy (PHx), carbon tetrachloride (CCl4) administration, 
or 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) feeding (Español-Suñer et al., 2012). On the 
other hand, studies have provided contradictory data as to whether hepatocyte-to-BEC 
conversion occurs in response to several liver injury models, including 2/3 PHx, bile duct ligation 
(BDL), and DDC feeding (Malato et al., 2011; Yanger et al., 2013). These studies indicating 
different regenerative responses in different liver injury models, as well as the ensuing conflict in 
the field regarding the degree of hepatic interlineage conversion between hepatocytes and 
cholangiocytes during liver injury, demonstrate the need for further study of specific cell markers 
in different injury models.  
 
The investigation of human pathological samples has demonstrated that the variation in cellular 
response to different injuries extends to human liver disease (Fabris et al., 2007; Falkowski et 
al., 2003; Gouw et al., 2011). For example, although the pediatric diseases Alagille syndrome 
(ALGS) and biliary atresia (BA) are both characterized by ductopenia and cholestasis, the 
cellular responses to these injuries are highly varied: BA is characterized by a pronounced 
ductular reaction not observed in AGS while AGS patient samples show a much higher number 
of “intermediate hepatobiliary cells,” displaying markers of both hepatocytes and BECs, than BA 
patient samples (Fabris et al., 2007). The differences observed in these otherwise 
phenotypically similar human diseases suggest that the same cellular observations could mean 
different phenomena in terms of diagnosis and prognosis, and that the mechanism of hepatic 
cell renewal or regeneration occurs differently in these different human liver diseases. 
 
At this point in time, the functional significance of intermediate hepatobiliary cells in liver disease 
is unknown. Alagille syndrome patients have varying disease severities and outcomes, and 
cellular indicators like intermediate hepatobiliary cells have the potential to be helpful in disease 
prognosis; however, no thorough studies have characterized the normal disease progression in 
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terms of intermediate cell presence or attempted to correlate intermediate cell presence with 
disease severity or outcome. As such, we cannot be sure if the presence of intermediate 
hepatobiliary cells is a positive indicator, indicating cellular reprogramming to generate new 
BECs, or a negative indicator, indicating a complete block in the BEC-differentiation process. If 
markers of cellular fates and responses are to be useful for clinical diagnostic and prognostic 
purposes, we must fully understand the temporal response of the cellular markers over the 
course of the injury and their prognostic meaning, if any. Similarly, if we intend to target in vivo 
progenitor therapies to treat human liver diseases, we must fully understand the origin and 
differentiation potential of possible progenitor cells such as intermediate hepatobiliary cells. 
Mouse and rat models will be essential to probe these important questions; however, the field 
with new lineage-tracing tools is just beginning to thoroughly investigate the cellular responses 
and contributions in different rodent liver injuries.  
 
Hepatocyte-to-BEC transdifferentiation has also been demonstrated to occur in several liver 
injury models and suggested to occur by marker analysis in human disease through a process 
by which hepatocytes begin to co-express biliary markers (Español-Suñer et al., 2012; Limaye 
et al., 2008a; Limaye et al., 2010; Yanger et al., 2013). One marker that has been found to 
denote cells undergoing the hepatocyte-to-BEC reprogramming is Sox9(Yanger et al., 2013), a 
protein that has received recent attention as a possible stem/progenitor cell marker in the 
developing and adult liver (Carpentier et al., 2011; Dorrell et al., 2011). As an early marker of 
hepatocytes undergoing conversion to BECs, and identifying cells with bipotential and 
clonogenic potentials in culture (Dorrell et al., 2011; Yanger et al., 2013), Sox9 has a high 
potential for being an important marker of liver regeneration and also of hepatic interlineage 
conversion and regenerative progress. 
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This study attempts to address a portion of the required in depth characterization of liver injury 
models by investigating the temporal response of Sox9 expression in a variety of commonly 
utilized acute and chronic rodent liver injury models. Examining the presence of Sox9+ 
hepatocytes or progenitor cells over time in hepatocyte proliferation-competent and non-
competent rodent liver injury models will help to better understand the cellular response. We 
find that Sox9+CK19- and Sox9+Hnf4!+ cells appear after DDC and BDL injuries in mouse but 
not after PHx in mouse or 2-acetylaminofluorene (2-AAF)/PHx in rat. This indicates that there 
are different cellular responses to different injury models in rodents. Of note, the activation of a 
ductular reaction does not appear to be directly related to the appearance of Sox9+CK19- and 
Sox9+Hnf4!+ cells. In the 2-AAF/PHx model, in which hepatocyte proliferation was fully 
impaired, Sox9+CK19- and Sox9+Hnf4!+ cells were not observed coincident with the ductular 
reaction. Specifically, activation of Sox9 expression in hepatocytes was observed in the models 
of cholestasis, DDC and BDL. Sox9+CK19- and Sox9+Hnf4!+ cells were found to display low 
rates of proliferation. Similar to rodent injury models, we observed Sox9+CK19- and 
Sox9+Hnf4!+ cells in a variety of liver samples from patients with cholestatic liver disease: AGS, 
BA, primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). The extent of 
Sox9+CK19- and Sox9+Hnf4!+ cells varied widely between the samples assayed. Therefore, a 
thorough examination of each human disease will have to be performed to assess if the 
presence Sox9+CK19- and Sox9+Hnf4!+ cells correlate to disease stage, severity, and/or 
prognosis. 
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Results 
 
SOX9 expression is activated in Hnf4!+ and CK19- cells in cholestatic human liver disease. 
 
To first assess the expression of SOX9 in several human cholestatic liver diseases, we 
performed immunofluorescence for Sox9 protein in human patient liver samples of AGS, BA, 
PBC, and PSC. Previous studies have found that within the normal human liver, SOX9 is 
expressed exclusively within BECs (Furuyama et al., 2011). We found the expression of SOX9 
in all four liver diseases we examined. To characterize the lineages of the cells that express 
SOX9, we performed co-immunostaining with the BEC marker CK19 (Figure 4.1A-D) or the 
human hepatocyte marker HepPar1 (Figure 4.1E-H). In all samples, Sox9 expression was found 
within CK19+ BECs and also within cells that express HepPar1 and do not express CK19, 
resembling hepatocytes. Nevertheless, there is variation in the extent of SOX9 expression 
between individuals diagnosed and tissue examined with the same disease. Additionally, there 
is a difference in the presence of ductular reactions between the different types of human 
cholestatic liver disease. A ductular reaction was observed in the PSC sample but not in the 
other three types of cholestatic liver disease. Previous work has found the expression of SOX9 
in other non-cholestatic liver diseases, including Joubert’s syndrome, chronic Hepatitis C Virus 
infection, and INH-induced massive hepatic necrosis (Yanger et al., 2013). Taken together, 
these results indicate that the expression of SOX9 in hepatocytes may be a common feature of 
human liver diseases. 
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Sox9 expression is activated in Hnf4!+ co-expressing hepatocytes in response to cholestasis-
inducing liver injuries. 
 
To determine whether hepatocyte expression of Sox9 is a general liver injury response, we 
characterized the response of Sox9 expression in several injury models, including PHx in mice, 
2-AAF/PHx in rats, BDL in mice, DDC feeding in mice, and RRV injection in mice.  BDL and 
DDC both induce chronic cholestatic injury, while PHx provides an acute injury model. The 
treatment of 2-AAF prior to PHx suppresses hepatocyte proliferation, providing a model of 
hepatocyte impairment. Finally, RRV injection provides a model of neonatal immune-induced 
obstructive cholestasis similar to biliary atresia. 
 
To examine the expression of Sox9 in the rodent liver injury models, we performed co-
immunostaining for Sox9 and either CK19 (Figure 4.2) or Hnf4! (Figure 4.3). Intermediate 
timepoints at which there was a response to injury were chosen for DDC, PHx, BDL, and 2-
AAF/PHx based on previous literature (Apte et al., 2008; Campbell et al., 2004; Ohno-Matsui et 
al., 2002; Preissegger et al., 1999; Shteyer et al., 2004) and our own analysis of injury 
progression. In DDC and BDL injuries, Sox9+CK19- and Sox9+Hnf4!+ cells were found that 
morphologically and histologically resemble hepatocytes. These cells are loosely localized to 
periportal zones. However, Sox9+CK19- and Sox9+Hnf4!+ cells were not found in either PHx or 
2-AAF/PHx injuries. In the RRV injury, Sox9+CK19- and Sox9+Hnf4!+ cells were observed 
around portal veins. However, as these early postnatal mice are still undergoing the final stages 
of ductal plate morphogenesis, it is not possible to definitively discriminate between injury-
induced cells and those that appear normally during the process of ductal plate morphogenesis. 
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At no time after PHx are Sox9+CK19- and Sox9+Hnf4!+ cells present. 
 
Following PHx, a model of acute injury in the liver, the hepatic cells rapidly expand in number to 
replace the lost mass. During this process, hepatocyte mass is recovered through the 
proliferation of previously-differentiated hepatocytes. Lineage-labeling studies suggest that PHx 
does not result in the interlineage conversion of hepatocytes to BECs or vice versa (Malato et 
al., 2011). To test whether Sox9+CK19- and Sox9+Hnf4!+ cells occur at any point during the 
injury and recovery from PHx, we analyzed a timecourse post-PHx injury. We assessed mice at 
12 hours, 24 hours, 36 hours, 3 days, 7 days, and 14 days after PHx (Figure 4.4). These 
timepoints cover an initial change in gene expression and normalization (Shteyer et al., 2004), 
timepoints of peak proliferation, and recovery of liver mass (Factor et al., 1997; Jungermann 
and Keitzmann, 1996; Shteyer et al., 2004). At no point during this timecourse did we see an 
increase in Sox9+CK19- and Sox9+Hnf4!+ cells over sham levels. A very small number of rare 
Sox9+Hnf4!+ cells are observed in control liver tissue, but PHx did not cause any increase in this 
cellular compartment. 
 
Sox9+CK19- and Sox9+Hnf4!+ cells appear rapidly and persist after BDL injury. 
 
BDL, a model of human chronic obstructive cholestatic liver disease, causes a toxic 
accumulation of bile acids subsequently causing hepatocyte apoptosis, fibrosis, and proliferation 
of BECs and hepatocytes (Bai et al., 2012; Miyoshi et al., 1999; Prado et al., 2003). There is 
some evidence that BDL injury causes a small number of hepatocytes to undergo interlineage 
conversion and become BECs (Yanger et al., 2013) and contribute to reactive ductules. To 
characterize the Sox9 expression in response to BDL, we analyzed intrahepatic tissue at 7 
days, 14 days, and 21 days after BDL (Figure 4.5).  
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Sox9+CK19- and Sox9+Hnf4!+ cells are visible in periportal areas by 7 days post-BDL (Figure 
4.5A,D,G). At 14 (Figure 4.5B,E,H) and 21 (Figure 4.5C,F,I) day post-BDL, the number of 
Sox9+Hnf4!+ cells increases and the cells are localized throughout the parenchyma. The cells 
still surround portal tracts and additionally extend throughout the parenchyma in tracks that 
bridge portal triads. In these bridging tracts, the cells begin to condense and morphologically 
resemble BECs in terms of their cell size and shape; however, they do not express CK19 and 
thus would not necessarily be considered mature BECs.   
 
Sox9+CK19- and Sox9+Hnf4!+ cells progressively increase with time of DDC feeding injury. 
 
DDC is a chemical-induced liver injury that models chronic cholestatic liver disease (Preisegger 
et al., 1999). DDC feeding induces the appearance of a ductular reaction, however, hepatocytes 
and cholangiocytes are still able to proliferate (Preisegger et al., 1999). During DDC treatment, 
reactive BECs are highly proliferative. To assess the progression of Sox9 expression over time 
during DDC injury, we performed co-immunostaining of Sox9 with either CK19 (Figure 4.6A-C) 
or Hnf4! (Figure 4.6D-F) at 3 days, 4 weeks, or 8 weeks of injury. During this time course, the 
extent of the ductular reaction progressively increases, such that no ductular reaction is 
observed at 3 days of DDC, but a profound ductular reaction is present after 8 weeks. After 3 
days of DDC, there are a small number of Sox9+CK19- and Sox9+Hnf4!+ cells present around 
portal areas. The number of Sox9+CK19- and Sox9+Hnf4!+ cells increase over time and are 
higher after 4 weeks of injury and 8 weeks of injury. 
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Sox9+Hnf4!+ cells present in BDL and DDC injury are not highly proliferative. 
 
To determine whether the large number of Sox9+Hnf4!+ cells present after BDL injury may 
represent the expansion of a proliferative progenitor population, we assessed the expression of 
Sox9 and the proliferative marker Ki67 by dual-immunofluorescence (Figure 4.7). Intrahepatic 
proliferation was observed at the timepoints where a high number of Sox9+Hnf4!+ cells are 
present in the liver post-BDL (Figure 4.5). However, proliferation was very rare in the prevalent 
Sox9+ cells at 7, 14 and 21 days post-BDL. This suggests that the Sox9+Hnf4!+ cells are not 
highly proliferative, amplifying progenitors. 
 
To determine whether the Sox9+Hnf4!+ cells that appear during DDC injury represent an 
amplifying progenitor population, we performed co-immunostaining with Sox9 and Ki67 to 
assess the proliferative status of Sox9+Hnf4!+ cells (Figure 4.8). At 7 days of DDC feeding 
(Figure 4.8A), there is very low proliferation both within Sox9+Hnf4!+ cells and throughout the 
tissue. By 28 days of injury (Figure 4.8B), there is proliferation occurring in both hepatocytes 
and BECs; however, the very few Sox9+Hnf4!+ cells are actively proliferating. These data 
indicate that Sox9+Hnf4!+ cells that arise in a DDC injury model most likely do not constitute a 
rapidly amplifying progenitor population. 
 
Sox9 expression in BECs is inversely correlated with proliferative status in uninjured mice 
during postnatal IHBD morphogenesis and homeostasis. 
 
The finding that Sox9+ hepatocytes display very low rates of proliferation, despite proliferation in 
surrounding hepatocytes prompted us to wonder whether the expression of Sox9 had a 
fundamental correlation with proliferation, either through directly or  
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indirectly decreasing proliferation or as a marker of a cellular subpopulation that has a different 
progenitor status or capacity for proliferation.  To test the correlation between Sox9 and 
proliferation in non-injury conditions, we examined Sox9 and Ki67 expression in control 
postnatal mice in mature IHBDs (Figure 4.9). Previous work has demonstrated that during 
ductal plate morphogenesis, ductal plate cells that activate Sox9 expression do not proliferate 
despite the extremely high rates of proliferation in surrounding Sox9- hepatoblasts during 
embryonic development (Carpentier et al., 2011). At P3 and P15, proliferation, as marked by 
Ki67 expression, is observed within IHBDs. Interestingly, the cells that express Ki67 express 
relatively low or undetectable Sox9 protein as compared to the surrounding, non-proliferative 
BECs. This indicates that Sox9 correlates inversely within proliferating cells even in control, 
uninjured livers and in embryonic hepatoblasts (Carpentier et al., 2011), hepatocytes, and 
BECs. From this data, we cannot discriminate whether low levels of Sox9 may demarcate a 
permanent subpopulation of BECs that maintain proliferative capacities and are therefore able 
to act as progenitors, or Sox9 expression may be downregulated transiently during the cell 
cycle. 
 
Sox9 is expressed surrounding nectrotic patches in multiple injury models. 
 
Although Sox9+CK19- and Sox9+Hnf4!+ cells were not normally found in PHx injury, rare Sox9+ 
cells that morphologically resemble hepatocytes surrounding the small number of necrotic 
patches in the liver (Figure 4.10A). This was also observed in RRV-injected livers (Figure 
4.10B). The necrotic patches in both PHx and RRV injuries were in the middle of the 
parenchyma and not juxtaposing veins or bile ducts.  
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Conclusion 
 
Expression of Sox9 in hepatocytes may be regulated by spatially-restricted signals or zones of 
competence. 
 
Previous work has demonstrated that only specific zones of hepatoblasts and hepatocytes in 
mouse liver are competent to respond autonomously to Notch overactivation and to adopt a 
BEC fate (Jeliazkova et al., 2013; Sparks et al., 2010; Yanger et al., 2013). The cells that were 
competent to respond to Notch activation were found within hepatocyte zones 1 and 2, including 
the periportal and intermediate range hepatocytes, but not within zone 3, which is comprised of 
pericentral hepatocytes. This data aligns with the spatial restrictions of Sox9 expression 
observed in this study. In BDL, the injury model with the most widespread activation of Sox9, a 
very high number of cells turn on Sox9 but the spatial pattern of Sox9 is restricted; Sox9 is only 
expressed around portal tracts and in bridging tracts between portal tracts, leaving many areas 
devoid of any Sox9+ cells (Figure 4.5). 
 
This pattern may be the result of two possible causes: 1. Specific zones of hepatocytes may be 
competent and non-competent to respond to injury-derived signals and express Sox9, or 2. 
Specific signals that activate Sox9 expression may be spatially restricted and only reach 
hepatocytes within a certain distance of portal tracts. The second possibility may indicate that a 
specific protein signal is involved in the injury response and may derive from cells within the 
periportal regions, such as periportal mesenchyme or infiltrating immune cells.  
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Sox9+Hnf4!+ cells do not represent highly proliferative amplifying progenitors.  
 
The finding that very few Sox9+ cells that morphologically resemble hepatocytes are active in 
the cell cycle suggests that these cells do not constitute a population of transit rapidly amplifying 
progenitor cells. In both BDL (Figure 4.7) and DDC (Figure 4.8) injury models, Sox9+ 
hepatocytes cells display very low proliferation, consistent with direct lineage conversion instead 
of amplification of a progenitor.  
 
The additional finding that Sox9 negatively correlates with the proliferative status of BECs in 
control animals indicates that the expression of Sox9 in non-proliferative hepatocytes may not 
be arbitrary; Sox9 may mark subpopulations of both hepatocytes and BECs, or hepatic 
progenitors, which have a lower proliferative capacity or some type of progenitor characteristic. 
Alternately, Sox9 may somehow directly or indirectly impede proliferation and may be transiently 
downregulated in cells undergoing proliferation. 
 
Studies of Sox9’s role in differentiation and proliferation in the liver and in other organs have 
yielded conflicting results (Delous et al., 2012; Ramalingam et al., 2012; Seymour et al., 2007). 
Both positive and negative correlations between Sox9 expression and patient tumor grade and 
survival have been found in gastroenterological tumors (Abdel-Samad et al., 2011; Guo et al., 
2012; Mazur et al., 2012).  In a recent study, an HPC population capable of clonal expansion 
and bipotential differentiation was found to be enriched for Sox9 expression (Dorrell et al., 
2011). However, only 1 in 34 cells within this population had clonal expansion capacity; our 
findings would suggest that the uncommon proliferative progenitors may, in fact, be cells with 
low or absent Sox9 expression within the population. 
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The prevalence and expression pattern of Sox9 in response to liver injury varies between 
different human liver diseases and rodent liver injury models. 
 
This study finds that Sox9 expression in Hnf4!+ and CK19- cells occurs, but to different extents, 
in four different human cholestatic liver diseases, and in the mouse BDL and DDC injury 
models. This phenomenon is not a general liver injury response, as Sox9+CK19- and 
Sox9+Hnf4!+ cells are absent from PHx and 2-AAF/PHx rodent injury models.  
 
The variation in both human and rodent liver injuries could represent different mechanisms of 
injury and/or regeneration. Hepatocyte-to-BEC conversion has been previously suggested in 
human liver disease based on immunohistochemistry and demonstrated with lineage tracing in 
rodent liver injury models. We hypothesize, based on this and published studies, that the 
expression of Sox9 in hepatocytes marks cells undergoing the process of interlineage 
conversion. If this is so, these cells may only appear in situations where hepatocyte-to-BEC 
conversion is required for recovery, namely injuries that damage BECs and where BEC 
proliferation is not sufficient to recover from the injury. This would be consistent with presence of 
Sox9+CK19- and Sox9+Hnf4!+ cells in BDL and DDC, where there is chronic cholestasis, but not 
in PHx, where proliferation alone is sufficient for recovery, or 2-AAF/PHx, where the primary 
injury is to the hepatocytes, not the BECs. 
 
Lineage tracing experiments have previously demonstrated that different rodent liver injury 
models have different responses in terms of hepatocyte-to-BEC or BEC-to-hepatocyte 
transdifferentiation (Español-Suñer et al., 2012; Yanger et al., 2013). However, the current few 
works on lineage-tracing hepatocytes or BECs under different injury conditions has provided 
some conflicting results on whether, and in what injury models, transdifferentiation occurs 
(Español-Suñer et al., 2012; Malato et al., 2011; Yanger et al., 2013). Despite contradictions 
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between studies in specific injury models, there are strong findings within studies that different 
injuries produce different cellular responses in terms of interlineage conversion, either 
hepatocyte-to-BEC or BEC-to hepatocyte (Español-Suñer et al., 2012; Yanger et al., 2013).  
 
Interestingly, in our BDL experimental paradigm, we find a large increase in the number of 
hepatocytes expressing Sox9, consistent with the idea that hepatocytes are undergoing a 
conversion into BECs. However, even at 21 days we see no evidence of a ductular reaction and 
the Sox9+ hepatocytes do not express CK19 (Figure 5).  While these cells may be undergoing a 
change in cell identity, we do not find any evidence suggesting that these cells do eventually 
complete the process of transdifferentiation and activate CK19 expression, specifically in the 
BDL model. 
 
This study supports the previously published findings that different injury models elicit different 
cellular responses and that hepatocytes can adopt BEC-like identities in response to certain 
injuries (Yanger et al., 2013). We add information regarding the expression of Sox9 in 
hepatocytes (CK19- and Hnf4!+) over the progressive response of multiple injury models. 
 
What remains unknown is how the expression of Sox9 correlates with disease progression, 
severity, and outcome in human patients. In both BDL and DDC injuries, the number of 
Sox9+CK19- and Sox9+Hnf4!+ cells were found to increase over time. Similarly, the expression 
of Sox9 in human liver disease could be used to assess disease progression or, similarly, extent 
of injury. Given that this study was performed on de-identified human tissue samples, the 
patient data is unknown. A thorough study of these human diseases tracking Sox9 expression 
over time in patients and correlating Sox9 expression with eventual disease outcome will be 
necessary in order to be able to use Sox9 as an informative disease marker.  
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As Sox9 has a potential role in defining intralineage cellular subpopulations it may have the 
potential to be used to promote progenitor cell or hepatocyte conversion toward a BEC fate in 
cholestatic diseases. Identifying the subpopulations marked by Sox9 and their specific 
properties and potentials for regeneration could inform future research on the specific cells with 
the highest therapeutic potential and serve as a regenerative marker in therapeutic testing in 
both rodents and humans. 
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CHAPTER 5 
 
VASCULAR AND EPITHELIAL MORPHOGENESIS IN THE LIVER IS DEPENDENT ON 
EPITHELIAL-DERIVED VEGF SIGNALING 
 
Introduction 
 
VEGF signaling is an essential mediator of vascular growth and behavior in both development 
and disease. In the liver, the secretion of VEGF from hepatocytes and cholangiocytes is 
believed to play an important role in liver protection and regeneration (Ishikawa et al., 1999; 
Mancinelli et al., 2009; Shimizu et al., 2001; Taniguchi et al., 2001) but to also promote the 
progression of liver tumors (Marschall et al., 2001; Moon et al., 2003; Park et al., 2000). This 
communication between hepatocytes, cholangiocytes, and endothelial cells via VEGF must be 
understood and regulated in a context-specific manner in order to harness the beneficial 
impacts of VEGF. 
 
The architecture of the hepatic vascular systems, including the portal vein (PV), hepatic artery 
(HA), and central vein (CV), are highly precise and stereotypic. It is unknown what signals 
regulate the architecture of these structures and whether signaling interactions between 
epithelial and endothelial tissues is crucial to generate the proper vascular patterning. Previous 
studies have suggested that an epithelial-endothelial VEGF signal from the intrahepatic bile duct 
(IHBD) is crucial for the development of the HA (Fabris et al., 2008; Morell et al., 2013). 
Interestingly, several human diseases also display correlated IHBD and vascular paucities, 
posing the question of how the epithelial and endothelial tissues may interact during 
development.  
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VEGF has previously been shown to be important for normal liver development during 
embryonic and early postnatal periods (Carpenter et al., 2005; Gerber et al., 1999). However, 
the studies conducted so far have utilized VEGF inhibition methods that ubiquitously block all 
VEGF signaling either globally in postnatal mice or specifically in the liver of embryonic mice. 
These methods inhibited the baseline level of signaling required for endothelial cell (EC) survival 
and homeostasis (Franco et al., 2011; Lee et al., 2007). It is unsurprising that these mice 
showed decreases in ECs. These studies also found reductions in vascular branching early in 
embryonic liver development, disorganized sinusoids, dismorphogenic liver sinusoidal 
endothelial cells (LSECs) and hepatocytes, and reduced lipid uptake into hepatocytes 
(Carpenter et al., 2005; Gerber et al., 1999). Due to the extreme impact on ECs in these mouse 
models, the studies conducted thus far have been unable to assess the role of VEGF in the 
growth and architectural establishment of the PV and HA. 
 
In this study, we utilize a unique mouse model in which liver VEGF signaling is decreased but 
not completely deleted. We utilized a combination of the transgene Tg(Alb-cre)21Mgn and the 
Vegfatm2Gne allele, Albumin-Cre; Vegfflox/flox (hereafter referred to as VKO), to delete VEGF from 
hepatoblast, bipotential liver progenitor, beginning at mid-gestation. This results in both 
hepatocyte and cholangiocyte deletion of VEGF. The production of VEGF from non-epithelial 
cells types is not impaired by this genetic deletion. This mouse model allows us to specifically 
address the question of whether the hepatic epithelium drives the architectural establishment 
and growth of the PV and HA through VEGF signaling. 
 
We find that mice are able to survive for several weeks postnatally after mid-gestational deletion 
of VEGF from the hepatic epithelium, but do display abnormalities in both the epithelial and 
endothelial tissues. VKO mice show an initial reduction in endothelium in the liver, but recover 
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postnatally without concomitant elevation of hepatic or serum VEGF. However, these mice 
display a progressive impairment in the postnatal elaboration of the PV and HA and disruptions 
in the sinusoidal network and in LSEC identity. These changes correlate with hypoxia in the liver 
and to alterations in hepatic zonation and gene expression. 
 
We conclude that secretion of VEGF specifically from the hepatic epithelium is required for the 
postnatal architectural development of the liver vascular systems and for proper hepatic 
oxygenation and hepatocyte zonal fates. Additionally, epithelial VEGF is required to maintain 
LSEC identity and function and for the postnatal phase of PV and HA elaboration.  
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Results 
 
Hepatoblast-specific deletion of VEGF reduces total VEGF levels in the liver at embryonic and 
adult timepoints. 
 
To determine the extent of VEGF protein reduction in VKO mice, VEGF protein levels in whole 
liver were analyzed through an ELISA assay. In control mice, the total liver VEGF was highest 
at embryonic day (E)16.5 and was significantly decreased at each subsequent timepoint (Figure 
5.1). The levels of VEGF in the liver of VKO mice were significantly reduced as compared to 
control at all timepoints analyzed (Figure 5.1). VEGF protein in the VKO liver was reduced, as 
compared to control, 66.7% at E16.5, 36.3% at P3, 30.7% at P15, and 52.5% at P30. 
 
To determine whether the loss of VEGF in the liver could influence systemic VEGF levels, 
perhaps to compensate for the hepatic loss of VEGF or as a result of decreased VEGF 
secretion from the liver into the bloodstream, we also measured VEGF protein in the blood 
serum. Similar to the pattern in the liver, serum VEGF protein in control mice was highest at the 
first timepoint measured, P3, and was significantly decreased at P15 and P30 (Figure 5.2). At 
P3 and P15, no change in serum VEGF protein levels between control and VKO mice. At P30, 
VKO mice exhibited a significant decrease in serum VEGF protein levels as compared to 
controls (Figure 5.2).  
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VKO mice display global phenotypes, including reduced body mass and indicators of 
hypertension. 
 
To determine the global effect of the hepatoblast-specific loss of VEGF on mice, we allowed 
mice to age until P60 and measured body, liver, and spleen mass at several postnatal 
timepoints. Several VKO mice display poor health and lethality between P30 and P60. While 
some VKO mice have comparable body masses to their littermate controls, there was a 
significant decrease in body mass between sex-matched control and VKO mice at P30, P45, 
and P60 (Figure 5.3). Due to the high rate of lethality before P60, we only analyzed one female 
VKO mouse that exhibited a lower body mass than all P60 control females. 
 
VKO mice at P30 and older timepoints displayed an obvious and consistent phenotype of 
peritoneal verices (data not shown). Blood vessels around the abdominal organs, including the 
stomach, intestine, and pancreas were enlarged. Occasionally, this phenotype was 
accompanied by death of the gut and/or a pink-toned pancreas, indicative of blood retention in 
the organ. Combined, these phenotypes can be indicative of hypertension. 
 
To assess hypertension in VKO mice, we utilized the surrogate measurement of splenomegaly. 
At P30, P45, and P60, VKO mice displayed splenomegaly, having a significantly increased 
spleen:body mass ratio (Figure 5.3). This suggests that there is hypertension in VKO mice P30 
and older. No differences in body mass or spleen:body mass ratio were observed in VKO mice 
P15 or younger (data not shown). 
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Due to the enlarged abdominal blood vessels and a difficulty in extracting serum from blood 
from VKO mice, we examined whether there were any changes in the circulating blood cell 
populations (Figure 5.4). We first looked at P60, when mice are visibly sick, but due to the high 
lethality prior to P60, we did not collect enough mice to perform statistical analysis. The one P60 
VKO mouse analyzed displayed a large increase in hematocrit, explaining the phenotype of 
thickened blood with reduced serum. We also analyzed mice at P30 and found a smaller but 
significant increase in hematocrit in VKO over controls at that time. The increase in hematocrit is 
similar to that found in Tam et al. (2006). In the aforementioned study, inhibiting VEGF 
systemically or specifically in the liver caused an upregulation of hepatocyte-produced 
erythropoietin, leading to increased hematocrit in a matter of weeks in adult mice. Our 
phenotype of elevated hematocrit in adult VKO mice is consistent with this previously published 
report. 
 
P30 VKO mice displayed an increase in the number of circulating red blood cells and 
neutrophils (Figure 5.5). No other hematopoietic cell populations were significantly changed at 
P30. 
 
VKO mice have altered liver morphology, health, and function by P30. 
  
To assess the health and function of the liver, we performed blood serum measurements for 
alanine aminotransferase (ALT), total bile acids (BA), and total bilirubin (TB) in P30 control and 
VKO mice (Figure 5.6). In P30 VKO mice, ALT and BA were consistently and significantly 
increased over control littermates. Levels of TB were inconsistent in P30 VKO mice, with some 
mice having normal or near-normal levels of TB and some mice displaying a mild but abnormal 
increase in TB. The increase in TB in P30 VKO mice over controls was statistically significant. 
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With the serum tests providing evidence that liver health and function was impaired (Figure 5.6), 
we assessed whether VKO mice displayed any changes in liver morphology. We assessed liver 
histopathology by hematoxylin and eosin (H&E) staining (Figure 5.7). The H&E stain did not 
reveal any differences in liver morphology between control and VKO mice at P3 (Figure 5.7A-B). 
However some differences in hepatocyte cord morphology were observed at P15 (Figure 5.7C-
D) and by P30, VKO mice displayed small areas of focal necrosis (white arrows) and dilated 
sinusoids (white arrowheads) (Figure 5.7E-F). 
 
To examine the zonation of hepatocytes, we assessed the expression of the zone-specific 
hepatocyte enzymes glutamine synthetase  (Figures 5.8, 5.9) and carbamoyl phosphate 
synthetase 1 (CPS1) (Figure 5.9). GS and CPS1 are enzymes involved in glutamine formation 
and urea formation, respectively, in hepatocytes (Jungermann and Keitzmann, 1996). GS 
expression in both VKO and control mice was observed in its normal location, in the 
hepatocytes surrounding central veins (Figure 5.8). However, the expression region of GS was 
abnormally expanded in VKO mice; at P15, there was a slight increase in the area of expression 
in the pericentral zone, and at P30, GS expression was observed in large clusters of 
hepatocytes not surrounding a CV (Figure 5.8). 
 
In control adult mouse livers, GS and CPS1 expression is mutually exclusive, with GS 
expressed only in pericentral hepatocytes and CPS1 expressed in periportal and intermediate 
hepatocytes (Figure 5.9). In P15 VKO mice, in line with the expansion of GS expression, there 
are a small number of hepatocytes present that co-express GS and CPS1 (Figure 5.9, 
arrowheads). At P30, the number of GS and CPS1 co-expressing cells has visually increased, 
and these cells are found both juxtaposing central veins and  
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in the abnormal GS-expression hepatocyte clusters that do not juxtapose central veins (Figure 
5.9). This altered gene expression indicates a loss of zonation and a disruption in zone-specific 
hepatocyte identity. 
 
VKO mice display hypoxia in the liver by P15. 
 
In the consideration that a liver morphogenesis phenotype is already apparent by P30, and 
increasing hematocrit after P30 may cause secondary effects confounding the immediate role of 
VEGF in liver development, we hereafter focus on P30 and earlier timepoints. Hepatocyte 
zonation has been hypothesized to result, at least in part, from the steep gradient in blood 
oxygen pressure across the hepatic lobule (Colnot and Perret, 2011). This hypothesis is 
consistent with our experimental model, in which we reduce expression of a known angiogenic 
factor. To determine if hypoxia may be playing a causative role in the altered zonal identity of 
hepatocytes, we used Hypoxyprobe to visualize regions of hypoxia in the livers of P15 and P30 
VKO and control mice (Figure 5.10). Hypoxyprobe (pimonidazole) binds peptide thiols in 
hypoxic cells where it competes with oxygen for electrons for activation. The activated form of 
pimonidazole can be detected in tissue by a specific antibody, thereby identifying regions of low 
oxygen tension. 
 
In control mice, hypoxia is faintly apparent in a zonal pattern, specifically around central veins 
marked by GS expression, at P15 and P30 (Figure 5.10B,F). In VKO mice, however, there is a 
visual increase in the area of hypoxia over controls at both P15 and P30 (Figure 5.10D,H). This 
indicates that the VKO mice do have abnormally hypoxic livers, which may be contributing to the 
observed altered hepatocyte zonal identities.  
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To assess whether regions of hypoxia correlate with the areas of expanded GS expression, 
serial liver sections were stained for GS and Hypoxyprobe (Figure 5.10). In P15 and P30 
controls, the areas of GS expression very closely lined up with the areas of faint Hypoxyprobe 
staining (Figure 5.10A-B, E-F). In P15 VKO livers, hypoxia is very disperse through the tissue, 
but the regions of GS staining do still correlate with the darkest Hypoxyprobe staining (Figure 
5.10C-D). In P30 livers, hypoxia is observed in areas of expanded GS staining; however, there 
is not a complete overlap between GS and Hypoxyprobe staining (Figure 5.10G-H). Large areas 
of GS staining exist that are not positive or only weakly positive for Hypoxyprobe. Interestingly, 
the strongest Hypoxyprobe staining is frequently seen in cells on the border of a GS+ patch, or 
in the middle of a GS+ patch in cells that juxtapose GS staining but do not express GS 
themselves (Figure 5.10G-H).   
 
VKO mice display an embryonic decrease in endothelial-lineage cells. 
 
After determining that VKO mice did have a liver phenotype in which hypoxia is increased and 
hepatocyte zonal identities are altered, we examined the different vascular compartments to see 
if any were abnormal in VKO mice and could be responsible for the aforementioned liver 
phenotypes. We focused our examination on the portal vein, the hepatic artery, and the hepatic 
sinusoids. 
 
Previous reports have demonstrated that inhibiting VEGF signaling ubiquitously in the liver 
results in a reduction in the number of endothelial cells (Carpenter et al., 2005; Gerber et al., 
1999). To determine if there is a similar reduction in endothelial cell number when only 
epithelial-VEGF expression is reduced from a mid-gestational timepoint, we stained with 
IsolectinB4 (IsoB4) in embryonic and postnatal livers (Figure 5.11). At E16.5 in VKO mice, there 
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is a reduction in the number of cells that stain positive for IsoB4 as compared to control. 
However, this reduction is no longer observed at P3 or at P15. This indicates that although there 
was an initial defect in the number of IsoB4-expressing endothelial-lineage cells, the loss is able 
to be compensated for postnatally. 
 
VKO mice have reduced portal vein branching and branch diameters at P30. 
 
To determine whether epithelial-VEGF plays a role in portal vein branching, we analyzed the 
number of portal vein branches in P15 and P30 VKO and control mice. We analyzed both the 
number of PV branches per liver area as a measure of vessel density and the number of PV 
branches per transverse section as an assessment of the vessel architectural pattern 
independent of any consequent reductions in liver size. 
 
Between P15-P30, control mice exhibit an increase in the number of PVs/liver section but a 
decrease in the number of PVs/liver area. This indicates that new PV branches are being 
formed during this time, but the rate of PV branch addition is relatively less than the rate of liver 
growth. At P15, there is no observable decrease in PVs/liver section or PVs/liver area in VKO 
mice as compared to control. However, there is a reduction in both PVs/liver section and in 
PVs/liver area in P30 VKO mice as compared to controls (Figure 5.12). 
 
To assess whether the size of the portal vein branches were affected in the VKO mouse liver, 
we generated 3-dimensional resin casts of the left lobe portal vein in P30 control and VKO mice 
(Figure 5.13). We examined three stereotypic branch points, which we labeled A, B, and C 
(Figure 5.13A) and measured the PV diameter on each of the two  
130 
131 
132 
 
133 
 
134 
 
branches generated from each branch point: A’, A”, B’, B”, C’, and C” (Figure 5.13B). At 5 of the 
6 locations assessed (A’, A”, B’, B”, and C”), the VKO mice displayed significantly smaller PV 
diameters than the control mice (Figure 5.13C). At one location (C’), no significant difference 
was observed between VKO and control mice (Figure 5.13C). This suggests that, in addition to 
having fewer PV branches, the P30 VKO mice also have narrower PV branches than control 
mice. 
 
VKO mice have reduced hepatic artery branching at P15 and P30. 
 
To determine whether epithelial-VEGF is required for hepatic artery branching, we assessed HA 
branches as normalized to liver tissue area and per liver section, the same way the PV 
branches were analyzed. 
 
Similar to the PV, we found that in control mice between P15 and P30, the number of HA 
branches/liver area decreases. This indicates that, similarly to the PV, the rate of HA branch 
addition is less than that of liver parenchymal expansion (Figure 5.14). In VKO mice as 
compared to controls, there were fewer HAs/liver area and HAs/liver section at P15 and P30. 
 
VKO mice demonstrate a loss of LSEC identity. 
 
To determine whether epithelial-VEGF plays a role in the development of the sinusoid network, 
we assessed the expression of endothelial markers in the liver. First, we analyzed the 
expression of endomucin in P15 and P30 VKO and control mouse livers. In control livers at P15 
and P30, the expression of endomucin is not uniform over all hepatic endothelial cells: 
endomucin is expressed in the endothelium of the HA, the CV,  
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and the pericentral sinusoids (Figure 5.15). No endomucin expression is observed in the 
endothelium of the PV or periportal sinusoids. In P15 VKO mice, a slight expansion of 
endomucin expression is observed as compared to controls. By P30, however, the pattern of 
endomucin in P30 VKO is highly abnormal (Figure 5.15). The restriction of expression within the 
hepatic zones is lost and endomucin is now observed in the periportal sinusoidal endothelium. 
Additionally, the concentration of endomucin+ cells is decreased in the regions of pericentral 
hepatocytes, with additional hepatocyte cords between the endomucin+ sinusoidal endothelium. 
 
To assess the differentiated identity of the LSECs, we assessed expression of PECAM. 
Normally, PECAM is not expressed in LSECs in adult mice. At P3, both PECAM (Figure 5.16) 
and endomucin (Figure 5.16 and 5.15) were expressed only within venous endothelium in 
control and VKO mice. In P15 controls, PECAM is expressed primarily in venous endothelium 
and in some sinusoidal endothelium that co-expresses endomucin (Figure 5.16C). In P15 VKO 
mice, PECAM is not only expressed in venous endothelium, but the expression of PECAM is 
also expanded to a greater number of sinusoid endothelial cells (Figure 5.16D). As previously 
noted, the expression of endomucin is slightly expanded in sinusoids in the P15 VKO liver as 
compared to control (Figure 5.15), and the pattern of PECAM shows a similar effect (Figure 
5.16D). By P30, the expression of PECAM is highly restricted in control mice: PECAM is 
expressed within the portal vein and central vein endothelium, but not within the sinusoidal 
endothelium (Figure 5.16E). In contrast, PECAM is expressed not only in venous endothelium, 
but is also very highly associated with the sinusoidal endothelium in P30 VKO mice (Figure 
5.16F). There does not seem to be any zonal or regional restrictions to PECAM expression 
within the sinusoidal endothelium. The expression of PECAM within LSECs indicates that these 
cells have lost features of their sinusoidal identity. Oftentimes this is correlated with a  
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decrease in fenestration and a reduction in in vivo function of particle transport (Carpenter et al., 
2005; Mitchell et al., 2011). The loss of sinusoidal identity in the VKO mice may be indicative of 
“capillarization.” 
142 
Conclusion 
 
VEGF levels differentially affect the PV, HA, and sinusoids. 
 
The VKO displays alterations in PV, HA, and sinusoids as compared to control, but the 
abnormal phenotypes appear in the different vascular tissues at different times. VKO mice 
display alterations in IsolectinB4+ endothelial-lineage cells as early as E16.5 but that recover by 
P3. HAs and LSECs show abnormal phenotypes by P15 that persist at P30, and PVs show 
abnormal phenotypes at P30. Similarly, hepatocytes show abnormalities that are subtle at P15 
and become more pronounced by P30. 
 
There are multiple possible explanations for these abnormalities. First, it may be that there are 
different required levels of VEGF for each vascular tissue. As the levels of VEGF decrease over 
development in VKO mice, it may be that the absolute hepatic VEGF levels drop below the 
required level for HA development and LSEC identity sooner than they drop below the level 
required for PV morphogenesis. This explanation fits with the known role for VEGF in arterial-
venous differentiation (Swift and Weinstein, 2009); high levels of VEGF promote arterial fates 
while ECs not receiving high VEGF signaling adopt a venous fate.   
 
A second explanation is that the different vessels rely primarily on VEGF derived from different 
tissues. Perhaps the PV receives the majority of its VEGF signal from the mesenchyme, while 
the sinusoids depend on VEGF from hepatocytes and the HA is directed by VEGF secreted 
from the IHBD. These alternate potential sources of VEGF could also contribute to the levels of 
VEGF that are normally received by each vascular tissue and that are required for normal 
development and function. 
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Third, it may be that VEGF serves a different function for the different vascular tissues based on 
the identity and specific mode of development of each tissue. VEGF has been described as 
having roles in endothelial proliferation, differentiation, branching morphogenesis, cell survival, 
and vascular permeability (Carpenter et al., 2005; Connolly et al., 1989; Gerber et al., 2002; 
Gerhardt et al., 2003; Krueger et al., 2011; Lee et al., 2007; Leung et al., 2013). The main role 
of VEGF may be different in the different endothelium, or may change at different stages of 
development. Based on our results, it is not possible to distinguish between these possibilities. 
 
Loss of epithelial-VEGF results in an inability to generate PV branches during postnatal growth. 
 
Between P15 and P30, control mice decrease the number of PVs per liver area, but increase 
the number of PV branches per section (Figure 5.12). This indicates that the PV system is 
expanding and adding new vessel branches, but it is doing so at a rate that is slower than the 
overall expansion of the liver parenchymal mass and area. 
 
VKO mice do not exhibit a similar addition of new PV branches during this period and instead 
actually exhibit a loss of PV branches in section (Figure 5.12). This may indicate that the PV 
branches formed prior to P15 are not maintained in the VKO model. Alternatively, it may be that 
the decrease in isolectin+ ECs initially observed at E16.5 (Figure 5.11) indicates a failure to 
produce enough venous endothelial progenitors, limiting the elaboration of the PV system past 
P15. While the average number of HA branches per liver section also decreases in VKO mice 
over time, this decrease is not significant (Figure 5.14). Hence, the failure to maintain branches 
may illuminate a unique role for epithelial VEGF in the homeostasis of the PV. 
 
We also observed a decrease in PV cast diameter in several stereotypic branch locations in the 
P30 VKO mice as compared to control (Figure 5.13C). Due to technical limitations, PV casts 
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were not generated at P15. The decrease in PV branches in P30 VKO mice may be due to a 
decrease in ECs that first has an effect on PV diameter and is only later manifested as a 
reduction in PV branches.  
 
LSECs undergo capillarization in vivo as a result of lost epithelial-VEGF signaling 
 
“Capillarization” is the loss of LSEC-specific features and involves a reduction in fenestrae, a 
reduction in scavenger behavior, formation of an organized basement membrane, and an 
upregulation of PECAM (DeLeve et al., 2004). This process is seen in vivo in the liver during 
cirrhosis and as a result of aging. In vitro, if LSECs are not either treated with VEGF or co-
cultured with a cell type that produces VEGF, LSECs undergo capillarization, displaying 
reduced fenestrae and increased PECAM expression (DeLeve et al., 2004; Le Couteur et al., 
2001; Yokomori et al., 2003). 
 
In agreement with in vitro studies, the decrease in VEGF protein in the VKO liver results in the 
capillarization of LSECs. In P15 and P30 control mice, PECAM expression is restricted to the 
major vessels and excluded from the LSECs. However, in VKO mice, the LSECs express high 
levels of PECAM at P15 and P30 (Figure 5.16). Our data, along with the previous studies in 
culture, suggest that the LSECs in VKO mice lose their specialized LSEC identity and may have 
reduced function in vivo. 
 
The capillarization process is believed to result in decreased function of the LSECs and can 
impede the transfer of both oxygen and particles between the blood stream and the hepatocytes 
(Le Couteur et al., 2001; Mitchell et al., 2011). This may be account, at least partially, for the 
observed hypoxia and the decreased liver function as seen in serum tests. 
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Hypoxia may occur as a result of HA paucity or LSEC capillarization. 
 
By P15, VKO mice display a substantial increase in hypoxia in the liver as compared to controls 
(Figure 5.8). At this time, there are alterations observed in both the HA and the sinusoids that 
could contribute to the hypoxic phenotype (Figure 5.14 and 5.16). 
 
Previous studies have indicated that capillarization and the loss of LSEC-specific 
characteristics, such as fenestration, correlates with changes in high energy phosphates and 
other metabolites in hepatocytes and a decreased ability to perform oxygen-dependent drug 
metabolism, consistent with a decrease in oxygen availability (Le Couteur et al., 2001). It may 
be that the LSECs in the VKO liver have a decreased capacity for the transfer of oxygen to 
hepatocytes, contributing to hypoxia in the parenchyma. 
 
Alternately, the decrease in HA branches provides a simple explanation for the decrease of 
oxygen in the liver parenchyma. The blood supplied to the liver by the HA has a much higher 
oxygen tension than that supplied by the PV, indicating that a reduction in HA input into the liver 
or HA density could have a large effect on the oxygenation of the blood in the liver (Tygstrup et 
al., 1962). The reduction in both HAs per liver area and per liver section provides an simple 
explanation for the increased liver hypoxia observed in the VKO mice, especially as recent 
studies have been unable to find a definitive link between LSEC capillarization and hepatocyte 
hypoxia (Cheluvappa et al., 2007). 
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Hepatocyte zonation is tied to hypoxia, but hypoxia does not account for defects in VKO 
hepatocyte zonation. 
 
While the regions of expanded GS expression are closely associated with hypoxia, 
Hypoxyprobe and GS expression do not always necessarily overlap (Figure 5.10). Instead, the 
two tend to frequently be juxtaposed in P30 VKO mice (Figure 5.10G-H). This indicates that 
hypoxia likely does not directly control GS expression in a cell-autonomous way. However, due 
to the close spatial association between GS and Hypoxyprobe, it remains likely that the two are 
connected and that hypoxia does play a role in the GS expression expansion and zonation 
abnormalities. 
 
There are several potential explanations for the increased GS expression observed in P30 VKO 
mice, including: 1. VEGF may play a direct role on restricting GS expression in periportal 
hepatocytes; 2. The altered vasculature may be signaling abnormally to hepatocytes, resulting 
in hepatocyte zonal fate changes; 3. The hypoxia may be regulating GS expression in a non-
cell-autonomous way by designating a boundary between GS+ and GS- hepatocytes; 4. The 
immature hepatocyte structure, resulting from lack of epithelial-endothelial signaling or reduced 
oxygen levels, may make hepatocytes less competent to signal to each other and establish a 
zonal boundary. There are no highly relevant published studies supporting any of these 
possibilities, so the explanation remains unclear. Interestingly, however, VEGF and GS 
expression are both frequently upregulated in cirrhosis and hepatocellular carcinoma 
(D'Ambrosio et al., 2012; Kwon et al., 2012; Lee et al., 2013). This provides some support 
against the idea that VEGF is a direct negative regulator of GS in hepatocytes. 
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Hnf4! and Wnt/"-catenin signaling have been found to regulate the expression of GS 
(CADORET et al., 2002). It is possible that these signaling pathways are affected by the hypoxia 
in the liver, resulting in abnormal inter-hepatocyte signaling and zonal boundaries. 
 
One surprising finding is that hypoxia very closely overlaps with GS expression in postnatal 
control livers, but does not in the expanded GS+ regions of the P30 VKO liver. This suggests 
that there is a different mechanism of GS regulation that emerges in the P30 VKO mice and 
differs from the normal mechanism of GS regulation in postnatal liver. 
 
Influence of epithelial-VEGF provides insightful information for the use of antiangiogenic agents 
in the treatment of liver disease. 
 
An upregulation of VEGF is observed in liver diseases, including hepatocellular carcinoma 
(Fabris et al., 2006; Marschall et al., 2001; Moon et al., 2003; Park et al., 2000). There are 
several VEGF inhibitor drugs approved by the FDA for the treatment of specific types of 
cancers; however, the use of VEGF inhibitors has been shown to have negative side effects in 
both pre-clinical and clinical studies (Kamba and McDonald, 2007). Global side effects include 
EC apoptosis and capillary regression, reduction in EC fenestrations, hypertension, 
hemorrhage, and thrombosis (Kamba and McDonald, 2007). The current study supports the 
finding that reducing hepatic VEGF levels can result in vascular regression, and specifically in 
the liver, we find impaired growth of the HA and PV as well as failure to maintain PV branches. 
We also add to this knowledge by demonstrating that reducing VEGF levels in the liver can 
have effects on hepatocyte zonal identity and LSEC identity. Importantly, this study does not 
use the complete blockage of VEGF, so we avoid disrupting the homeostasis of ECs. Use of 
this experimental model also allows us to distinguish that disruptions in the liver epithelial and 
endothelial tissues does not require a complete blockage of VEGF signaling, but can instead 
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occur when VEGF is simply at lower levels than normal. This suggests that dosage will be very 
important to minimize side effects on the liver in any VEGF inhibitor treatment.   
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CHAPTER 6 
 
SUMMARY AND FUTURE DIRECTIONS 
 
Intercellular Signaling in Development and Disease 
 
Signals involved in BEC differentiation 
 
Notch signaling is known to be highly important for the process of IHBD formation through 
ductal plate morphogenesis (Geisler et al., 2008; Hofmann et al., 2010; Jeliazkova et al., 2013; 
Kodama et al., 2004; Lozier et al., 2008a; Sparks et al., 2010; Tanimizu and Miyajima, 2004; 
Zong et al., 2009). Similarly, Notch signaling has been implicated as playing a role in 
hepatocyte-to-BEC conversion in the adult mouse liver (Fan et al., 2012; Jeliazkova et al., 2013; 
Yanger et al., 2013). However, the work demonstrated in Chapter 3 of this dissertation 
demonstrates that Notch is not required for the hepatocyte-to-BEC conversion. Additionally, 
based on the regeneration of BECs in the DKO mouse and the liver phenotypes of mice with 
impaired Notch signaling during ductal plate morphogenesis, it is clear that signals other than 
Notch are important contributors to BEC differentiation during both ductal plate morphogenesis 
and hepatocyte-to-BEC conversion. During ductal plate morphogenesis, disruption in Notch 
signaling impairs the remodeling of the ductal plate, but does not completely prevent the initial 
specification of ductal plate BECs. This phenotype is consistently found in a number of mouse 
models targeting different Notch pathway components (Hofmann et al., 2010; Kodama et al., 
2004; Lozier et al., 2008b; Sparks et al., 2010). These studies suggest that Notch signaling, 
while necessary for the remodeling of the ductal plate into a mature IHBD, is not required for the 
specification of BECs and the activation of biliary genes such as Sox9 and cytokeratin19 
(CK19). Thus, Notch does not act in isolation during ductal plate morphogenesis, nor is it 
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required for activation of BEC genes expressed in the ductal plate, such as Sox9 and 
cytokeratin. 
 
The differentiation of BECs in the DKO mouse model deficient for Notch signaling confirms the 
idea that Notch signaling is not absolutely required for the differentiation of BECs. In the DKO 
mouse model, cells are able to activate Sox9 expression and, subsequently, CK19 expression 
while expressing no Rbpj protein (Figures 3.5, 3.7, 3.8).  
 
The identification of signals that can induce BEC differentiation and IHBD regeneration, either 
independently or in collaboration with Notch signaling, could be useful for the treatment of IHBD 
insufficiency diseases. One pediatric IHBD insufficiency disease, Alagille syndrome, is caused 
by genetic disruptions in Notch signaling components; due to the genetic etiology of this 
disease, therapies targeting Notch signaling would not be helpful to promote BEC differentiation 
in Alagille syndrome patients. Notch signaling may also have limited potential as a therapeutic in 
other cholestatic diseases due to its demonstrated contribution to the generation of 
cholangiocarcinoma from hepatocytes in a mouse model (Fan et al., 2012; Sekiya and Suzuki, 
2012) and the association between Notch signaling and poor prognosis observed in some 
studies of human hepatocellular carcinoma (Ahn S, 2013; Zhou et al., 2013). 
 
Together, these findings indicate that there must be other pathways that are involved in normal 
ductal plate morphogenesis and are capable of overcoming the absence of Notch signaling 
during IHBD regeneration. The identity of this signal(s) is unknown. However, it is likely that 
Sox9 may play an important role in mediating and promoting the hepatocyte-to-BEC conversion 
process based on its known role controlling the timing of ductal plate morphogenesis and its 
expression early in the hepatocyte-to-BEC conversion process. It is likely that the proximal 
factors driving hepatocyte-to-BEC promote the upregulation of Sox9.  Several candidate factors 
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are found based on molecules known to be upreguated in liver disease or with a known ability to 
regulate Sox9 expression. 
 
An important future direction of this project will be to identify the signaling pathways that direct 
BEC differentiation and IHBD regeneration in the DKO mouse. In order to do this, molecular 
profiling could be done to identify pathways that are differentially activated and suppressed 
between cells that are at different stages along the hepatocyte-to-BEC conversion process in 
the P30 DKO mouse liver, including Sox9- normal hepatocytes, Sox9+ hepatocytes, CK19+ 
peripheral BECs, and CK19+ mature BECs in hilar IHBDs. Targeting the P30 timepoint would 
provide the ability to look for gene expression differences that occur between Sox9+ and Sox9- 
hepatocytes, at the first stage of hepatocyte-to-BEC conversion, and then in CK19+ peripheral 
BECs at the second stage of conversion. These cells would presumably still have a gene 
expression profile that reflects the signals activation of the signaling pathways that drove their 
recent differentiation. The molecular differences between these CK19+ BECs and the 
surrounding Sox9+ hepatocytes would hopefully reveal the factor that is able to induce cells to 
activate CK19 and complete the process of hepatocyte-to-BEC conversion. 
 
The role of Sox9 in hepatocyte-to-BEC conversion and liver regeneration 
 
The expression of Sox9 seems to be an important feature of the hepatic response to cholestatic 
injury and the hepatocyte-to-BEC conversion process, as the expression of Sox9 in hepatocytes 
is observed in multiple cholestatic mouse and human liver injuries (Figures 3.5, 3.7, 3.8, 4.1, 
4.3) (Yanger et al., 2013). What we cannot address at this time is what the functional 
significance of Sox9 expression is within the injured livers. 
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The function of Sox9 during hepatocyte-to-BEC conversion can, however, be hypothesized 
based on known interactions between Sox9 and other molecules in the liver and its 
demonstrated functional roles in the pancreas and intestine. 
 
A similar role of Sox9 in cell fate conversion has been observed in the pancreas. During acinar-
to-ductal metaplasia in the pancreas, pancreatic acinar cells covert to duct-like cells. These 
metaplastic cells can eventually lead to intraepithelial neoplasia and invasive pancreatic ductal 
adenocarcinoma. The role of Sox9 in this acinar-to-ductal cell conversion is illustrated by the 
finding that Sox9 expression is found in human metaplastic acinar cells in pancreatitis and 
pancreatic adenocarcinoma and that acinar-to-ductal metaplasia is severely inhibited in mouse 
models in the absence of Sox9 protein (Prevot et al., 2012). However, the overexpression of 
Sox9 in cultured cells was not sufficient to inhibit the expression of acinar genes or induce the 
expression of ductal genes (Prevot et al., 2012). These data suggest that Sox9 may play a 
central role in promoting conversion to ductal cell fates, both in the pancreas and the liver, but 
requires collaboration with other factors in order to induce the cell fate conversion. 
 
At this time, we are unable to definitively state whether Sox9 is required for the hepatocyte-to-
BEC conversion we see in DKO mouse livers and other liver injury models. In order to 
determine whether Sox9 is required of sufficient for hepatocyte-to-BEC conversion in the DKO 
adult mouse liver, studies inhibiting or overexpressing Sox9 would be required. To determine 
the requirement of Sox9 for hepatocyte-to-BEC conversion, a triple-knockout mouse model 
could be made where Sox9 is deleted within the hepatic epithelium in addition to Rbpj and Hnf6. 
Conversely, to determine whether Sox9 is sufficient to drive hepatocyte-to-BEC conversion, the 
overexpression of Sox9 specifically in adult mouse hepatocytes could be performed either with 
a genetic mouse model or by the introduction of Sox9 via an adenovirus into cultured 
hepatocytes. If Sox9 is sufficient to drive hepatocyte-to-BEC conversion, the transcriptional 
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analysis of cells undergoing that process could also provide useful information on the factors 
involved in the conversion process. 
 
In the embryonic and postnatal developing liver, as well in rodent liver injuries in the DKO 
mouse or in BDL or DDC injury, Sox9-expressing hepatocytes and BECs are not proliferative 
(Figures 3.14, 4.7, 4.8) (Carpentier et al., 2011). This is consistent with known roles for Sox9 in 
promoting differentiation while limiting proliferation in the intestine and lung (Bastide et al., 2007; 
Mori-Akiyama et al., 2007)(Rockich, 2013 #340). It seems likely that Sox9 is playing the same 
role in the liver. However, we are not yet able to address whether the inverse correlation 
between Sox9 and proliferation is due to a direct influence of Sox9 in regulating the cell cycle. It 
may alternatively be that Sox9 plays a direct role in cell differentiation, which then in turn 
reduces proliferation, or that Sox9 only denotes a population of cells which are simultaneously 
undergoing a cell fate change and a reduction in proliferation without having a direct effect on 
either process. To assess the direct role of Sox9 in influencing proliferation, it would be useful to 
perform chromatin immunoprecipitation studies to determine if Sox9 interacts with the enhancer 
regions of cell cycle genes. It would also be useful to delete and overexpress Sox9 in cultured 
cells, specifically primary hepatocytes or BECs, to determine if the amount of Sox9, 
independent of any other effects on DKO hepatocytes in vivo, is still correlated with the 
proliferation status of cells. 
 
If Sox9 is indeed playing a critical role in the hepatocyte-to-BEC conversion process, the 
molecules upstream and downstream of Sox9 are of interest in order to fully understand the 
mechanism of Notch- and Hnf6-independent BEC differentiation.  
 
Notch and Hnf6 have both been demonstrated to regulate the expression of Sox9 in several 
organs (Figure 6.1) (Chen et al., 2012; Clotman et al., 2002; Haller et al., 2012; Meier-Stiegen et 
154 
al., 2010; Muto et al., 2009). However, Sox9 is still able to be upregulated and expressed in the 
DKO liver in the absence of both Rbpj and Hnf6, demonstrating that alternate signaling 
pathways or stimuli are sufficient to induce Sox9 expression. One possibility explaining the 
continued expression of Sox9 is the possible upregulation of redundant or compensatory 
molecules to Rbpj and Hnf6. Despite the loss of Hnf6, the related family member Onecut2 
remains undeleted in the liver. It is possible that Onecut2 is able to compensate for the loss of 
Hnf6 in the DKO mouse (Figure 6.1). Furthermore, the transcription factor Hnf1" has been 
shown to be regulated downstream of Hnf6 and to be important for ductal plate morphogenesis 
(Coffinier et al., 2002). While we do not believe that Hnf1" is a crucial factor for the initiation of 
the hepatocyte-to-BEC conversion program, as it is not expressed in Sox9+ hepatocytes or in 
any CK19- cells in the liver, it may be that Hnf1" is important in the later stages of the 
hepatocyte-to-BEC conversion process to generate mature peripheral BECs and for remodeling 
into peripheral IHBDs (Figure 6.1). Hnf1" may reinforce Sox9 expression or work in conjunction 
with Sox9 to promote the complete differentiation of peripheral BECs (Figure 6.1). Although 
Rbpj is required for all canonical Notch signaling, we cannot at this time rule out that 
noncanonical Notch signaling is able to occur and may provide some compensation for the loss 
of Rbpj. 
 
 
There have also been findings that Sox9 can be regulated by other signaling pathways, namely 
Wnt (in the intestine), Fgf (in the pancreas), Shh (in the liver and esophagus) and hypoxia 
inducible factor (HIF) (in the bone) (Figure 6.1) (Blache et al., 2004; Mori-Akiyama et al., 2007; 
Seymour et al., 2012; Zhang et al., 2011). These signals are all candidates for the stimulus that 
is able to activate Sox9 expression in the DKO liver in the absence of Rbpj and Hnf6. 
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At this point in time, we do not believe that Wnt signaling is a promising candidate to activate 
Sox9 expression and drive hepatocyte-to-BEC conversion in the DKO mouse. This conclusion is 
based on recent findings that suggest that both canonical and non-canonical Wnt ligands 
(Wnt3a and Wnt5a, respectively) play an active role in suppressing biliary fates during 
embryonic development and liver regeneration (Boulter et al., 2012; Kiyohashi et al., 2013). 
Therefore, we do not hypothesize that Wnt plays a role in promoting biliary fates and activating 
Sox9 expression in the DKO mouse liver; however, we cannot exclude the possibility that Wnt 
may be involved in the hepatocyte-to-BEC process. HIF signaling has been found to regulate 
the expression of Sox9 in bone, providing yet another candidate factor to be involved in the 
expression of Sox9 in DKO mice (Zhang et al., 2011). However, this association has not been 
examined in the liver. Additionally, the relationship between Fgf and Sox9 has not yet been 
examined in the liver. Both pathways would be candidates for future testing to determine 
whether either pathway directly regulates the expression of Sox9.  
 
Additionally, there is evidence that Sonic hedgehog (Shh) may regulate the expression of Sox9 
in the liver and in the esophagus (Clemons et al., 2012; Pritchett et al., 2012). Interestingly, Shh 
expression has been found to increase after BDL, correlating with an expansion of BECs, and is 
believed to play a role in promoting BEC fates and ductular reactions (Omenetti et al., 2008). 
These data position Shh as an interesting candidate to drive hepatocyte-to-BEC morphogenesis 
and Sox9 expression in the DKO mice.  
 
To test for the necessity and sufficiency of Fgf, HIF, Wnt and Shh signaling pathways in the 
hepatocyte-to-BEC conversion process, first the expression of pathway components and 
downstream targets could be assayed in Sox9+ hepatocytes and peripheral BECs to determine 
if the pathway is active within the cells undergoing hepatocyte-to-BEC conversion. Additionally, 
a culture assay could be generated whereby isolated primary hepatocytes are treated with 
157 
agonists and antagonists of the candidate signaling pathways. The hepatocytes could be tested 
for expression of hepatocyte and BEC genes, such as Hnf4!, Sox9, and CK19, which has been 
demonstrated to change expression during the hepatocyte-to-BEC conversion process in vivo, 
to determine if the activation or repression of any signaling pathways, alone or in combination, is 
sufficient or necessary to promote a BEC-like gene expression profile in cultured primary 
hepatocytes. Pathways that demonstrate an influence over hepatocyte-to-BEC conversion in 
vitro could also be examined in vivo through the administration of pathway agonists or 
antagonists, or the genetic manipulation to delete or overexpress pathway components, in the 
background of the DKO mouse model. The inhibition of any pathways that are necessary for the 
hepatocyte-to-BEC conversion process will result in the failure to produce Sox9+ hepatocytes 
and/or the failure to generate CK19+ peripheral BECs at P30. 
 
Specific alleles that could be crossed into the DKO mouse model to test the necessity of each of 
these candidate pathways for hepatocyte-to-BEC conversion in vivo include: floxed Patched (to 
eliminate Shh signaling), floxed "-catenin (to eliminate canonical Wnt signaling), floxed Fgf 
receptor 1, 2, or 3 (to reduce Fgf signaling), and floxed HIF1! or HIF2! (to eliminated HIF 
signaling). 
 
It is possible that signaling pathways not discussed here may be involved in the hepatocyte-to-
BEC conversion process. In order to test a wider variety of pathways with less biased in the 
pwathways analyzed, the same in vitro approach could be utilized to perform a screen with a 
small molecule library. In this experiment, small molecules would be added to isolated primary 
hepatocytes in culture to determine their effect on the expression of hepatocyte and BEC 
markers. If any molecules are determined to promote a BEC-like cell fate within primary 
hepatocytes, the known effects of that small molecule on signaling pathways could be used to 
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identify previously unexplored candidate signals involved in the hepatocyte-to-BEC conversion 
process in vivo. 
 
In addition to what factors may be promoting Sox9 expression, it is also of interest what the role 
of Sox9 may be in driving hepatocyte-to-BEC conversion. Little is known about the downstream 
targets of Sox9 in the liver, but one molecule, osteopontin (Opn) has been shown to be directly 
transcriptionally regulated by Sox9 and to play a role in liver disease (Pritchett et al., 2012). 
Sox9 and Opn are co-localized in BECs during embryonic development and adult homeostasis 
in the mouse, and both genes are simultaneously increased and co-localized in rodent and 
human models of fibrosis (Pritchett et al., 2012). Sox9 binds a conserved enhancer region of the 
Opn gene, and the abrogation of Sox9 in the liver significantly decreased the production of Opn, 
demonstrating a direct link between the two molecules (Pritchett et al., 2012). Opn is a marker 
of BECs, and thus, the connection between Sox9 and Opn in the liver provides evidence that 
Sox9 may play an active role in upregulating BEC genes during the hepatocyte-to-BEC 
conversion process. 
 
The origin of BEC-promoting signals in liver injury situations 
 
In addition to what type of signal(s) is responsible for activating Sox9 and initiating the 
hepatocyte-to-BEC conversion program, it is also important to determine from whence this 
signal is arising, including the cell type involved and the spatial location in the tissue. If 
important signals are arising from a specific cell type, this would provide a potential target for 
pro-regenerative therapeutic interventions in cholestatic liver disease. 
 
In the DKO mouse model, Sox9+ intermediate cells first appear immediately surrounding 
necrotic lesions in the tissue (Figure 3.8). This finding presents the possibility that the 
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hepatocyte-to-BEC conversion in DKO mice is driven by a signal that is in some way associated 
with the necrosis. Previous studies have found that Wnt derived from macrophages is involved 
in cell fate decisions during chronic liver disease (Boulter et al., 2012); it may be that in DKO 
mice, immune cells that are attracted to and infiltrate focal necrotic regions release signals that 
drive Sox9 expression in hepatocytes and hepatocyte-to-BEC conversion. 
 
A possible signal derived from the disease state or immune response 
 
A remaining possibility in the question of what activates Sox9 expression is that the trigger for 
Sox9 expression may not be a secreted protein at all, but may be the disease state itself. The 
spatial expression of Sox9 around necrotic lesions may represent that an aspect of the disease 
state or immune response, which is associated with necrosis, could be promoting the 
expression of Sox9 in adjacent hepatocytes. Potential factors that could trigger the hepatocyte-
to-BEC conversion include the necrosis itself, hypoxia, or cholestasis and bile acid 
accumulation. 
 
While the presence of necrotic lesions clearly seems relevant to the activation of Sox9 in the 
DKO mouse, the presence of focal necrosis is not necessary for the expression of Sox9 in 
hepatocytes. Sox9 expression appears in hepatocytes in DDC and BDL liver injury models in 
locations where there is no focal necrosis (Figure 4.3). In these cases, it may be that the 
cholestatic phenotype, or necrotic signals derived from individual dying cells as opposed to 
large patches, is able to drive Sox9 expression. Alternatively, it may be that signals that can be 
associated with necrotic patches, such as secretions from immune cells, are simply deriving 
from other places or from a more diffuse immune infiltration in other types of liver injury. 
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Studies in rat have shown that VEGF expression is upregulated follow hepatic necrosis, 
providing another possible signal that may explain the spatial pattern of Sox9 expression 
(Ishikawa et al., 1999). In the injured mouse liver, VEGF receptor expression is detected in 
hepatocytes, but at much lower levels than it is expressed in LSECs (Yamane et al., 1994). 
There is no known direct connection between VEGF signaling and Sox9 expression.  
 
Hypoxia could directly influence gene expression in hepatocytes, as hepatocytes are able to 
sense oxygen tension. Sox9 is regulated downstream of hypoxia in the bone. Hepatocytes have 
a built-in mechanism for sensing hypoxia, and it is possible that regions of hypoxia associated 
with focal necrotic lesions are sufficient to trigger a response in hepatocytes. To determine the 
direct effect of oxygen tension on the expression of Sox9 in hepatocytes, primary hepatocytes 
could be cultured in a variety of atmospheric oxygen pressured and assayed for differential 
expression of Sox9. 
 
Another possibility is that the cholestatic disease state is responsible for driving Sox9 
expression. During cholestatic injuries, such as in the DKO mouse model, the back-up of bile 
acids may be sensed by hepatocytes and initiate the hepatocyte-to-BEC conversion response. If 
the presence of a cholestatic injury is sufficient to drive Sox9 expression, this would explain the 
differences in Sox9 expression between cholestatic and non-cholestatic liver injury models in 
rodents (Figures 4.2, 4.3). Similarly, cholestasis and bile acid build-up could be a signal that 
more BECs are needed, explaining the response of the hepatocytes to activate Sox9 and BEC 
genes under cholestatic injury conditions. To test if bile acids are capable of promoting Sox9 
expression in hepatocytes, a simple experiment could be performed where cultured hepatocytes 
are treated with exogenous bile acids to determine whether or not Sox9 becomes activated. 
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Comparing BEC-specification mechanisms in ductal plate morphogenesis and hepatocyte-to-
BEC conversion 
 
Ductal plate morphogenesis and hepatocyte-to-BEC conversion are similar in several ways: 
they both include the upregulation of Sox9 as one of the earliest steps in the BEC differentiation 
process, they both occur without proliferation of differentiation cells, the formation of cytokeratin-
expressing BECs is spatially restricted to portal areas within zone 1 in the liver, and they both 
occur less efficiently without Notch signaling (Sparks et al., 2010; Yanger et al., 2013). There 
are also many differences between the two processes. For example, peripheral ductal plate 
morphogenesis cannot occur in the combined absence of Rbpj and Hnf6, but hepatocyte-to-
BEC conversion can. Additionally, the BECs specified through ductal plate morphogenesis are 
restricted to immediately surrounding the PV, but during hepatocyte-to-BEC conversion, 
hepatocytes in any zone can activate Sox9, and the first Sox9 expression occurs surrounding 
necrotic lesions. In ductal plate morphogenesis, a mature IHBD is formed from two layers of 
ductal plate cells, but during hepatocyte-to-BEC morphogenesis, IHBDs are formed from 
remodeled ductular reactions. As the spatial location is so important for the signaling 
mechanism of ductal plate morphogenesis, and the spatial pattern of differentiation is different in 
hepatocyte-to-BEC conversion, it is likely that the differentiation mechanism is not completely 
conserved between the two processes. 
 
It is likely that, despite the differences in gene requirements and spatial mechanisms, similar 
intracellular signaling cascades downstream of Sox9 are activated in both ductal plate 
morphogenesis and hepatocyte-to-BEC morphogenesis. However, the immediate upstream 
signal may be different between the two processes. In ductal plate morphogenesis, the first 
signal initiating Sox9 expression likely is derived from a periportal tissue and may be from the 
portal vein endothelium or the portal vein mesenchyme. In hepatocyte-to-BEC conversion, 
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however, and specifically in the DKO mouse model, the first signal promoting Sox9 expression 
is not tied to the portal area and instead appears to originate from necrotic lesions. It is possible 
that the same signal is involved but is derived from two different areas in embryonic and 
postnatal livers. Such signals might include hypoxia, immune-secreted signals, or a number of 
secreted signaling molecules known to be present in the liver that have already been discussed. 
 
Regulation of Liver Zonation 
 
The architectural zonation of liver tissues 
 
Within the liver, zonation is found within both epithelial and endothelial tissues. With the 
endothelium, differences are apparent between the PV and CV as well as between the 
periportal and pericentral LSECs. It stands to reason that the differences between the PV and 
CV are important to restrict ductal plate morphogenesis. Otherwise, the origin and purpose of 
endothelial zonation is poorly understood. Within the epithelial tissues, there is a well-
established zonal difference in gene expression across the lobule in hepatocytes. The purpose 
of this zonation is believed to be to segregate multiple hepatocyte functions to specific cell 
populations, thus generating specific groups of specialized cells. Previous work has 
demonstrated that Wnt/"-catenin plays a role in regulated zonal gene expression in hepatocytes 
(Figure 6.2A); however, the source of differential Wnt signaling between the periportal and 
pericentral hepatocytes is not known. Another factors hypothesized to be involved in generating 
and maintaining zonation in hepatocytes in oxygen tension, which varies greatly along the axis 
of the lobule (Figure 6.2A). In addition to hepatocytes, IHBD branches also show a zonal 
architecture within the liver lobule, as they appear only next to PVs.  
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Factors regulating IHBD zonation 
 
The appearance of ductal plates during embryonic development is restricted to the periportal 
hepatocytes, indicating that either the signal inducing BEC specification is closely spatially 
regulated, and/or that only the periportal hepatoblasts are competent to respond to the signal 
that promotes BEC specification. Despite the widespread activation of Sox9 in hepatocytes 
throughout the parenchyma of the P30 DKO mouse (Figure 3.7), the expression of CK19 is only 
activated in periportal areas, and peripheral IHBDs only regenerate next to PVs. In a variety of 
injury models, ductular reactions are spatially restricted to the periportal areas and to the portal 
bridges, the areas that bridge the portal tracts along the periphery of the hepatic lobule. This 
spatial restriction is apparent in the location of reactive ductules in the P60 DKO mouse (Figure 
3.6), and, interestingly, also in the expression of Sox9 in hepatocytes in the livers of mice 
subjected to BDL (Figure 4.5). Even in mouse models where activated Notch is overexpressed 
in all hepatoblasts or hepatocytes, conversion of hepatocytes into BEC only occurs in zone 1 
and zone 2 hepatocytes; zone 3 hepatocytes did not activate a biliary program despite 
expressing activated Notch (Jeliazkova et al., 2013; Sparks et al., 2010; Yanger et al., 2013). 
 
Clearly, there is some signal that limits Sox9 expression and BEC differentiation to only specific 
zones in the liver. However, that signal is unknown and is surprisingly not the focus of any 
substantial efforts of investigation (at least to the author’s knowledge). The spatial restriction in 
BEC differentiation could reflect either a difference in competency of hepatocytes in different 
zones to receive and/or respond to a pro-BEC differentiation signal or the spatial restriction of a 
pro-BEC signal to periportal areas. The signal could be either instructive, driving the expression 
of Sox9 and cytokeratins, or permissive, allowing only the periportal hepatocytes to respond to 
pro-biliary stimuli. As the question of what signals could initial this process were contemplated 
previously, the remaining and related question is: from what cells is this signal derived and how 
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is it spatially restricted? 
 
A future direction of this work is to identify the other signal that is responsible for the spatial 
restriction in BEC differentiation competency. This could be performed through the molecular 
comparison of wsCK+ ductal plate cells and surrounding wsCK- non-ductal plate hepatoblasts, 
especially in a Notch-impaired embryo, or of CK19+ and surrounding Sox9+CK19- cells in a P30 
DKO mouse liver. By comparing cells in close proximity, but ultimately having a different 
differentiation status in terms of cytokeratin expression, the differences in intracellular signaling 
and/or gene expression could identify the factor(s) that is responsible for pushing cells past the 
signaling threshold between hepatocyte and BEC fates. These findings could then be 
extrapolated back to determine the extracellular cues that control the BEC differentiation 
competency and the cellular source of these signals. 
 
As concurrent lobular zonation has been observed in BECs, as described above, and 
hepatocytes and ECs, as will be discussed following, it may be that the primary regulation of 
zonation occurs in only one of these tissues first and that tissue subsequently regulates the 
zonal patterning of the other tissues. As ductular reactions are restricted to periportal areas and 
portal bridges, it may be that the zonal signals spatially restricting ductular reactions are derived 
from either the PV, the portal mesenchyme/stroma, the periportal LSECs, or the higher oxygen 
tension in periportal zones. As the communication between tissues has been frequently 
documented, including in the case of mesenchymal-to-epithelial Notch signaling during ductal 
plate morphogenesis (Hofmann et al., 2010), it will be important to carefully consider the 
influence of certain tissues over others during the establishment and maintenance of zonation in 
the liver. While it may not be feasible due to challenges in the mouse model, and interesting 
future experiment would be to test the role of hepatocyte and endothelial zonation in regulating 
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ductular reaction zonation by causing a ductular reaction-inducing injury in the VKO mice who 
have zonation defects in hepatocytes and LSECs, as will be described below, or in another 
mouse model where the hepatocyte or LSEC zonation is altered. 
 
Factors regulating endothelial zonation 
 
There is endothelial heterogeneity between the PV and CV as well as between the periportal 
and perivenous LSECs (Figure 5.15, Figure 6.2A). As described in Chapter 1, the PV and CV 
are derived from the same fetal veins but are separated early in hepatic development. Thus far, 
there is no known information on how the PV and CV endothelium become distinct from each 
other, nor is there information known regarding the regulation of periportal and perivenous 
LSEC identities.  
 
Future directions in determining the molecular factors and signals that differentiate the PV from 
the CV may involve transcriptional profiling of the veins early in development and in adulthood. 
A difference exists as early as E13.5, at the onset of ductal plate morphogenesis and just days 
after the two vessels become established as separate structures (Collardeau-Frachon and 
Scoazec, 2008; Gouysse et al., 2002). Analysis of the transcriptomes of the PV and CV 
endothelium early in development could identify the factor(s), if any, that is responsible for 
differentiating the mesenchyme around the PV and CV and/or conferring BEC specification 
competency in the periportal hepatoblasts only. 
 
An interesting experiment, while technically challenging, would be to examine the role of blood 
flow in the divergent differentiation of the PV and CV during embryonic development. If an ex 
vivo bioreactor could be built that would support fluid flow through the embryonic liver, a 
reversal of fluid flow direction could be performed to determine whether fluid directionality is 
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sufficient to regulate the cascade of signals and events that ultimately regulates the formation of 
the ductal plate around only PVs and not CVs. 
 
Novel findings on the zonal heterogeneity of LSECs are shown in Chapter 5 of this dissertation. 
What is found in the work discussed is that the loss of epithelial VEGF signaling results in the 
alteration of zonal gene expression within LSECs (Figure 6.2B). The molecule endomucin, 
which is normally expressed in CVs and pericentral LSECs but not in PVs or periportal LSECs, 
loses its spatial restrictions in the VKO mouse model and is expressed in LSECs across the 
lobular axis (Figure 6.2B). Without any known information on how zonal endothelial identities 
are regulated during normal liver development and homeostasis, it is difficult to speculate on the 
cause of their dysregulation in the VKO mouse model. With concurrent zonation defects in the 
hepatocytes and LSECs, it remains impossible at this stage to definitively determine whether 
the LSEC zonal defects are proximal to the hepatocyte zonal defect, or vice versa, or whether 
both the hepatocyte and LSEC defects are primary to the loss of epithelial VEGF and are not 
interdependent. Similarly, it remains unknown the reduction in VEGF protein in the liver directly 
or indirectly changes the zonal expression pattern of endomucin in LSECs.  
 
There are several possibilities regarding the cause of altered LSEC zonal gene expression, 
including: 1. Hepatocyte-secreted VEGF gradients directly regulate expression of LSEC zonal 
genes; 2. Hypoxia regulates zonal identities of LSECs; 3. Altered hepatocyte fates result in 
altered signaling to LSECs. All of these possibilities have potential to be true, as it is known that 
hepatocytes can signal to LSECs through VEGF and that VEGF plays a large role in the identity 
of LSECs (DeLeve et al., 2004). Additionally, studies on hepatocyte-derived VEGF expression 
in liver injury have found that the strongest upregulation of VEGF comes from periportal 
hepatocytes, allowing for the possibility that a zonal VEGF gradient is generated by hepatocytes 
in the normal liver and is responsible for generating LSEC zonation (Taniguchi et al., 2001). It 
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may be that in both homeostasis and regeneration, a VEGF gradient across the liver influences 
endomucin expression, with high VEGF periportally inhibiting endomucin expression. 
 
In order to test whether oxygen tension or VEGF protein levels may have a direct effect on 
zonal identities and gene expression in LSECs, the atmospheric oxygen pressure and the 
amount of exogenous VEGF could be modulated in a culture system for LSECs. The LSECs 
could be assayed for the expression of endomucin as a readout of zonal identity. If the culturing 
technique does confirm that either oxygen tension or VEGF protein levels does directly 
modulate the expression of endomucin, independent of indirect signals from any other cell type 
or source, the molecular profiling and comparison of LSECs either expressing or not expressing 
endomucin could be used for further identification of zonal differences within the sinusoid 
compartment and potentially also between PVs and CVs. 
 
Factors regulating hepatocyte zonation 
 
In the control liver, expression of zonal genes, such as GS and CPS1, demarcate tight 
boundaries in zonal hepatocyte subpopulations (Figure 6.2A). In the VKO mouse, however, 
there are disruptions in hepatocyte zonal gene expression, and abnormal co-expression of GS 
and CPS1is apparent in hepatocytes (Figure 6.2B). In P30 VKO mice, the expression of the 
perivenous gene GS is expanded periportally and the expression of the periportal gene CPS1 is 
expanded pericentrally; overlap between the two proteins is observed both in pericentral and 
periportal hepatocytes, indicating a breakdown in the establishment and/or maintenance of the 
zonal hepatocyte boundaries (Figure 5.9). In addition to zonal hepatocyte disruptions, VKO 
mouse livers shown alterations in LSEC zonation and in oxygen tension, the latter is believed to 
directly result from a decrease in PV and HA branches in the VKO mouse as compared to 
control (Figure 6.2B). Due to these concurrent phenotypes, a number of possibilities exist to 
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explain the disruption in hepatocyte zonation: 1. The hepatocyte gene expression could be 
directly regulated through VEGF signaling and thus altered in the loss of epithelial VEGF; 2. The 
hepatocyte defects could be directly caused by the change in oxygen tension across the liver 
lobule; or 3. The hepatocyte defects could be secondary to LSEC zonation defects, which could 
be caused either by hypoxia or directly by VEGF signaling reductions.  
 
There is evidence that some hepatocyte zonal genes but not others are regulated by oxygen 
tension. Erythropoietin, for example, as well hepatocyte zonation genes such as PEPCK and 
GK, are found to be influenced by oxygen tension (Jungermann and Kietzmann, 1997; 
Kietzmann et al., 1992; Tam et al., 2006) while others, including GS, were not (Jungermann and 
Keitzmann, 1996). If GS is not sensitive to hypoxia, then the hypoxia observed in VKO livers 
(Figure 5.10) would not be directly responsible for the expansion in GS expression (Figure 5.8). 
The absence of a direct regulation of GS by hypoxia is also supported by the finding that in P30 
VKO mice, regions of hypoxia and regions of expanded GS expression are not necessarily 
overlapping (Figure 5.10). 
 
The finding that GS expression is changed provides evidence that the defect in the VKO livers is 
due to more than just a decrease in oxygen tension, and may also be caused by signaling 
defects within the liver. While we cannot exclude the possibility that GS expression in 
hepatocytes is directly regulated by oxygen tension in the VKO model, several alternative 
explanations could be responsible for the altered GS expression, including: 1. VEGF protein has 
a direct role in repressing GS expression; 2. A signal derived specifically from periportal LSECs 
represses GS expression in hepatocytes; 3. A signal derived specifically from perivenous 
LSECs promotes GS expression; 4. GS expression is inhibited by a secreted molecule from the 
PV, HA, or associated mesenchyme, and is decreased due to the reduction in PV and HA 
branches. There is currently no signal that has been identified that performs any of the roles 
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described above. However, one potential signaling candidate can be inferred based on the 
known regulation of GS signaling. 
 
Wnt/"-catenin signaling is known to directly regulate the expression of GS in the liver. "-catenin 
is both necessary and sufficient to induce the expression of GS in hepatocytes (Benhamouche 
et al., 2006; Colletti et al., 2009; Colnot and Perret, 2011).  While there has been no direct 
evidence that Wnt secreted from LSECs drives zonal gene expression in hepatocytes, it has 
been demonstrated that LSECs in the adult mouse liver express multiple Wnt ligands, whereas 
hepatocytes express multiple Frizzled receptors of Wnt (Zeng et al., 2007). The expression of 
Wnt ligands and receptors in LSECs and hepatocytes, respectively, enhances the hypothesis 
that signals from the endothelium could be responsible for the altered hepatocyte zonation. A 
future direction in this area will be to address the role of hypoxia in the altered hepatocyte 
zonation. 
 
The influence of hypoxia on GS expression can be tested by separating the effects of hypoxia 
from the direct effects of VEGF protein reduction. This can be accomplished by inducing a 
hypoxic state in animals without inhibiting VEGF signaling. Additionally, the effects of VEGF 
inhibition could be tested without the associated hypoxia by inhibiting VEGF signaling in the liver 
with an inducible gene disruption of VEGF in a postnatal mouse or through the administration of 
VEGF inhibitors. By separating the hypoxia and the VEGF loss, it could be determined which of 
these factors is responsible for the alterations in hepatic zonation. 
 
Another future direction in this project would be to determine the role of "-catenin in the VKO 
phenotype. It has already been shown by altering Wnt/"-catenin pathway components 
genetically that Wnt/"-catenin is both required and sufficient for GS expression. By combining a 
conditional knockout of "-catenin and Vegf within the liver epithelium, we would be able to 
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determine whether the VKO phenotype of expanded GS expression is mediated by "-catenin 
signaling.  
 
Cellular Plasticity in Development and Disease 
 
Differential responses in cell plasticity depending on degree and type of injury 
 
In the various genetic, chemical, and surgical injury models examined in this dissertation, the 
cellular responses to injury varied widely. In the DKO model, new BECs were formed from 
hepatocytes, an extensive ductular reaction was formed, and functional peripheral IHBDs were 
generated (Figures 3.1, 3.3). In the DDC model, Sox9+ hepatocytes and a CK19+ ductular 
reaction were both induced by injury. In the BDL model, a large number of Sox9+ hepatocytes 
were induced by injury, but no ductular reactions were observed. In the 2-AAF/PHx model, a 
ductular reaction was observed, but no Sox9+ hepatocytes were present. Finally, in the PHx 
model, no Sox9+ hepatocytes or ductular reactions were observed (Figures 4.2, 4.3). This 
variation in response indicates that the mechanisms of cellular reactions vary based on the 
specific injury. This variation could be caused by the degree of injury or the specific tissues 
affected. 
 
Sox9+ hepatocytes were observed in all the cholestatic injury models examined, including the 
DKO, DDC, and BDL models, but not in the non-cholestatic injuries. However, there is no simple 
consistency in which injuries did or did not generate reactive ductules. Interestingly, a previous 
study has indicated that reactive ductules can have one of two molecular profiles, either a 
Notch+ profile or a Wnt+ profile (Wang et al., 2009). This may indicate that there are multiple 
ways that the ductular reaction can be induced and that it may not be possible to identify one 
commonality between all ductular reaction-inducing injuries. 
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Future directions include determining the role of the ductual reaction in the injury, and 
specifically trying to determine whether the emergence of the ductular reaction serves a function 
in alleviating the disease state. To test the role of the ductular reaction in a cholestatic liver 
injury model, we could induce a ductular reaction with DDC in control mice and mice with 
genetical manipulations impairing the ductular reaction, such as inhibitions in Notch signaling. 
Between the control and mutant mice, we could perform tests on liver function and damage to 
determine whether, in the same liver injury model, there are differences in severity of liver 
damage depending on the extent of the ductular reaction. 
 
Signals influencing liver injury and regeneration 
 
Signaling molecules that have known importance in liver regeneration also play roles in liver 
regeneration and cell plasticity in the postnatal liver. The role of Sox9 has already been 
discussed. Of specific interest are Hnf6 and Wnt. 
 
Hnf6 is an important mediator of IHBD morphogenesis during embryonic development and is 
sufficient to promote biliary cell fates in the pancreas when overexpressed in cultured cells 
(Clotman et al., 2002; Prevot et al., 2012). Hnf6 has been found to be downregulated in the liver 
after BDL and to inhibit the proliferation of BECs when overexpressed after BDL in mice 
(Holterman et al., 2002). Hnf6 regulates several critical liver functions, including cholesterol 
catabolism and bile acid synthesis, through the direct transcriptional control of cholesterol 7-
alpha hydroxylase (CYP7A1) (Wang et al., 2004). Similarly to Sox9, is appears that Hnf6 
promotes cellular differentiation and function while restricting proliferation, but that the 
repression of Hnf6 during liver injury may be an important tool for promoting cellular proliferation 
and regeneration. While we know that Hnf6 is not absolutely required for BEC specification and 
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IHBD regeneration in DKO mice, we do not at this time know the role of Hnf6 in hepatocyte-to-
BEC conversion, and overall liver response to injury, in the non-genetic injury models examined. 
As Hnf6 promotes the expression of BEC genes, including Sox9, we may hypothesize that Hnf6 
is involved in the hepatocyte-to-BEC conversion mechanism and may work coordinately with 
Sox9 to inhibit proliferation in the cells undergoing conversion. 
 
Another molecule of interest for its role in liver regeneration is Wnt signaling. As previously 
mentioned, a recent study has demonstrated that Wnt3a, secreted from macrophages, opposes 
Notch signaling and promotes the hepatocyte cell fates in a liver injury model (Boulter et al., 
2012). Within the adult mouse liver, "-catenin has demonstrated roles in the export of bile 
(Behari et al., 2010), and "-catenin-null livers demonstrated reduced regeneration after 
acetaminophen-induced injury (Apte et al., 2009). During liver injury in the rat, "-catenin was 
found to promote the differentiation of reactive BECs into hepatocytes (Williams et al., 2010). 
Despite the positive regulation of Sox9 by Wnt in other organs, in the liver, Wnt/"-catenin may 
function to promote hepatocyte, and not BEC, fates. 
 
Significance of Sox9 expression in human liver disease and regeneration 
 
Sox9 is not required for BEC differentiation or IHBD formation (Antoniou et al., 2009). However, 
it does play a role in ductal plate morphogenesis and clearly identifies, and may play a role in, 
cells that have progenitor characteristics or lineage conversion potential (Figures 3.7, 4.3) 
(Antoniou et al., 2009; Dorrell et al., 2011; Malato et al., 2011; Yanger et al., 2013). Additionally, 
Sox9 is expressed in hepatocytes or hepatobiliary intermediate cells in a variety of different 
human liver diseases (Figure 4.1) (Yanger et al., 2013). However, what these Sox9-expressing 
hepatobiliary intermediate cells in human liver disease actually represent is unknown. 
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In the pediatric liver disease Alagille syndrome, some patients recover from cholestasis 
seemingly spontaneously after a few years of age. Others, however, do not. The only treatment 
for Alagille syndrome currently is liver transplantation. Due to the stress of undergoing 
transplantation and the shortage of transplantable livers, there is a real need to better methods 
of predicting prognosis in Alagille patients, so that we can avoid transplantations in those 
patients who would have recovered on their own otherwise and identify the patients who will not 
recover earlier. As Sox9 is one of the first markers of hepatocytes undergoing a BEC 
conversion, the presence of Sox9+ hepatocytes in Allagille syndrome patients, and potentially 
patients of other liver diseases, may be useful as an indicator of prognosis. 
 
In the DKO mouse model, it appears that the expression of Sox9 denotes the first stage or 
regeneration, as Sox9+ hepatocytes precede CK19+ peripheral BECs and, subsequently, mature 
peripheral IHBDs. As the regeneration progresses and the injury resolves, widespread 
expression of Sox9 in the liver subsides. In the DDC and DKO injuries, however, where the 
injury persists, the expression of Sox9 persists. It is unclear if the persistent and increasing 
Sox9+ cells are primarily indicative of either and increase in regenerative efforts or an increase 
in the disease state. Similarly, although we observe the expression of Sox9 in several human 
liver diseases, we do not know if the presence alone of Sox9+ intermediate cells in human liver 
disease is indicative of degree of injury, ongoing regeneration, both, or neither. 
 
A future direction for this project is to perform a thorough analysis of Sox9+ intermediate cells in 
the liver of human liver disease patients and determine whether the presence of Sox9+ 
intermediate cells has any correlation to disease severity and progression and/or outcome. To 
do this, a number of biopsy samples will be required, hopefully from patients in different stages 
of disease progression. By matching patients with similar disease indicators on lab tests (for 
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example, total bilirubin levels) to control for differences in disease severity, we can determine if 
there are cellular differences in the extent of Sox9 expression that correlate with outcome.  
177 
APPENDIX A 
 
USE OF THE ENDOTHELIAL-SCL-CRET MOUSE LINE TO LINEAGE TRACE ENDOTHELIAL 
CELLS AND DELETE RPBJ WITHIN ENDOTHELIUM DURING HEPATIC DEVELOPMENT  
 
Introduction 
 
The vascular tissues of the liver, the portal vein (PV) central vein (CV), hepatic artery (HA), and 
liver sinusoidal endothelial cells (LSECs), have highly distinct functions and architectures. 
Similarly, their development is thought to be very different; while the PV and CV are proposed to 
arise from the remodeled vitelline and umbilical veins (Collardeau-Frachon and Scoazec, 2008), 
the HA is thought to arise through angiogenesis from the dorsal aorta, and the LSECs from 
resident endothelial cells (ECs) in the septum transversum mesenchyme (Gouysse et al., 2002). 
However, no studies have definitively answered the fundamental questions regarding the 
development of the hepatic vascular tissues, including what EC populations contribute to each 
structure and whether angiogenesis, vasculogenesis, or both are responsible for their formation.  
 
Notch signaling has been implicated as being a crucial regulator of both angiogenesis and 
vasculogenesis and to interact cooperatively with VEGF signaling in multiple organs and 
species (Herbert and Stainier, 2011). Yet, it is not known whether Notch plays a role in the 
development of any hepatic vascular tissues. As the hepatic vasculature of the liver is highly 
unique in both function and development, the characterization of angiogenesis as it occurs in 
other organs cannot necessarily be assumed to hold true in the liver. Hence, the involvement of 
Notch in hepatic vascular development remains unknown.  
 
In this study, we utilized a mouse model of tamoxifen inducible Cre-mediated recombination of a 
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reporter allele in ECs in an attempt to characterize their contribution to hepatic vascular 
development. The endothelial-SCL-CreERT (Göthert et al., 2004) transgenic allele utilizes the 5’ 
enhancer region of the stem cell leukemia (SCL) locus previously shown to be expressed 
specifically in ECs and a subset of hematopoietic cells (Gottgens et al., 2004). For several 
reasons, we have chosen to use the Gt(ROSA)26Sortm1(EYFP)Cos (ROSA26R-EYFP) (Srinivas et 
al., 2001) reporter allele, which is silent until Cre excises a transcriptional stop cassette. First, 
enhanced yellow fluorescent protein (EYFP) is easily detected with antibodies and thus will 
allow us to immunostain for markers of cell identity and proliferation along with the EYFP 
lineage marker. Second, the ROSA26 promoter provides a promoter that is active in all cells, so 
that once Cre activates this allele, EYFP will remain expressed regardless of the cell fate. Third, 
activation of EYFP expression occurs via recombination of DNA and thus is a heritable event 
that will ensure EYFP expression even when Cre is no longer present. Thus, we will be able to 
perform a spatio-temporal analysis of the populations of ECs present at different developmental 
timepoints and identify the structure to which they and their progeny contribute. 
We used the endothelial-SCL-CreERT in combination with ROSA26R-EYFP reporter mouse 
model to lineage trace ECs over several timepoints and to delete the Notch signaling mediator 
Rbpj to assess the role of Notch signaling in hepatic vascular development. We found that the 
endothelial-SCL-lineage label was not able to distinguish between the populations of ECs in 
terms of their contribution to different vascular structures at different timepoints. We additionally 
found no phenotype in mice with Rbpj deleted in ECs. However, the absence of phenotype may 
be due to an incomplete recombination of Rbpj. 
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Results 
 
To determine whether the expression of the endothelial-SCL-lineage label is able to differentiate 
subpopulations of ECs at different developmental stages, we performed a series of lineage 
tracing experiments in endothelial-SCL-CreERT; ROSA26R-EFYP mice where recombination 
was either induced at different timepoints and recombination within the tissue was analyzed at a 
common timepoint, or where recombination was induced at one common timepoint and then 
recombination within the tissue assessed at a variety of later timepoints. Timepoints were 
targeted over a variety of different developmental stages, including prior to liver bud formation 
(before E9.5), during disruption and remodeling of the vitelline and umbilical veins (E10-E12.5), 
embryonic development after venous remodeling (E12.5-P0), and postnatal growth of the 
vascular tissues (P0-P30). See Figure A.1 for a graphic summary of timepoints analyzed for 
endothelial-SCL-lineage tracing. 
 
We found no differences in which vascular tissues expressed the endothelial-SCL-lineage label 
in any experiments. For example, we found that whether we induced endothelial-SCL-lineage-
labeling at E12.5 or P15, very different developmental stages, we still saw that endothelial-SCL-
lineage-labeled cells contributed to the mature PV, HA, and sinusoids when the livers were 
analyzed at P30 (Figure A.2). 
 
Next, we attempted to determine whether Notch signaling, and the Notch mediator Rbpj, is 
required for any of the crucial stages of liver vascular development. We induced recombination 
of the Rbpjtm1Hon allele (Rbpjflox/flox) (Han et al., 2002) at a variety of timepoints (See Figure A.3 
for a graphic summary of timepoints analyzed for endothelial-SCL-CreERT mediated deletion of 
Rbpj). In no experimental paradigm did we find a difference between the control and 
180 
 
181 
 
182 
 
endothelial-SCL-CreERT; Rbpjflox/flox; ROSA26R-EYFP  (Rbpj'endo). The Rbpj'endo mice did not 
display any lethality. When we analyzed the postnatal masses of control and Rbpj'endo mice, we 
found no difference (Figure A.4). This was surprising, as previous studies have shown that Rbpj 
is required in the endothelium, and either global or endothelial-specific disruptions in Rbpj lead 
to severe vascular malformations (Dou et al., 2008; Gridley, 2007; Oka et al., 1995; Siekmann 
and Lawson, 2007). 
 
To determine whether we were getting complete recombination and deletion of Rbpj, we 
performed immunohistochemistry for Rbpj protein in knockout mouse livers. When comparing 
Rbpj'endo mice and controls that were injected with Tamoxifen at E12.5 and analyzed at E17, no 
differences were observed. In both genotypes, some cells that resemble ECs demonstrated the 
expression of Rbpj (Figure A.5A-B). We additionally analyzed a P30 Rbpj'endo mouse that was 
injected with Tamoxifen at E11.5 (Figure A.5C). In this mouse, we were able to visualize mature 
veins and see morphologically-determined ECs. Several ECs retained expression of Rbpj. 
 
183 
 
184 
 
185 
 
186 
Conclusion 
 
The lineage tracing experiments demonstrate that the endothelial-SCL-CreERT mouse line is not 
able to distinguish between EC subpopulations that have different contributions to the different 
hepatic vascular tissues. This result may be explained in several ways: 1. There are no EC 
subpopulations with different contributions to different hepatic vascular structures; 2. There are 
different EC subpopulations that have different contributions to the different hepatic vascular 
tissues, but the expression of endothelial-SCL-CreERT is not able to distinguish between them 
potentially due to its expression in an early EC common progenitor or in a hematopoietic 
progenitor lineage (Gottgens et al., 2004); or 3. There are different EC subpopulations, but the 
persistence of Tamoxifen in the system (Reinert et al., 2012) makes it impossible to get precise 
enough temporal specificity of recombination. With the current tools, it is not possible to 
distinguish between these possibilities. 
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Methods 
 
Lineage tracing was performed on endothelial-SCL-CreERT; ROSA26R-EYFP mice (Göthert et 
al., 2004; Srinivas et al., 2001). Rpbj deletion in ECs was performed with endothelial-SCL-
CreERT;Rbpjflox/flox;ROSA26R-EYFP  (Göthert et al., 2004; Han et al., 2002; Srinivas et al., 2001) 
mice. Tamoxifen was suspended in corm oil and given as a single dose of 2mg/mouse 
intraperitoneal injection to induce recombination. See Chapter 2 of this dissertation for details on 
immunohistochemistry. 
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APPENDIX B 
 
A SYSTEM FOR CULTURING THE FETAL LIVER BUD 
 
Introduction 
 
The signals and intercellular interactions that direct the development of the hepatic bud after 
specification are of high interest to researchers. Previous studies have shown suggestive 
evidence that epithelial-endothelial interactions are important in hepatogenesis (Matsumoto et 
al., 2001); however, these findings have not been able to be confirmed in an in vivo model due 
to insufficient tools to specifically target the hepatic bud-surrounding endothelial cells (ECs) and 
avoid global vascular disruptions leading to embryonic lethality prior to liver bud vascularization. 
In order to circumvent this in vivo challenge and to characterize the endothelial-epithelial 
signaling and interactions, it is necessary to generate an in vitro system that is able to closely 
recapitulate the process of in vivo hepatic bud development and expansion. 
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Results 
 
We have developed an in vitro culture system where the liver bud, as early as E9.0, can be 
cultured with both epithelial and endothelial tissues. In this system, the fetal liver bud explant 
can survive for several days in culture and the endothelial cells survive and form branching 
vascular networks. This method was adapted from a previously published technique 
(Matsumoto et al., 2001). 
 
Live fluorescent lineage-specific labels facilitate the process of liver bud dissection and aid the 
ability to distinguish epithelial and endothelial cells while in culture. In the mouse model utilized, 
the endothelial cells are inducibly labeled with enhanced yellow fluorescent protein (EYFP) 
expression through endothelial-SCL-CreERT (Göthert et al., 2004) and 
Gt(ROSA)26Sortm1(EYFP)Cos (ROSA26R-EYFP) (Srinivas et al., 2001) alleles. In these mice, the 
ROSA26R-EYFP allele is silent until Cre-mediated excision of the transcriptional stop cassette. 
Induction of EYFP expression can either be done through a maternal injection of tamoxifen prior 
to harvest, or through the addition of 4-hydroxytamoxifen in the culture media.  
 The foregut endoderm and hepatic bud is labeled by a transgene, Tg(Ttr-RFP)1Hadj, using 
transthyretin (Ttr) regulatory elements to drive expression of red fluorescent protein (RFP) 
(Kwon and Hadjantonakis, 2009). Ttr is known to be expressed in the embryonic endoderm, 
including the liver, pancreas, stomach, and intestine (Kwon and Hadjantonakis, 2009).Through 
crossing these transgenes and alleles together, we generated a mouse where both the hepatic 
bud and endothelium are fluorescently marked. 
 
At E9.5, Ttr-RFP can be seen throughout the gut tube of the embryo and the liver bud is visible 
(Figure B.1A). After resecting the liver bud, the RFP fluorescence is still visible in the epithelial  
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hepatic primordium (Figure B.1B). The liver explants also contained the septum transversum 
mesenchyme, which does not express RFP (Figure B.1B). 
 
The injection of tamoxifen in vivo results in a highly efficient recombination of the ROSA26R-
EYFP allele and expression of EYFP in vasculature (Figure B.2). Tamoxifen injection at E7.5 
into a pregnant female is sufficient to lineage label endothelium throughout the embryo at E9.5 
(Figure B.2). 
 
After several days in culture, vascular networks formed that expressed the EC marker platelet 
cell-derived endothelial cell adhesion molecule (PECAM) (Figure B.3).  
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Conclusion 
 
The culture system allows for the concurrent growth and expansion of both the epithelial and 
endothelial tissues.  
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Methods 
 
Mice with dual-fluorescent tissue labels were generated by combining the alleles Ttr-RFP (Kwon 
and Hadjantonakis, 2009); endothelial-Scl-CreERT (Göthert et al., 2004); and ROSA26R-EYFP 
(Srinivas et al., 2001). 
 
The culture protocol was done as follows: 
 
Materials needed: 
- Transwell polycarbonate filter membranes and plates: 6.5mm diameter, 0.45mm pore 
size (Corning, Corning, NY, product #3413) 
- Dulbecco’s modified Eagle medium (Gibco 11885: Low glucose, pyruvate, .37% 
NaHCO3) 
- Fetal bovine serum 
- Matrigel (Becton Dickinson, Franklin Lakes, NJ) 
- Pen-Strep 
- Etched tungsten micro needles, 0.5mm rod diameter, 1 um tip diameter (FST, Foster 
City, CA, item no. 10130-20) 
- Pin holder 
- No. 5 forceps 
 
Dissection and culture protocol: 
1. To make 50 mLs of dissection solution, mix 49.5 mL PBS with 0.5 mL 1% Pen-Strep. 
The dissection solution will stay good for 2-4 weeks at 4°C. 
2. To make 50 mL of culture medium mix (without Matrigel) 44.5 mL DMEM, 5 mL 10% 
fetal bovine serum, and 0.5 mL Pen-Strep. Filter the mixture. The culture medium 
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without matrigel is good for 2-4 weeks at 4°C. At the time of use, add 10 µL Matrigel per 
5 mL media. The culture medium with Matrigel will not keep. 
3. Add 250 µL culture media with Matrigel to each well of the 24-well Transwell plate below 
the filter membranes. Put plate at 37°C. 
4. Under a fluorescent stereoscope, dissect E9-E10 embryos out of the uterus in dissecting 
solution. 
5. Use the RFP fluorescence to visualize the hepatic endoderm bud. Cut embryos 
transversely caudal to fetal liver bud. Carefully resect the hepatic bud, including the 
RFP-expressing hepatic endoderm with surrounding mesenchyme tissue. 
6. In a cell culture hood, transfer hepatic buds onto Transwell filter inserts and put into 24-
well plate. 
7. Culture buds at 37°C in a humidified atmosphere of 5% CO2 and 95% air. 
8. Change media every 2 days. Use previously made culture medium and add Matrigel 
fresh each time. 
 
To induce EYFP expression in vivo prior to dissection, intraperitneally inject 100 µL of 2 mg/mL 
tamoxifen solution. Tamoxifen is dissolved in 10% ethanol; 90% corn oil. 
 
To induce EYFP expression in culture after resection, add 1 µM 4-hydroxytamoxifen (Sigma-
Aldrich, St. Louis, MO) to culture media and incubate for 2 days before replacing with fresh 
media. 
 
Wholemount immunofluorescence was performed with the following protocol: 
Fix whole E9.5 embryo overnight at 4C. Wash embryo thoroughly with PBS. Permeabilize with 
0.5% Triton X-100 in PBS (0.5% PBT) for 30 minutes at room temperature, rocking. Block 
overnight at 4C in blocking solution (5% normal donkey serum and 1% bovine serum albumin in 
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0.5% PBT. Incubate embryo with primary antibody diluted in blocking serum overnight at 4C. 
Dilute rat ! PECAM antibody 3/500 and rabbit ! GFP antibody 1/500 (see Chapter 2 for 
antibody information). Wash the embryo 3 x 20 minutes at room termperature in 0.1% PBT. 
Wash in PBS overnight at 4C. Incubate embryo with secondary antibody diluted 1:1 in blocking 
buffer and 0.1% PBT. Dilute ! rat-Cy2 1:500 and ! rabbit-Cy3 1:500. Wash embryo 2 x 1 hour 
in 0.1% PBT at room temperature, rocking. Incubate in a nuclear staining agent, such as DAPI 
or bis-benzamide, if desired, for 20 minutes at room temperature. Wash 3 times in PBS for at 
least 30 minutes each at room temperature, rocking, or overnight at 4C for one of the final 
washes. 
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APPENDIX C 
 
THE RESULTS OF EPITHELIAL-OVEREXPRSSION OF VEGF IN THE FETAL LIVER 
 
Introduction 
 
The studies described in Chapter 5 of this dissertation illustrate the requirement of epithelial-
secreted VEGF protein in liver development through the knockout of VEGF specifically in the 
liver epithelium. To further clarify the role of VEGF during liver development, we performed the 
complementary experiment and induced the overexpression of VEGF in the liver epithelium. For 
further information on VEGF and its role in liver development, please see Chapter 5. 
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Results 
 
To determine the role of VEGF in embryonic liver development, we generated a mouse that 
overexpresses VEGF specifically within the liver epithelium. The VEGF-overexpression (VFOE) 
mouse uses an Tg(Alb-Cre)21Mgn/J (Albumin-Cre) transgene to drive the Cre-mediated 
recombination of the Gt(ROSA)26Sortm1(tTA)Roos/J (ROSA26-tTA) allele to remove the stop codon 
and drive the expression of tetracycline. Tetracycline then binds to tetracycline-dependent 
promoter elements in a transgene upstream of the full-length cDNA of VEGF165 (Ohno-Matsui et 
al., 2002; Sun et al., 2007). All Albumin-Cre-recombined lineages will overexpress VEGF165. 
 
Previous studies have found that Albumin-Cre-mediated recombination occurs in hepatoblasts 
during embryonic development, with recombination of the ROSA26 locus occurring in the 
majority of cells by E16 (Sparks et al., 2010). Immunostaining using an antibody that detects all 
major isoforms of VEGF, including VEGF165, demonstrates that, the levels of VEGF protein are 
visually increased in the liver of VFOE mice by E15.5 (Figure C.1). 
 
VFOE is embryonic lethal, with no surviving embryos past E16.5. The number of mice collected 
with control and VFOE genotypes at each age is shown in Table C.1. 
 
To determine the effect of hepatic epithelial-overexpression of VEGF on liver histomorphology, 
liver tissues from E13.5, E15.5, and E16.5 VFOE and control mice were analyzed by 
hematoxylin and eosin stain. At E13.5, no differences are observed between control and VFOE 
mice (Figure C.2A-B). By E15.5, differences can be found between VFOE and control mice. At 
this time, VFOE mice display abnormal disruptions  
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in the epithelial architecture, yielding large spaces filled with circulating hematopoietic lineage 
cells (Figure C.2C-D). By E16.5, there is a complete disruption of the epithelial architecture in 
VFOE mouse livers, with a further expansion of the vascular spaces and similar increase in the 
number of hematopoietic lineage cells observed in the liver (Figure C.2E-F). There is almost no 
identifiable epithelial organization in the VFOE liver at this time. 
 
To determine the effect of the VFOE on the cellular identity of the liver epithelium, we assessed 
the expression of several liver cell fate markers in control and VFOE mouse livers at E15.5 and 
E16.5. We first examined the expression of biliary cell markers widespread cytokeratin (wsCK), 
a marker of several cytokeratin proteins that is expressed in the ductal plate and in mature 
biliary cells, and Sox9, a marker of both biliary epithelial cells (BECs) in the ductal plate and in 
intrahepatic bile ducts and a marker of hepatic progenitor cells (Carpentier et al., 2011). We 
were surprised to find a large increase in wsCK expression in VFOE mice, specifically at E16.5 
(Figure C.3D) and in the areas where tissues disruptions, including large gaps in the epithelial 
structure that appear to be filled with hematopoietic lineage cells, were observed in the 
peripheral regions of the liver (Figure C.2F). However, when we examined expression of Sox9, 
we did not find a similar expansion of the Sox9 expressing cells as wsCK (Figure C.4D). We 
also examined the expression of the hepatocyte marker Hnf4!. While Hnf4! was seen 
throughout the parenchyma in E15.5 and E16.5 control livers, the expression was decreased in 
E15.5 VFOE livers and absent from E16.5 VFOE livers (Figure C.5). 
 
With the abnormal protein expression observed in these cells, we stained the livers for Hnf1!/", 
or Hnf1, which should mark all hepatic epithelial cells at these embryonic timepoints. In E13.5, 
E15.5, and E16.5 control mice, Hnf1 expression was seen  
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throughout the liver in hepatoblasts and in ductal plate structures (Figure C.6A,C,E). Hnf1 was 
also seen in VFOE livers at E13.5 and E15.5 (Figure C.6B,D), but was not observed in the 
VFOE liver at E16.5 (Figure C.6F). This confusing data suggests that the liver epithelial tissue 
has either disappeared from the embryonic liver and been replaced with cells that express only 
wsCK, or that the liver epithelium has adopted an abnormal fate by which the cells express only 
wsCK but no other liver lineage markers. 
 
To determine whether changes in proliferation or apoptosis could explain the changes observed 
in the E16.5 VFOE livers, we assessed proliferation at E15.5 (Figure C.7) and apoptosis at 
E15.5 and E16.5 (Figure C.8). No changes in either proliferation or apoptosis were found 
between control and VFOE livers. 
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Conclusion 
 
VEGF overexpression causes major disruptions in the epithelial structure and identity of the liver 
epithelial cells. These disruptions include both physical disruptions in the liver tissue 
architecture and disruptions in the gene expression of liver cell type markers.  
 
At this time, it is unclear what is causing these disruptions. It could be that the expression of 
VEGF has direct effects on the hepatoblasts, and VEGF overexpression promotes abnormal 
gene expression and cell fate. Alternatively, the direct effect could be on the hematopoietic 
lineages that appear to expand in the VFOE tissues. The enormous expansion of the 
hematopoietic population may induce secondary effects on the epithelial tissue, either through 
altered signaling or through physically changing the structure of the liver, through crowding out 
the epithelial cells or causing hemorrhages, for example. 
 
The overexpression of VEGF in this specific mouse model will not be able to be used to study 
the role of VEGF in the architectural establishment and growth of the hepatic blood vessels. 
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Methods 
 
VFOE mice were generated by crossing Albumin-Cre (Postic and Magnuson, 2000) mice, 
ROSA26-tTA (Wang et al., 2008) mice, and TRE/VEGF (Ohno-Matsui et al., 2002) mice. 
 
See Chapter 2 for histology and immunostaining methods. 
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APPENDIX D 
 
A TECHNIQUE FOR CASTING THE HEPATIC PORTAL VEIN WITH OR WITHOUT THE 
SIMULTANEOUS CAST OF THE INTRAHEPATIC BILE DUCT 
 
Introduction 
 
The three-dimensional tissue structures in the liver pose a challenge for studying hepatic 
morphogenesis: how can we assess the in vivo architecture of one structure alone within its 
context in the liver, or the spatial and developmental relationship between two structures? 
 
The question of tissue architecture interrelatedness is of special interest in the liver, as it is 
believed that the architectural pattern of the portal vein (PV) dictates the structure of the 
intrahepatic bile duct (IHBD), the hepatic artery (HA), and the hepatic nerves. The portal vein is 
the first of these structures to form, followed by the IHBD and then the HA. The IHBD and HA 
follow the pattern of the portal vein as they undergo their own morphogenesis. Indeed, there 
are, under normal conditions, no branches of the IHBD or HA that exist away from a PV branch. 
 
With this intimate developmental and spatial connection between tissues, it is of interest to 
assess how changes in one tissue are manifested in the other. This requires a way to view both 
tissues in three-dimensions at the same time. Unfortunately, the liver, because of its dense 
nature, is not amenable to techniques such as fluorescent labeling and in vivo imaging of cells 
contributing to ductal and vascular elements. 
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Results 
 
Our lab has generated a technique for the visualization of three-dimensional resin casting of the 
IHBD (Sparks et al., 2010). This technique has subsequently been adapted to use in the portal 
vein (Walter et al., 2012) and for double-casts of the PV and IHBD simultaneously (Figure D.1). 
 
In the double resin cast of the IHBD and the PV, we can see that one PV is followed by several 
IHBD branches, and that the IHBD will occasionally wrap around the PV. The IHBD branches 
are various sizes, even when they are following the same PV branch (Figure D.1). 
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Conclusion 
 
The double resin cast provides a novel way to visualize the architecture of two 3-dimensional 
tissues at the same time and to analyze their relationship to each other. In this case, we were 
able to visualize both the IHBD and the PV. In 2-dimensions, we can see the IHBD branches 
next to the PV and we can see that there can be a variety of IHBD sizes next to the same PV 
branch. These findings are confirmed in the 3-dimensional double resin casts of the IHBD and 
PV. Additionally, the double casts allow us to see the way that the two structures relate to each 
other along their lengths; we see that large IHBD branches tend to follow the PV in a fairly 
parallel manner, while small IHBD branches can either run parallel to the PV or can wrap 
around the PV (Figure D.1.) 
 
This technique could be adapted to any other two luminal structures that can be cast. 
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Methods 
  
Resin casts were performed as previously described (Walter et al., 2012). Please see Walter et 
al. (2012) for a detailed protocol and videos. 
 
To generate a cast of the portal vein, first sacrifice a mouse, expose the abdominal cavity, and 
flush the PV by cutting a nick in the cardinal vein and injecting PBS into the extrahepatic PV. 
Then, tie a tight ligature around the cardinal vein, anterior to the nick, and a loose ligature 
around the portal vein near the base of the liver. Attach a cannula made of stretched PE10 
tubing to a 32 gauge, ( inch needle and insert the cannula into the portal vein. Tighten the 
ligature to hold the cannula in place. Mix 0.1 grams of catalyst with 1 mL of resin and pull into a 
syringe. Attach the syringe to the cannula-needle and push resin into the portal vein. Allow the 
resin to harden at room temperature, then remove the liver from the mouse and fix in 4% 
paraformaldehyde. Wash in PBS, then dehydrate to methanol. Wash the liver in a 1:2 solution of 
benzyl alcohol and benzyl benzoate to clear the liver tissue and visualize the resin cast. 
 
Double resin casts were performed using the previously described method with some 
modifications to accommodate casts in both the IHBD and the PV. After the mouse was 
sacrificed, the PV was immediately flushed with PBS. Afterward, ligatures were tied around the 
cardinal vein above the site of the nick, the extrahepatic PV and the extrahepatic IHBD. The 
ligature around the cardinal vein is tightened, but the others remain loose. The portal vein is 
cast first and is done as described above (Walter et al., 2012). Next, the IHBD is cast as 
described but with fluorescent resin. To generate fluorescent resin, add 0.05 mg/mL Nile Red 
(Sigma Aldrich, St. Louis, MO) to resin. The fluorescence is able to withstand the clearing 
process with BABB. To image the double resin cast, first take a bright field image of both casts. 
Then, take an image of the fluorescence in the IHBD casts at 543). Apply a false color to the 
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fluorescent image and overlay it on the bright field image using Photoshop or a comparable 
photo editing program. The image resulting from this process will show the PV in the white color 
of the resin and the IHBD in the false color assigned to the fluorescent image.  
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APPENDIX E 
 
CYTOKERATIN19-EXPRESSING CELLS DO NOT FUNCTION AS BIPOTENTIAL LIVER 
PROGENITORS DURING DDC-INDUCED LIVER INJURY OR REGENERATION 
 
Introduction 
 
The origin and identity of the adult liver stem cell has been a focus of investigation due to the 
therapeutic potential of this cell for chronic liver disease. A definitive liver stem cell has not been 
identified. This is partly due to disparate findings between different liver injury models that vary 
both in liver phenotype and severity of injury, suggesting that potential hepatic progenitor cell 
(HPC) populations are heterogeneous morphologically and molecularly as wells as in their 
response to injury (Dorrell et al., 2011; Español-Suñer et al., 2012; Glaser et al., 2009; Shin et 
al., 2011; Strazzabosco and Fabris, 2008; Tietz and LaRusso, 2006).  
 
A common feature of chronic liver disease in human and mouse models is the emergence of a 
ductular reaction. Cytokeratin19 (CK19)-expressing reactive ductular cells are thought to arise 
from previously differentiated biliary epithelial cells (BECs) or HPCs lining bile ducts and 
ductules, and to contain bipotential progenitors called “oval cells.” While these reactive BEC 
populations have demonstrated capacity to differentiate into both hepatocytes and BECs 
(Dorrell et al., 2011; Shin et al., 2011; Wang et al., 2003), the in vivo regenerative contribution of 
these cells to hepatic physiology and architecture remain debated. 
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Results 
 
To examine the origin and contribution potential of reactive BECs, we performed lineage tracing 
using different mouse lines designed to express the Cre recombinase protein in specific cell 
lineages in a chemical liver injury mouse model. 3,5-diethoxycarbonyl-1,4-dihydrocollidine 
(DDC), a derivative of the anti-fungal compound griseofulvin, feeding induces the emergence of 
a ductular reaction and a chronic cholestatic liver injury model in mice. 
  
We performed hepatoblast lineage tracing using a mouse containing Tg(Alb-cre)21Mgn (Albumin-
Cre) (Postic and Magnuson, 2000) and Gt(ROSA)26Sortm1(EYFP)Cos (ROSA26R-EYFP) (Srinivas 
et al., 2001). The ROSA26R-EYFP allele is a Cre-activated reporter, which upon recombination 
results in EYFP expression that is stably inherited by all descendants regardless of their 
differentiated fate. We found that all BECs and hepatocytes express the EYFP lineage label in 
an uninjured adult mouse liver (Figure E.1A). After three weeks of DDC treatment, all reactive 
BECs similarly possessed the EYFP lineage label, indicating an Albumin-Cre-expressing 
hepatoblast origin (Figure E.1B). 
 
To determine the contribution potential of reactive BECs, we performed temporal-specific 
lineage labeling of BECs with Krt19tm1(cre/ERT)Ggu (Cytokeratin19-CreERT) (Means et al., 2008) in 
combination with the Cre-mediated reporter ROSA26R-EYFP (Srinivas et al., 2001). To indelibly 
label BECs of quiescent IHBDs and reactive ductules, we injected tamoxifen at different times to 
induce reporter allele recombination and expression of EYFP. To ensure that the lineage label is 
specific, we analyzed the expression of EYFP after tamoxifen injection with no DDC injury 
(Figure E.2A). To assess any interlineage  
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conversion of BECs to hepatocytes during normal homeostatic maintenance, we injected 
tamoxifen and waited for 4.5 months before analyzing the mice (Figure E.2B). We found that 
after 4.5 months of homeostatic maintenance, the lineage label was still not observed in any 
hepatocytes. 
 
To assess the bipotentiality of CK19-expressing cells in response to an injury, we injected 
tamoxifen either before or throughout the DDC treatment. We found that whether we labeled 
BECs prior to the injury, targeting quiescent BECs (Figure E.2C), or during the injury, targeting 
reactive BECs (Figure E.2D), we found no hepatocytes expressing the lineage label after a 
period of recovery. This indicates that CK19-expressing cells that are present in an uninjured 
liver and that are present under a DDC injury condition do not provide any substantial 
contribution to hepatocytes during or after DDC injury. 
 
To further test if a quiescent progenitor exists that expresses CK19 under injury but has a slow 
rate of expansion, we induced lineage labeling after 1 week of DDC treatment. We then allowed 
the mice to recover for 1 week. At this point, no hepatocytes expressed the EYFP lineage label 
(Figure E.3A). We then re-subjected the mice to another week of DDC feeding to re-activate any 
labeled quiescent stem cell that may exist. After one week of re-injury, we still did not see any 
hepatocytes that expressed the EFYP lineage label (Figure E.3B). 
 
Finally, we assessed whether CK19-expressing cells during embryonic hepatogenesis may give 
rise to adult bipotential progenitor cells. Previous studies have suggested that ductal plate cells 
that regress into hepatocytes may serve as a bipotential progenitor compartment in adult mice 
(Carpentier et al., 2011). We induced lineage labeling  
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embryonically by injecting pregnant females with tamoxifen between embryonic day (E)17.5-
19.5. We allowed the mice to age for 8 weeks, at which time the lineage label was observed 
only in CK19-expressing BECs (Figure E.4A). We subjected the mice to 3 weeks of DDC 
treatment. After DDC treatment, no hepatocytes were observed that possessed the EYFP 
lineage label (Figure E.4B). We also assessed mice after 3 weeks of DDC treatment and a 
recovery period of 3 weeks; again, no hepatocytes were found that expressed the lineage label 
(Figure E.4C). 
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Conclusion 
 
The lineage-tracing data indicate that DDC injury does not stimulate an abundant bipotential 
progenitor that expresses CK19 and provides a substantial contribution to the hepatocyte 
lineage. We assessed several CK19-expressing populations, including quiescent and activated 
BECs along with CK19-expressing cells in the embryonic ductal plate. None of these 
populations contained a bipotential progenitor cell that gave rise to hepatocytes under DDC 
injury conditions. 
 
Due to the incomplete recombination observed with the Cytokeratin19-CreERT mouse, we are 
not able to conclude that no Cytokeratin19-CreERT–lineage cells have the potential to give rise 
to hepatocytes; we only state that it is unlikely that CK19-expressing populations contribute 
significantly to hepatocytes in a DDC-induced injury model. 
 
It may also be that the Cytokeratin19-CreERT recombination occurs most frequently in the cells 
that express the highest amount of CK19 and may also be the most differentiated BECs. Hence, 
we may be missing a population of weakly-expressing CK19+ cells that do have bipotentiality. 
This idea is somewhat supported by the finding that no cells lineage-traced embryonically gave 
rise to hepatocytes. Previous data utilizing another BEC marker, Sox9, has been able to 
lineage-trace ductal plate cells and find that some of them regress into periportal hepatocytes 
(Carpentier et al., 2011). The lack of lineage-traced hepatocytes in our Cytokeratin19-CreERT 
mouse line may indicate that the cells that express CK19, and Cytokeratin19-CreERT, may 
represent a more highly-differentiated subset of ductal plate cells that are already committed to 
the BEC lineage and do no regress into hepatocytes. 
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It may also be that the DDC feeding injury model is not the correct model to activate a CK19-
expressing bipotential progenitor. Please see Chapter 4 of this dissertation for a comparison of 
different rodent liver injury models. 
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Methods 
 
Hepatoblast-specific lineage-tracing mice were generated by crossing the Albumin-Cre allele 
(Postic and Magnuson, 2000) with the ROSA26R-EYFP allele (Srinivas et al., 2001). BEC 
lineage tracing mice were generated by crossing the Cytokeratin19-CreERT allele (Means et al., 
2008) with the ROSA26R-EYFP allele (Srinivas et al., 2001). 
 
Tamoxifen was prepared at 40 mg/mL in a solution of 90% corn oil; 10% ethanol. 
 
Embryonic lineage tracing was performed by injecting 2mg of tamoxifen into a pregnant female 
at 17.5-19.5 days of gestation. 
 
Lineage tracing before injury was done by injecting a series of 4 tamoxifen injections, 4 mg 
each, ever other day over the course of 7 days. 
 
Lineage tracing over the course of injury was done by injecting a series of tamoxifen injections 
into mice, starting before DDC feeding and ending after DDC food was removed. For the first 
injection, 4 mg tamoxifen was administered 5 days before starting DDC feeding. For the second 
injection, 4 mg of tamoxifen was administered on the first day of DDC feeding. The third, fourth, 
and fifth injections were each 2 mg of tamoxifen and were administered after 7, 14, and 21 days 
of DDC feeding, respectively. The final dose of tamoxifen was 4 mg and was administered 4 
days after the removal of DDC food. 
 
Lineage tracing after 1 week of DDC and prior to re-injury was done by injecting a single dose of 
4mg tamoxifen on the 7th day of DDC feeding, at which time the DDC food was removed from 
the mice. 
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See Chapter 2 of this dissertation for immunohistochemistry methods. 
232 
 
REFERENCES 
 
Abdel-Samad, R., Zalzali, H., Rammah, C., Giraud, J., Naudin, C., Dupasquier, S., Poulat, F., 
Boizet-Bonhoure, B., Lumbroso, S., Mouzat, K., Bonnans, C., Pignodel, C., Raynaud, P., 
Fort, P., Quittau-Prevostel, C., Blache, P., 2011. MiniSOX9, a dominant-negative variant 
in colon cancer cells. Oncogene 30, 2493-2503. 
Ahn S, H.J., Park CK, 2013. Notch1 and Notch4 are markers for poor prognosis of 
hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 12, 286-294. 
Aird, W.C., 2007. Phenotypic heterogeneity of the endothelium II. Representative vascular 
beds. Circulation research 100, 174-190. 
Allen, J.W., Bhatia, S.N., 2003. Formation of steady-state oxygen gradients in vitro: Application 
to liver zonation. Biotechnology and Bioengineering 82, 253-262. 
Andersson, E.R., Sandberg, R., Lendahl, U., 2011. Notch signaling: simplicity in design, 
versatility in function. Development 138, 3593-3612. 
Antoniou, A., Raynaud, P., Cordi, S., Zong, Y., Tronche, F.ß., Stanger, B.Z., Jacquemin, P., 
Pierreux, C.E., Clotman, F., Lemaigre, F.P., 2009. Intrahepatic Bile Ducts Develop 
According to a New Mode of Tubulogenesis Regulated by the Transcription Factor 
SOX9. Gastroenterology 136, 2325-2333. 
Apte, U., Singh, S., Zeng, G., Cieply, B., Virji, M.A., Wu, T., Monga, S.P.S., 2009. Beta-Catenin 
Activation Promotes Liver Regeneration after Acetaminophen-Induced Injury. The 
American journal of pathology 175, 1056-1065. 
Apte, U., Thompson, M.D., Cui, S., Liu, B., Cieply, B., Monga, S.P.S., 2008. Wnt/"-catenin 
signaling mediates oval cell response in rodents. Hepatology 47, 288-295. 
Bai, H., Zhang, N., Xu, Y., Chen, Q., Khan, M., Potter, J.J., Nayar, S.K., Cornish, T., Alpini, G., 
Bronk, S., Pan, D., Anders, R.A., 2012. Yes-associated protein regulates the hepatic 
response after bile duct ligation. Hepatology 56, 1097-1107. 
Bastide, P., Darido, C., Pannequin, J., Kist, R., Robine, S., Marty-Double, C., Bibeau, F.d.r., 
Scherer, G., Joubert, D., Hollande, F.d.r., Blache, P., Jay, P., 2007. Sox9 regulates cell 
proliferation and is required for Paneth cell differentiation in the intestinal epithelium. The 
Journal of Cell Biology 178, 635-648. 
Behari, J., Yeh, T.-H., Krauland, L., Otruba, W., Cieply, B., Hauth, B., Apte, U., Wu, T., Evans, 
R., Monga, S.P.S., 2010. Liver-Specific "-Catenin Knockout Mice Exhibit Defective Bile 
Acid and Cholesterol Homeostasis and Increased Susceptibility to Diet-Induced 
Steatohepatitis. The American journal of pathology 176, 744-753. 
Benedito, R., Roca, C., Sörensen, I., Adams, S., Gossler, A., Fruttiger, M., Adams, R.H., 2009. 
The Notch Ligands Dll4 and Jagged1 Have Opposing Effects on Angiogenesis. Cell 137, 
1124-1135. 
233 
Benhamouche, S., Decaens, T., Godard, C., Chambrey, R., Rickman, D.S., Moinard, C., 
Vasseur-Cognet, M., Kuo, C.J., Kahn, A., Perret, C., Colnot, S., 2006. Apc Tumor 
Suppressor Gene Is the  Zonation-Keeper  of Mouse Liver. Developmental cell 10, 759-
770. 
Bhatia, S.N., Toner, M., Foy, B.D., Rotem, A., O'Neil, K.M., Tompkins, R.G., Yarmush, M.L., 
1996. Zonal liver cell heterogeneity: effects of oxygen on metabolic functions of 
hepatocytes. Cellular Engineering. 
Blache, P., van de Wetering, M., Duluc, I., Domon, C., Berta, P., Freund, J.-N.l., Clevers, H., 
Jay, P., 2004. SOX9 is an intestine crypt transcription factor, is regulated by the Wnt 
pathway, and represses the CDX2 and MUC2 genes. The Journal of Cell Biology 166, 
37-47. 
Bockhorn, M., Goralski, M., Prokofiev, D., Dammann, P., Grünewald, P., Trippler, M., Biglarnia, 
A., Kamler, M., Niehues, E.M., Frilling, A., Broelsch, C.E., Schlaak, J.F., 2007. VEGF is 
Important for Early Liver Regeneration After Partial Hepatectomy. The Journal of 
surgical research 138, 291-299. 
Bolós, V., Grego-Bessa, J., de la Pompa, J.L., 2007. Notch Signaling in Development and 
Cancer. Endocrine Reviews 28, 339-363. 
Bort, R., Signore, M., Tremblay, K., Barbera, J.P.M., Zaret, K.S., 2006. Hex homeobox gene 
controls the transition of the endoderm to a pseudostratified, cell emergent epithelium for 
liver bud development. Developmental Biology 290, 44-56. 
Boulter, L., Govaere, O., Bird, T.G., Radulescu, S., Ramachandran, P., Pellicoro, A., Ridgway, 
R.A., Seo, S.S., Spee, B., Van Rooijen, N., Sansom, O.J., Iredale, J.P., Lowell, S., 
Roskams, R., Forbes, S.J., 2012. Macrophage-derived Wnt opposes Notch signaling to 
specify hepatic progenitor cell fate in chronic liver disease. Nat Med 18, 572-579. 
CADORET, #160, Axelle, OVEJERO, #160, Christine, TERRIS, #160, Benoit, SOUIL, #160, 
Evelyne, LEVY, #160, Laurence, LAMERS, #160, H., W., KITAJEWSKI, #160, Jan, 
KAHN, #160, Axel, PERRET, #160, Christine, 2002. New targets of &#946;-catenin 
signaling in the liver are involved in the glutamine metabolism. Nature Publishing Group, 
Basingstoke, ROYAUME-UNI. 
Campbell, K.M., Sabla, G.E., Bezerra, J.A., 2004. Transcriptional reprogramming in murine 
liver defines the physiologic consequences of biliary obstruction. Journal of Hepatology 
40, 14-23. 
Carlson, T.R., Yan, Y., Wu, X., Lam, M.T., Tang, G.L., Beverly, L.J., Messina, L.M., 
Capobianco, A.J., Werb, Z., Wang, R., 2005. Endothelial expression of constitutively 
active Notch4 elicits reversible arteriovenous malformations in adult mice. Proceedings 
of the National Academy of Sciences of the United States of America 102, 9884-9889. 
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., 
Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawling, J., Moons, L., Collen, 
D., Risau, W., Nagy, A., 1996. Abnormal blood vessel development and lethality in 
embryos lacking a single VEGF allele. Nature 380, 435-439. 
234 
Carpenter, B., Lin, Y., Stoll, S., Raffai, R.L., McCuskey, R., Wang, R., 2005. VEGF is crucial for 
the hepatic vascular development required for lipoprotein uptake. Development 132, 
3293-3303. 
Carpentier, R., Español-Suñer, R., van Hul, N., Kopp, J.L., Beaudry, J.Ä., Cordi, S., Antoniou, 
A., Raynaud, P., Lepreux, S., Jacquemin, P., Leclercq, I.A., Sander, M., Lemaigre, F.P., 
2011. Embryonic Ductal Plate Cells Give Rise to Cholangiocytes, Periportal 
Hepatocytes, and Adult Liver Progenitor Cells. Gastroenterology 141, 1432-1438.e1434. 
Carpino, G., Cardinale, V., Onori, P., Franchitto, A., Berloco, P.B., Rossi, M., Wang, Y., 
Semeraro, R., Anceschi, M., Brunelli, R., Alvaro, D., Reid, L.M., Gaudio, E., 2012. Biliary 
tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: an 
anatomical in situ study yielding evidence of maturational lineages. Journal of Anatomy 
220, 186-199. 
Cheluvappa, R., Hilmer, S.N., Kwun, S.Y., Jamieson, H.A., O’Reilly, J.N., Muller, M., Cogger, 
V.C., Le Couteur, D.G., 2007. The effect of old age on liver oxygenation and the hepatic 
expression of VEGF and VEGFR2. Experimental Gerontology 42, 1012-1019. 
Chen, S., Tao, J., Bae, Y., Jiang, M.-M., Bertin, T., Chen, Y., Yang, T., Lee, B., 2012. Notch 
gain of function inhibits chondrocyte differentiation via Rbpj-dependent suppression of 
Sox9. Journal of Bone and Mineral Research, n/a-n/a. 
Clemons, N.J., Wang, D.H., Croagh, D., Tikoo, A., Fennell, C.M., Murone, C., Scott, A.M., 
Watkins, D.N., Phillips, W.A., 2012. Sox9 drives columnar differentiation of esophageal 
squamous epithelium: a possible role in the pathogenesis of Barrett's esophagus. 
American Journal of Physiology - Gastrointestinal and Liver Physiology 303, G1335-
G1346. 
Clotman, F., Lannoy, V., Reber, M., Cereghini, S., Cassiman, D., Jacquemin, P., Roskams, T., 
Rousseau, G., Lemaigre, F., 2002. The onecut transcription factor HNF6 is required for 
normal development of the biliary tract. Development 129, 1819 - 1828. 
Coffinier, C., Gresh, L., Fiette, L., Tronche, F., Schutz, G., Babinet, C., Pontoglio, M., Yaniv, 
M., Barra, J., 2002. Bile system morphogenesis defects and liver dysfunction upon 
targeted deletion of HNF1beta. Development 129, 1829 - 1838. 
Collardeau-Frachon, S., Scoazec, J.-Y., 2008. Vascular Development and Differentiation 
During Human Liver Organogenesis. The Anatomical Record: Advances in Integrative 
Anatomy and Evolutionary Biology 291, 614-627. 
Colletti, M., Cicchini, C., Conigliaro, A., Santangelo, L., Alonzi, T., Pasquini, E., Tripodi, M., 
Amicone, L., 2009. Convergence of Wnt Signaling on the HNF4!-Driven Transcription in 
Controlling Liver Zonation. Gastroenterology 137, 660-672. 
Colnot, S., Perret, C., 2011. Liver Zonation, in: Monga, S.P.S. (Ed.), Molecular Pathology of 
Liver Diseases. Springer, pp. 7-15. 
Connolly, D.T., Heuvelman, D.M., Nelson, R., Olander, J.V., Eppley, B.L., Delfino, J.J., Siegel, 
N.R., Leimgruber, R.M., Feder, J., 1989. Tumor vascular permeability factor stimulates 
endothelial cell growth and angiogenesis. The Journal of Clinical Investigation 84, 1470-
1478. 
235 
Crawford, L.W., Foley, J.F., Elmore, S.A., 2010. Histology atlas of the developing mouse 
hepatobiliary system with emphasis on embryonic days 9.5-18.5. Toxicologic pathology 
38, 872-906. 
D'Ambrosio, R., Aghemo, A., Rumi, M.G., Ronchi, G., Donato, M.F., Paradis, V., Colombo, M., 
Bedossa, P., 2012. A morphometric and immunohistochemical study to assess the 
benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. 
Hepatology 56, 532-543. 
Darwiche, H., Oh, S.-H., Steiger-Luther, N.C., Williams, J.M., Pintilie, D.G., Shupe, T.D., 
Petersen, B.E., 2011. Inhibition of Notch signaling affects hepatic oval cell response in 
rat model of 2AAF-PH. Hepatic medicine: evidence and research 3, 89. 
DeLeve, L.D., Wang, X., Hu, L., McCuskey, M.K., McCuskey, R.S., 2004. Rat liver sinusoidal 
endothelial cell phenotype is maintained by paracrine and autocrine regulation. 
American Journal of Physiology - Gastrointestinal and Liver Physiology 287, G757-
G763. 
Delous, M., Yin, C., Shin, D., Ninov, N., Debrito Carten, J., Pan, L., Ma, T.P., Farber, S.A., 
Moens, C.B., Stainier, D.Y.R., 2012. sox9b Is a Key Regulator of Pancreaticobiliary 
Ductal System Development. PLoS Genet 8, e1002754. 
Desmet, V., 2011. Ductal plates in hepatic ductular reactions. Hypothesis and implications. I. 
Types of ductular reaction reconsidered. Virchows Archiv 458, 251-259. 
Desmet, V., Roskams, T., Van Eyken, P., 1995. Ductular reaction in the liver. Pathol Res Pract 
191, 513 - 524. 
Desmet, V.J., 1992. Congenital diseases of intrahepatic bile ducts: Variations on the theme 
“ductal plate malformation”. Hepatology 16, 1069-1083. 
Dessaud, E., McMahon, A.P., Briscoe, J., 2008. Pattern formation in the vertebrate neural tube: 
a sonic hedgehog morphogen-regulated transcriptional network. Development 135, 
2489-2503. 
Dill, M.T., Tornillo, L., Fritzius, T., Terracciano, L., Semela, D., Bettler, B., Heim, M.H., Tchorz, 
J.S., 2013. Constitutive Notch2 signaling induces hepatic tumors in mice. Hepatology 57, 
1607-1619. 
Ding, B.-S., Nolan, D.J., Butler, J.M., James, D., Babazadeh, A.O., Rosenwaks, Z., Mittal, V., 
Kobayashi, H., Shido, K., Lyden, D., 2010. Inductive angiocrine signals from sinusoidal 
endothelium are required for liver regeneration. Nature 468, 310-315. 
Discher, D.E., Mooney, D.J., Zandstra, P.W., 2009. Growth Factors, Matrices, and Forces 
Combine and Control Stem Cells. Science 324, 1673-1677. 
Dorrell, C., Erker, L., Schug, J., Kopp, J.L., Canaday, P.S., Fox, A.J., Smirnova, O., Duncan, 
A.W., Finegold, M.J., Sander, M., Kaestner, K.H., Grompe, M., 2011. Prospective 
isolation of a bipotential clonogenic liver progenitor cell in adult mice. Genes & 
Development 25, 1193-1203. 
236 
Dou, G.-R., Wang, Y.-C., Hu, X.-B., Hou, L.-H., Wang, C.-M., Xu, J.-F., Wang, Y.-S., Liang, Y.-
M., Yao, L.-B., Yang, A.-G., Han, H., 2008. RBP-J, the transcription factor downstream 
of Notch receptors, is essential for the maintenance of vascular homeostasis in adult 
mice. The FASEB Journal 22, 1606-1617. 
Eichmann, A., Makinen, T., Alitalo, K., 2005. Neural guidance molecules regulate vascular 
remodeling and vessel navigation. Genes & development 19, 1013-1021. 
Español-Suñer, R., Carpentier, R., Van Hul, N., Legry, V., Achouri, Y., Cordi, S., Jacquemin, 
P., Lemaigre, F., Leclercq, I.A., 2012. Liver Progenitor Cells Yield Functional 
Hepatocytes in Response to Chronic Liver Injury in Mice. Gastroenterology 143, 1564-
1575.e1567. 
Fabris, L., Cadamuro, M., Fiorotto, R., Roskams, T., Spirlì, C., Melero, S., Sonzogni, A., Joplin, 
R.E., Okolicsanyi, L., Strazzabosco, M., 2006. Effects of angiogenic factor 
overexpression by human and rodent cholangiocytes in polycystic liver diseases. 
Hepatology 43, 1001-1012. 
Fabris, L., Cadamuro, M., Guido, M., Spirli, C., Fiorotto, R., Colledan, M., Torre, G., Alberti, D., 
Sonzogni, A., Okolicsanyi, L., Strazzabosco, M., 2007. Analysis of Liver Repair 
Mechanisms in Alagille Syndrome and Biliary Atresia Reveals a Role for Notch 
Signaling. The American Journal of Pathology 171, 641-653. 
Fabris, L., Cadamuro, M., Libbrecht, L., Raynaud, P., Spirlì, C., Fiorotto, R., Okolicsanyi, L., 
Lemaigre, F., Strazzabosco, M., Roskams, T., 2008. Epithelial expression of angiogenic 
growth factors modulate arterial vasculogenesis in human liver development. Hepatology 
47, 719-728. 
Factor, V.M., Jensen, M.R., Thorgeirsson, S.S., 1997. Coexpression of C-myc and 
transforming growth factor alfa in the liver promotes early replicative senescence and 
diminishes regenerative capacity after partial hepatectomy in transgenic mice. 
Hepatology 26, 1434-1443. 
Falkowski, O., An, H.J., Ianus, I.A., Chiriboga, L., Yee, H., West, A.B., Theise, N.D., 2003. 
Regeneration of hepatocyte ‚Äòbuds‚Äô in cirrhosis from intrabiliary stem cells. Journal 
of Hepatology 39, 357-364. 
Fan, B., Malato, Y., Calvisi, D.F., Naqvi, S., Razumilava, N., Ribback, S., Gores, G.J., 
Dombrowski, F., Evert, M., Chen, X., Willenbring, H., 2012. Cholangiocarcinomas can 
originate from hepatocytes in mice. The Journal of Clinical Investigation 122, 2911-2915. 
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K.S., Powell-Braxton, L., 
Hillan, K.J., Moore, M.W., 1996. Heterozygous embryonic lethality induced by targeted 
inactivation of the VEGF gene. Nature 380, 439-442. 
Ferrara, N., Davis-Smyth, T., 1997. The Biology of Vascular Endothelial Growth Factor. 
Endocrine Reviews 18, 4-25. 
Fiorotto, R., Raizner, A., Morell, C.M., Torsello, B., Scirpo, R., Fabris, L., Spirli, C., 
Strazzabosco, M., 2013. Notch signaling regulates tubular morphogenesis during repair 
from biliary damage in mice. Journal of hepatology 59, 124-130. 
237 
Fong, G.-H., Rossant, J., Gertsenstein, M., Breitman, M.L., 1995. Role of the Flt-1 receptor 
tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66-70. 
Franco, M., Roswall, P., Cortez, E., Hanahan, D., Pietras, K., 2011. Pericytes promote 
endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w 
expression. Blood 118, 2906-2917. 
Furuyama, K., Kawaguchi, Y., Akiyama, H., Horiguchi, M., Kodama, S., Kuhara, T., Hosokawa, 
S., Elbahrawy, A., Soeda, T., Koizumi, M., 2010. Continuous cell supply from a Sox9-
expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nature 
genetics 43, 34-41. 
Furuyama, K., Kawaguchi, Y., Akiyama, H., Horiguchi, M., Kodama, S., Kuhara, T., Hosokawa, 
S., Elbahrawy, A., Soeda, T., Koizumi, M., Masui, T., Kawaguchi, M., Takaori, K., Doi, 
R., Nishi, E., Kakinoki, R., Deng, J.M., Behringer, R.R., Nakamura, T., Uemoto, S., 2011. 
Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine 
pancreas and intestine. Nature genetics 43, 34-41. 
Gaudio, E., Barbaro, B., Alvaro, D., Glaser, S., Francis, H., Franchitto, A., Onori, P., Ueno, Y., 
Marzioni, M., Fava, G., 2006. Administration of r-VEGF-A prevents hepatic artery 
ligation-induced bile duct damage in bile duct ligated rats. American Journal of 
Physiology-Gastrointestinal and Liver Physiology 291, G307-G317. 
Geisler, F., Nagl, F., Mazur, P.K., Lee, M., Zimber-Strobl, U., Strobl, L.J., Radtke, F., Schmid, 
R.M., Siveke, J.T., 2008. Liver-specific inactivation of Notch2, but not Notch1, 
compromises intrahepatic bile duct development in mice. Hepatology (Baltimore, Md.) 
48, 607-616. 
Gerber, H.-P., Malik, A.K., Solar, G.P., Sherman, D., Liang, X.H., Meng, G., Hong, K., 
Marsters, J.C., Ferrara, N., 2002. VEGF regulates haematopoietic stem cell survival by 
an internal autocrine loop mechanism. Nature 417, 954-958. 
Gerber, H.P., Hillan, K.J., Ryan, A.M., Kowalski, J., Keller, G.A., Rangell, L., Wright, B.D., 
Radtke, F., Aguet, M., Ferrara, N., 1999. VEGF is required for growth and survival in 
neonatal mice. Development 126, 1149-1159. 
Gerhardt, H., Golding, M., Fruttiger, M., Ruhrberg, C., Lundkvist, A., Abramsson, A., Jeltsch, 
M., Mitchell, C., Alitalo, K., Shima, D., Betsholtz, C., 2003. VEGF guides angiogenic 
sprouting utilizing endothelial tip cell filopodia. The Journal of Cell Biology 161, 1163-
1177. 
Glaser, S.S., Gaudio, E., Rao, A., Pierce, L.M., Onori, P., Franchitto, A., Francis, H.L., Dostal, 
D.E., Venter, J.K., DeMorrow, S., Mancinelli, R., Carpino, G., Alvaro, D., Kopriva, S.E., 
Savage, J.M., Alpini, G.D., 2009. Morphological and functional heterogeneity of the 
mouse intrahepatic biliary epithelium. Lab Invest 89, 456-469. 
Goldman, O., Han, S., Sourrisseau, M., Dziedzic, N., Hamou, W., Corneo, B., D‚ÄôSouza, S., 
Sato, T., Kotton, D.N., Bissig, K.-D., Kalir, T., Jacobs, A., Evans, T., Evans, M.J., Gouon-
Evans, V., 2013. KDR Identifies a Conserved Human and Murine Hepatic Progenitor and 
Instructs Early Liver Development. Cell Stem Cell 12, 748-760. 
238 
Göthert, J.R., Gustin, S.E., van Eekelen, J.A.M., Schmidt, U., Hall, M.A., Jane, S.M., Green, 
A.R., Göttgens, B., Izon, D.J., Begley, C.G., 2004. Genetically tagging endothelial cells 
in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood 104, 
1769-1777. 
Gottgens, B., Broccardo, C., Sanchez, M.-J., Deveaux, S., Murphy, G., G*+thert, J.R., 
Kotsopoulou, E., Kinston, S., Delaney, L., Piltz, S., Barton, L.M., Knezevic, K., Erber, 
W.N., Begley, C.G., Frampton, J., Green, A.R., 2004. The scl +18/19 Stem Cell 
Enhancer Is Not Required for Hematopoiesis: Identification of a 5‚Ä, Bifunctional 
Hematopoietic-Endothelial Enhancer Bound by Fli-1 and Elf-1. Molecular and Cellular 
Biology 24, 1870-1883. 
Gouw, A.S.H., Clouston, A.D., Theise, N.D., 2011. Ductular reactions in human liver: Diversity 
at the interface. Hepatology 54, 1853-1863. 
Gouysse, G., Couvelard, A., Frachon, S., Bouvier, R., Nejjari, M., Dauge, M.-C., Feldmann, G., 
Hénin, D., Scoazec, J.-Y., 2002. Relationship between vascular development and 
vascular differentiation during liver organogenesis in humans. Journal of hepatology 37, 
730-740. 
Gridley, T., 2007. Notch signaling in vascular development and physiology. Development 134, 
2709-2718. 
Gualdi, R., Bossard, P., Zheng, M., Hamada, Y., Coleman, J.R., Zaret, K.S., 1996. Hepatic 
specification of the gut endoderm in vitro: cell signaling and transcriptional control. 
Genes & Development 10, 1670-1682. 
Guilak, F., Cohen, D.M., Estes, B.T., Gimble, J.M., Liedtke, W., Chen, C.S., 2009. Control of 
Stem Cell Fate by Physical Interactions with the Extracellular Matrix. Cell Stem Cell 5, 
17-26. 
Guo, X., Xiong, L., Sun, T., Peng, R., Zou, L., Zhu, H., Zhang, J., Li, H., Zhao, J., 2012. 
Expression features of SOX9 associate with tumor progression and poor prognosis of 
hepatocellular carcinoma. Diagnostic Pathology 7, 44. 
Haller, R., Schwanbeck, R., Martini, S., Bernoth, K., Kramer, J., Just, U., Rohwedel, J., 2012. 
Notch1 signaling regulates chondrogenic lineage determination through Sox9 activation. 
Cell Death Differ 19, 461-469. 
Hamaguchi, Y., Yamamoto, Y., Iwanari, H., Maruyama, S., Furukawa, T., Matsunami, N., 
Honjo, T., 1992. Biochemical and Immunological Characterization of the DNA Binding 
Protein (RBP-Jx) to Mouse Jx Recombination Signal Sequence. Journal of Biochemistry 
112, 314-320. 
Han, H., Tanigaki, K., Yamamoto, N., Kuroda, K., Yoshimoto, M., Nakahata, T., Ikuta, K., 
Honjo, T., 2002. Inducible gene knockout of transcription factor recombination signal 
binding protein‚RBPJ reveals its essential role in T versus B lineage decision. 
International Immunology 14, 637-645. 
Hardingham, T.E., Oldershaw, R.A., Tew, S.R., 2006. Cartilage, SOX9 and Notch signals in 
chondrogenesis. Journal of Anatomy 209, 469-480. 
239 
Hellström, M., Phng, L.-K., Hofmann, J.J., Wallgard, E., Coultas, L., Lindblom, P., Alva, J., 
Nilsson, A.-K., Karlsson, L., Gaiano, N., 2007. Dll4 signalling through Notch1 regulates 
formation of tip cells during angiogenesis. Nature 445, 776-780. 
Herbert, S.P., Stainier, D.Y.R., 2011. Molecular control of endothelial cell behavior during blood 
vessel morphogenesis. Nature Reviews Molecular Cellular Biology 12, 551-564. 
Hoeben, A., Landuyt, B., Highley, M.S., Wildiers, H., Van Oosterom, A.T., De Bruijn, E.A., 
2004. Vascular Endothelial Growth Factor and Angiogenesis. Pharmacological Reviews 
56, 549-580. 
Hofmann, J.J., Zovein, A.C., Koh, H., Radtke, F., Weinmaster, G., Iruela-Arispe, M.L., 2010. 
Jagged1 in the portal vein mesenchyme regulates intrahepatic bile duct development: 
insights into Alagille syndrome. Development 137, 4061-4072. 
Holterman, A.-X.L., Tan, Y., Kim, W., Yoo, K.W., Costa, R.H., 2002. Diminished hepatic 
expression of the HNF-6 transcription factor during bile duct obstruction. Hepatology 35, 
1392-1399. 
Ishikawa, K., Mochida, S., Mashiba, S., Inao, M., Matsui, A., Ikeda, H., Ohno, A., Shibuya, M., 
Fujiwara, K., 1999. Expressions of Vascular Endothelial Growth Factor in 
Nonparenchymal as Well as Parenchymal Cells in Rat Liver after Necrosis. Biochemical 
and Biophysical Research Communications 254, 587-593. 
Jeliazkova, P., Jörs, S., Lee, M., Zimber-Strobl, U., Ferrer, J., Schmid, R.M., Siveke, J.T., 
Geisler, F., 2013. Canonical Notch2 signaling determines biliary cell fates of embryonic 
hepatoblasts and adult hepatocytes independent of Hes1. Hepatology, n/a-n/a. 
Jung, J., Zheng, M., Goldfarb, M., Zaret, K.S., 1999. Initiation of Mammalian Liver 
Development from Endoderm by Fibroblast Growth Factors. Science 284, 1998-2003. 
Jungermann, K., Keitzmann, T., 1996. Zonation of Parenchymal and Nonparenchymal 
Metabolism in Liver. Annual Review of Nutrition 16, 179-203. 
Jungermann, K., Kietzmann, T., 1997. Role of oxygen in the zonation of carbohydrate 
metabolism and gene expression in liver : Oxygen sensing on the cellular and molecular 
level. Nature Publishing Group, Basingstoke, ROYAUME-UNI. 
Jungermann, K., Kietzmann, T., 2000. Oxygen: Modulator of metabolic zonation and disease of 
the liver. Hepatology 31, 255-260. 
Kaestner, K.H., 2005. The Making of the Liver: Competence in the Foregut Endoderm and 
Induction of Liver-Specific Genes. Cell Cycle 4, 1146-1148. 
Kamba, T., McDonald, D.M., 2007. Mechanisms of adverse effects of anti-VEGF therapy for 
cancer. British Journal of Cancer 96, 1788-1795. 
Kato, T., Ito, Y., Hosono, K., Suzuki, T., Tamaki, H., Minamino, T., Kato, S., Sakagami, H., 
Shibuya, M., Majima, M., 2011. Vascular endothelial growth factor receptor-1 signaling 
promotes liver repair through restoration of liver microvasculature after acetaminophen 
hepatotoxicity. Toxicological Sciences 120, 218-229. 
240 
Kietzmann, T., Schmidt, H., Probst, I., Jungermann, K., 1992. Modulation of the glucagon-
dependent activation of the phosphoenolpyruvate carboxykinase gene by oxygen in rat 
hepatocyte cultures Evidence for a heme protein as oxygen sensor. FEBS Letters 311, 
251-255. 
Kietzmann, T., Schmidt, H., Unthanfechner, K., Probst, I., Jungermann, K., 1993. A Ferro-
Heme Protein Senses Oxygen Levels, Which Modulate the Glucagon-Dependent 
Activation of the Phosphoenolpyruvate Carboxykinase Gene in Rat Hepatocyte Cultures. 
Biochemical and Biophysical Research Communications 195, 792-798. 
Kiyohashi, K., Kakinuma, S., Kamiya, A., Sakamoto, N., Nitta, S., Yamanaka, H., Yoshino, K., 
Fujiki, J., Murakawa, M., Kusano-Kitazume, A., Shimizu, H., Okamoto, R., Azuma, S., 
Nakagawa, M., Asahina, Y., Tanimizu, N., Kikuchi, A., Nakauchi, H., Watanabe, M., 
2013. Wnt5a signaling mediates biliary differentiation of fetal hepatic stem/progenitor 
cells in mice. Hepatology 57, 2502-2513. 
Kodama, Y., Hijikata, M., Kageyama, R., Shimotohno, K., Chiba, T., 2004. The role of notch 
signaling in the development of intrahepatic bile ducts. Gastroenterology 127, 1775-
1786. 
Krueger, J., Liu, D., Scholz, K., Zimmer, A., Shi, Y., Klein, C., Siekmann, A., Schulte-Merker, 
S., Cudmore, M., Ahmed, A., le Noble, F., 2011. Flt1 acts as a negative regulator of tip 
cell formation and branching morphogenesis in the zebrafish embryo. Development 138, 
2111-2120. 
Kwon, G.S., Hadjantonakis, A.-K., 2009. Transthyretin mouse transgenes direct RFP 
expression or Cre-mediated recombination throughout the visceral endoderm. genesis 
47, 447-455. 
Kwon, S., Jeong, S., Jang, J., Lee, J., Lee, S., Kim, S., Kim, Y.Y., Kim, H., Kim, B., Jin, S.-Y., 
2012. Cyclooxygenase-2 and vascular endothelial growth factor in chronic hepatitis, 
cirrhosis and hepatocellular carcinoma. Clinical and Molecular Hepatology 18, 287-294. 
Lassau, J., Bastian, D., 1983. Organogenesis of the venous structures of the human liver: a 
hemodynamic theory. Anatomia Clinica 5, 97-102. 
Lautt, W.W., 2009. Hepatic Circulation: Physiology and Pathopysiology. Morgan & Claypool 
Life Sciences, San Rafael, CA. 
Le Couteur, D.G., Cogger, V.C., Markus, A.M.A., Harvey, P.J., Yin, Z.-L., Ansselin, A.D., 
McLean, A.J., 2001. Pseudocapillarization and associated energy limitation in the aged 
rat liver. Hepatology 33, 537-543. 
Lee, C.S., Friedman, J.R., Fulmer, J.T., Kaestner, K.H., 2005. The initiation of liver 
development is dependent on Foxa transcription factors. Nature 435, 944-947. 
Lee, J.M., Yang, J., Newell, P., Singh, S., Parwani, A., Friedman, S.L., Nejak-Bowen, K.N., 
Monga, S.P., 2013. Beta-Catenin signaling in hepatocellular cancer: Implications in 
inflammation, fibrosis, and proliferation. Cancer Letters. 
241 
Lee, S., Chen, T.T., Barber, C.L., Jordan, M.C., Murdock, J., Desai, S., Ferrara, N., Nagy, A., 
Roos, K.P., Iruela-Arispe, M.L., 2007. Autocrine VEGF Signaling Is Required for 
Vascular Homeostasis. Cell 130, 691-703. 
Leung, A., Ciau-Uitz, A., Pinheiro, P., Monteiro, R., Zuo, J., Vyas, P., Patient, R., Porcher, C., 
2013. Uncoupling VEGFA Functions in Arteriogenesis and Hematopoietic Stem Cell 
Specification. Developmental Cell 24, 144-158. 
Limaye, P., Alarcon, G., Walls, A., Nalesnik, M., Michalopoulos, G., Demetris, A., Ochoa, E., 
2008a. Expression of specific hepatocyte and cholangiocyte transcription factors in 
human liver disease and embryonic development. Lab Invest 88, 865 - 872. 
Limaye, P., Bowen, W., Orr, A., Apte, U., Michalopoulos, G., 2010. Expression of hepatocytic- 
and biliary-specific transcription factors in regenerating bile ducts during hepatocyte-to-
biliary epithelial cell transdifferentiation. Comparative Hepatology 9, 9. 
Limaye, P.B., Bowen, W.C., Orr, A.V., Luo, J., Tseng, G.C., Michalopoulos, G.K., 2008b. 
Mechanisms of hepatocyte growth factor–mediated and epidermal growth factor–
mediated signaling in transdifferentiation of rat hepatocytes to biliary epithelium. 
Hepatology 47, 1702-1713. 
Lobov, I.B., Renard, R.A., Papadopoulos, N., Gale, N.W., Thurston, G., Yancopoulos, G.D., 
Wiegand, S.J., 2007. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative 
regulator of angiogenic sprouting. Proceedings of the National Academy of Sciences 
104, 3219-3224. 
Loebel, D.A.F., Watson, C.M., De Young, R.A., Tam, P.P.L., 2003. Lineage choice and 
differentiation in mouse embryos and embryonic stem cells. Developmental Biology 264, 
1-14. 
Lozier, J., McCright, B., Gridley, T., 2008a. Notch signaling regulates bile duct morphogenesis 
in mice. PLoS ONE 3, e1851-e1851. 
Lozier, J., McCright, B., Gridley, T., 2008b. Notch Signaling Regulates Bile Duct 
Morphogenesis in Mice. PLoS ONE 3, e1851. 
Malato, Y., Naqvi, S., Sch*ºrmann, N., Ng, R., Wang, B., Zape, J., Kay, M.A., Grimm, D., 
Willenbring, H., 2011. Fate tracing of mature hepatocytes in mouse liver homeostasis 
and regeneration. The Journal of Clinical Investigation 121, 4850-4860. 
Mancinelli, R., Onori, P., Gaudio, E., Franchitto, A., Carpino, G., Ueno, Y., Alvaro, D., 
Annarale, L.P., DeMorrow, S., Francis, H., 2009. Taurocholate Feeding to Bile Duct 
Ligated Rats Prevents Caffeic Acid-Induced Bile Duct Damage by Changes in 
Cholangiocyte VEGF Expression. Experimental Biology and Medicine 234, 462-474. 
Marschall, Z.v., Cramer, T., Höcker, M., Finkenzeller, G., Wiedenmann, B., Rosewicz, S., 2001. 
Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human 
hepatocellular carcinoma. Gut 48, 87-96. 
Matsumoto, K., Yoshitomi, H., Rossant, J., Zaret, K.S., 2001. Liver Organogenesis Promoted 
by Endothelial Cells Prior to Vascular Function. Science 294, 559-563. 
242 
Mazur, P.K., Riener, M.-O., Jochum, W., Kristiansen, G., Weber, A., Schmid, R.M., Siveke, 
J.T., 2012. Expression and Clinicopathological Significance of Notch Signaling and Cell-
Fate Genes in Biliary Tract Cancer. Am J Gastroenterol 107, 126-135. 
McCright, B., Lozier, J., Gridley, T., 2002. A mouse model of Alagille syndrome: Notch2 as a 
genetic modifier of Jag1 haploinsufficiency. Development 129, 1075-1082. 
Means, A.L., Xu, Y., Zhao, A., Ray, K.C., Gu, G., 2008. A CK19CreERT knockin mouse line 
allows for conditional DNA recombination in epithelial cells in multiple endodermal 
organs. genesis 46, 318-323. 
Meier-Stiegen, F., Schwanbeck, R., Bernoth, K., Martini, S., Hieronymus, T., Ruau, D., Zenke, 
M., Just, U., 2010. Activated Notch1 Target Genes during Embryonic Cell Differentiation 
Depend on the Cellular Context and Include Lineage Determinants and Inhibitors. PLoS 
ONE 5, e11481. 
Michalopoulos, G., Barua, L., Bowen, W., 2005. Transdifferentiation of rat hepatocytes into 
biliary cells after bile duct ligation and toxic biliary injury. Hepatology 41, 535 - 544. 
Michalopoulos, G., Bowen, W., Mule, K., Lopez-Talavera, J., Mars, W., 2002. Hepatocytes 
undergo phenotypic transformation to biliary epithelium in organoid cultures. Hepatology 
36, 278 - 283. 
Michalopoulos, G.K., DeFrances, M.C., 1997. Liver Regeneration. Science 276, 60-66. 
Mitchell, S.J., Huizer-Pajkos, A., Cogger, V.C., McLachlan, A.J., Le Couteur, D.G., Jones, B., 
de Cabo, R., Hilmer, S.N., 2011. Age-Related Pseudocapillarization of the Liver 
Sinusoidal Endothelium Impairs the Hepatic Clearance of Acetaminophen in Rats. The 
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 66A, 400-
408. 
Miyoshi, H., Rust, C., Roberts, P.J., Burgart, L.J., Gores, G.J., 1999. Hepatocyte apoptosis 
after bile duct ligation in the mouse involves Fas. Gastroenterology 117, 669-677. 
Moeini, A., Cornellà, H., Villanueva, A., 2012. Emerging signaling pathways in hepatocellular 
carcinoma. Liver Cancer 1, 83-93. 
Mohanty, S., Shivakumar, P., Sabla, G., Bezerra, J., 2006. Loss of interleukin-12 modifies the 
pro-inflammatory response but does not prevent duct obstruction in experimental biliary 
atresia. BMC Gastroenterol 6, 1-10. 
Moon, W.S., Rhyu, K.H., Kang, M.J., Lee, D.G., Yu, H.C., Yeum, J.H., Koh, G.Y., Tarnawski, 
A.S., 2003. Overexpression of VEGF and ANgiopoietin 2: A Key to High Vascularity of 
Hepatocellular Carcinoma? Modern Pathology 16, 552. 
Morell, C.M., Fabris, L., Strazzabosco, M., 2013. Vascular biology of the biliary epithelium. 
Journal of Gastroenterology and Hepatology 28, 26-32. 
Mori-Akiyama, Y., van den Born, M., van Es, J.H., Hamilton, S.R., Adams, H.P., Zhang, J., 
Clevers, H., de Crombrugghe, B., 2007. SOX9 Is Required for the Differentiation of 
Paneth Cells in the Intestinal Epithelium. Gastroenterology 133, 539-546. 
243 
Muto, A., Iida, A., Satoh, S., Watanabe, S., 2009. The group E Sox genes Sox8 and Sox9 are 
regulated by Notch signaling and are required for Muller glial cell development in mouse 
retina. Experimental Eye Research 89, 549-558. 
Oda, T., Elkahloun, A.G., Pike, B.L., Okajima, K., Krantz, I.D., Genin, A., Piccoli, D.A., Meltzer, 
P.S., Spinner, N.B., Collins, F.S., Chandrasekharappa, S.C., 1997. Mutations in the 
human Jagged1 gene are responsible for Alagille syndrome. Nat Genet 16, 235-242. 
Oe, H., Kaido, T., Mori, A., Onodera, H., Imamura, M., 2004. Hepatocyte growth factor as well 
as vascular endothelial growth factor gene induction effectively promotes liver 
regeneration after hepatectomy in Solt-Farber rats. Hepato-gastroenterology 52, 1393-
1397. 
Ohno-Matsui, K., Hirose, A., Yamamoto, S., Saikia, J., Okamoto, N., Gehlbach, P., Duh, E.J., 
Hackett, S., Chang, M., Bok, D., Zack, D.J., Campochiaro, P.A., 2002. Inducible 
Expression of Vascular Endothelial Growth Factor in Adult Mice Causes Severe 
Proliferative Retinopathy and Retinal Detachment. The American Journal of Pathology 
160, 711-719. 
Oka, C., Nakano, T., Wakeham, A., de la Pompa, J.L., Mori, C., Sakai, T., Okazaki, S., 
Kawaichi, M., Shiota, K., Mak, T.W., 1995. Disruption of the mouse RBP-J kappa gene 
results in early embryonic death. Development 121, 3291-3301. 
Omenetti, A., Popov, Y., Jung, Y., Choi, S.S., Witek, R.P., Yang, L., Brown, K.D., Schuppan, 
D., Diehl, A.M., 2008. The hedgehog pathway regulates remodelling responses to biliary 
obstruction in rats. Gut 57, 1275-1282. 
Owen, M.R., Sherratt, J.A., Wearing, H.J., 2000. Lateral Induction by Juxtacrine Signaling Is a 
New Mechanism for Pattern Formation. Developmental Biology 217, 54-61. 
Park, Y.N., Kim, Y.-B., Yang, K.M., Park, C., 2000. Increased Expression of Vascular 
Endothelial Growth Factor and Angiogenesis in the Early Stage of Multistep 
Hepatocarcinogenesis. Archives of Pathology & Laboratory Medicine 124, 1061-1065. 
Parviz, F., Matullo, C., Garrison, W.D., Savatski, L., Adamson, J.W., Ning, G., Kaestner, K.H., 
Rossi, J.M., Zaret, K.S., Duncan, S.A., 2003. Hepatocyte nuclear factor 4alpha controls 
the development of a hepatic epithelium and liver morphogenesis. Nature Genetics 34, 
292-296. 
Petersen, B.E., Bowen, W.C., Patrene, K.D., Mars, W.M., Sullivan, A.K., Murase, N., Boggs, 
S.S., Greenberger, J.S., Goff, J.P., 1999. Bone Marrow as a Potential Source of Hepatic 
Oval Cells. Science 284, 1168-1170. 
Petersen, B.E., Goff, J.P., Greenberger, J.S., Michalopoulos, G.K., 1998. Hepatic oval cells 
express the hematopoietic stem cell marker thy-1 in the rat. Hepatology 27, 433-445. 
Phng, L.K., Gerhardt, H., 2009. Angiogenesis: A Team Effort Coordinated by Notch. 
Developmental Cell 16, 196-208. 
Postic, C., Magnuson, M.A., 2000. DNA excision in liver by an albumin-Cre transgene occurs 
progressively with age. genesis 26, 149-150. 
244 
Prado, I.B., Santos, M.H.H.d., Lopasso, F.P., Iriya, K., Laudanna, A.A., 2003. Cholestasis in a 
murine experimental model: lesions include hepatocyte ischemic necrosis. Revista do 
Hospital das Clínicas 58, 27-32. 
Preisegger, K.H., Factor, V.M., Fuchsbichler, A., et al., 1999. Atypical ductular proliferation its 
inhibition by transforming growth factor beta1 in the 3,5-diethoxycarbonyl-1,4-
dihydrocollidine mouse model for chronic alcoholic liver disease. Lab Invest 79, 103-109. 
Preissegger, K.H., Factor, V.M., Fuchsbichler, A., Stumptner, C., Denk, H., Thorgeirsson, S.S., 
1999. Atypical ductular proliferation and its inhibition by transforming growth factor beta1 
in the 3,5-diethoxycarbonyl-1,4-dihydrocollidine mouse model for chronic alcoholic liver 
disease. Laboratory Investigation 79, 103-109. 
Prevot, P.-P., Simion, A., Grimont, A., Colletti, M., Khalaileh, A., Van den Steen, G., Sempoux, 
C., Xu, X., Roelants, V., Hald, J., Bertrand, L., Heimberg, H., Konieczny, S.F., Dor, Y., 
Lemaigre, F.P., Jacquemin, P., 2012. Role of the ductal transcription factors HNF6 and 
Sox9 in pancreatic acinar-to-ductal metaplasia. Gut. 
Pritchett, J., Harvey, E., Athwal, V., Berry, A., Rowe, C., Oakley, F., Moles, A., Mann, D.A., 
Bobola, N., Sharrocks, A.D., Thomson, B.J., Zaitoun, A.M., Irving, W.L., Guha, I.N., 
Hanley, N.A., Hanley, K.P., 2012. Osteopontin is a novel downstream target of SOX9 
with diagnostic implications for progression of liver fibrosis in humans. Hepatology 56, 
1108-1116. 
Ramalingam, S., Daughtridge, G.W., Johnston, M.J., Gracz, A.D., Magness, S.T., 2012. 
Distinct levels of Sox9 expression mark colon epithelial stem cells that form colonoids in 
culture. American Journal of Physiology - Gastrointestinal and Liver Physiology 302, 
G10-G20. 
Reinert, R.B., Kantz, J., Misfeldt, A.A., Poffenberger, G., Gannon, M., Brissova, M., Powers, 
A.C., 2012. Tamoxifen-Induced Cre-loxP Recombination Is Prolonged in Pancreatic 
Islets of Adult Mice. PLoS ONE 7, e33529. 
Ren, X.S., Sato, Y., Harada, K., Sasaki, M., Yoneda, N., Lin, Z.H., Nakanuma, Y., 2011. Biliary 
infection may exacerbate biliary cystogenesis through the induction of VEGF in 
cholangiocytes of the polycystic kidney (PCK) rat. The American journal of pathology 
179, 2845-2854. 
Roskams, T.A., Libbrecht, L., Desmet, V.J., 2003. Progenitor Cells in Diseased Human Liver. 
Semin Liver Dis 23, 385-396. 
Rosmorduc, O., Wendum, D., Corpechot, C., Galy, B., Sebbagh, N., Raleigh, J., Housset, C., 
Poupon, R., 1999. Hepatocellular hypoxia-induced vascular endothelial growth factor 
expression and angiogenesis in experimental biliary cirrhosis. The American journal of 
pathology 155, 1065-1073. 
Rossi, J.M., Dunn, N.R., Hogan, B.L.M., Zaret, K.S., 2001. Distinct mesodermal signals, 
including BMPs from the septum transversum mesenchyme, are required in combination 
for hepatogenesis from the endoderm. Genes & Development 15, 1998-2009. 
245 
Sackett, S.D., Li, Z., Hurtt, R., Gao, Y., Wells, R.G., Brondell, K., Kaestner, K.H., Greenbaum, 
L.E., 2009. Foxl1 is a marker of bipotential hepatic progenitor cells in mice. Hepatology 
49, 920-929. 
Sekiya, S., Suzuki, A., 2012. Intrahepatic cholangiocarcinoma can arise from Notch-mediated 
conversion of hepatocytes. The Journal of Clinical Investigation 0. 
Seymour, P.A., Freude, K.K., Tran, M.N., Mayes, E.E., Jensen, J., Kist, R., Scherer, G., 
Sander, M., 2007. SOX9 is required for maintenance of the pancreatic progenitor cell 
pool. Proceedings of the National Academy of Sciences 104, 1865-1870. 
Seymour, P.A., Shih, H.P., Patel, N.A., Freude, K.K., Xie, R., Lim, C.J., Sander, M., 2012. A 
Sox9/Fgf feed-forward loop maintains pancreatic organ identity. Development 139, 
3363-3372. 
Shalaby, F., Rossant, J., Yamaguchi, T.P., Gertsenstein, M., Wu, X.-F., Breitman, M.L., Schuh, 
A.C., 1995. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. 
Nature 376, 62-66. 
Shimizu, H., Mitsuhashi, N., Ohtsuka, M., Ito, H., Kimura, F., Ambiru, S., Togawa, A., 
Yoshidome, H., Kato, A., Miyazaki, M., 2005. Vascular endothelial growth factor and 
angiopoietins regulate sinusoidal regeneration and remodeling after partial hepatectomy 
in rats. World Journal of Gastroenterology 11, 7254. 
Shimizu, H., Miyazaki, M., Wakabayashi, Y., Mitsuhashi, N., Kato, A., Ito, H., Nakagawa, K., 
Yoshidome, H., Kataoka, M., Nakajima, N., 2001. Vascular endothelial growth factor 
secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation 
during regeneration after partial hepatectomy in rats. Journal of Hepatology 34, 683-689. 
Shin, S., Walton, G., Aoki, R., Brondell, K., Schug, J., Fox, A., Smirnova, O., Dorrell, C., Erker, 
L., Chu, A.S., Wells, R.G., Grompe, M., Greenbaum, L.E., Kaestner, K.H., 2011. Foxl1-
Cre-marked adult hepatic progenitors have clonogenic and bilineage differentiation 
potential. Genes & Development 25, 1185-1192. 
Shteyer, E., Liao, Y., Muglia, L.J., Hruz, P.W., Rudnick, D.A., 2004. Disruption of hepatic 
adipogenesis is associated with impaired liver regeneration in mice. Hepatology 40, 
1322-1332. 
Si-Tayeb, K., Lemaigre, F.P., Duncan, S.A., 2010. Organogenesis and Development of the 
Liver. Developmental Cell 18, 175-189. 
Siekmann, A.F., Lawson, N.D., 2007. Notch signalling limits angiogenic cell behaviour in 
developing zebrafish arteries. Nature 445, 781-784. 
Sosa-Pineda, B., Wigle, J.T., Oliver, G., 2000. Hepatocyte migration during liver development 
requires Prox1. Nature Genetics 25, 254-255. 
Sparks, E.E., Huppert, K.A., Brown, M.A., Washington, M.K., Huppert, S.S., 2010. Notch 
signaling regulates formation of the three-dimensional architecture of intrahepatic bile 
ducts in mice. Hepatology 51, 1391-1400. 
246 
Sparks, E.E., Perrien, D.S., Huppert, K.A., Peterson, T.E., Huppert, S.S., 2011. Defects in 
hepatic Notch signaling result in disruption of the communicating intrahepatic bile duct 
network in mice. Disease Models & Mechanisms 4, 359-367. 
Spee, B., Carpino, G., Schotanus, B.A., Katoonizadeh, A., Borght, S.V., Gaudio, E., Roskams, 
T., 2010. Characterisation of the liver progenitor cell niche in liver diseases: potential 
involvement of Wnt and Notch signalling. Gut 59, 247-257. 
Srinivas, S., Watanabe, T., Lin, C.-S., William, C., Tanabe, Y., Jessell, T., Costantini, F., 2001. 
Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 
locus. BMC Developmental Biology 1, 4. 
Stanulovi$, V.S., Kyrmizi, I., Kruithof-de Julio, M., Hoogenkamp, M., Vermeulen, J.L.M., Ruijter, 
J.M., Talianidis, I., Hakvoort, T.B.M., Lamers, W.H., 2007. Hepatic HNF4! deficiency 
induces periportal expression of glutamine synthetase and other pericentral enzymes. 
Hepatology 45, 433-444. 
Strazzabosco, M., Fabris, L., 2008. Functional Anatomy of Normal Bile Ducts. The Anatomical 
Record: Advances in Integrative Anatomy and Evolutionary Biology 291, 653-660. 
Strazzabosco, M., Fabris, L., 2013. The balance between Notch/Wnt signaling regulates 
progenitor cells’ commitment during liver repair: Mystery solved? Journal of hepatology 
58, 181-183. 
Streuli, C.H., 2009. Integrins and cell-fate determination. Journal of Cell Science 122, 171-177. 
Suchting, S., Freitas, C., le Noble, F., Benedito, R., Bréant, C., Duarte, A., Eichmann, A., 2007. 
The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and 
vessel branching. Proceedings of the National Academy of Sciences 104, 3225-3230. 
Sun, Y., Chen, X., Xiao, D., 2007. Tetracycline-inducible Expression Systems: New Strategies 
and Practices in the Transgenic Mouse Modeling. Acta Biochimica et Biophysica Sinica 
39, 235-246. 
Swift, M.R., Weinstein, B.M., 2009. Arterial–Venous Specification During Development. 
Circulation Research 104, 576-588. 
Tam, B.Y.Y., Wei, K., Rudge, J.S., Hoffman, J., Holash, J., Park, S.-k., Yuan, J., Hefner, C., 
Chartier, C., Lee, J.-S., Jiang, S., Nayak, N.R., Kuypers, F.A., Ma, L., Sundram, U., Wu, 
G., Garcia, J.A., Schrier, S.L., Maher, J.J., Johnson, R.S., Yancopoulos, G.D., Mulligan, 
R.C., Kuo, C.J., 2006. VEGF modulates erythropoiesis through regulation of adult 
hepatic erythropoietin synthesis. Nature Medicine 12, 793-800. 
Tanaka, A., Tsuneyama, K., Mikami, M., Uegaki, S., Aiso, M., Takikawa, H., 2007. Gene 
expression profiling in whole liver of bile duct ligated rats: VEGF!A expression is 
up!regulated in hepatocytes adjacent to the portal tracts. Journal of gastroenterology 
and hepatology 22, 1993-2000. 
Taniguchi, E., Sakisaka, S., Matsuo, K., Tanikawa, K., Sata, M., 2001. Expression and Role of 
Vascular Endothelial Growth Factor in Liver Regeneration After Partial Hepatectomy in 
Rats. Journal of Histochemistry & Cytochemistry 49, 121-129. 
247 
Tanimizu, N., Miyajima, A., 2004. Notch signaling controls hepatoblast differentiation by 
altering the expression of liver-enriched transcription factors. Journal of Cell Science 
117, 3165-3174. 
Tao, X.-R., Li, W.-L., Su, J., Jin, C.-X., Wang, X.-M., Li, J.-X., Hu, J.-K., Xiang, Z.-H., Lau, 
J.T.Y., Hu, Y.-P., 2009. Clonal mesenchymal stem cells derived from human bone 
marrow can differentiate into hepatocyte-like cells in injured livers of SCID mice. Journal 
of Cellular Biochemistry 108, 693-704. 
Tietz, P.S., LaRusso, N.F., 2006. Cholangiocyte Biology. Current Opinion in Gastroenterology 
22, 279-287. 
Tremblay, K.D., Zaret, K.S., 2005. Distinct populations of endoderm cells converge to generate 
the embryonic liver bud and ventral foregut tissues. Developmental Biology 280, 87-99. 
Trindade, A., Ram Kumar, S., Scehnet, J.S., Lopes-da-Costa, L., Becker, J., Jiang, W., Liu, R., 
Gill, P.S., Duarte, A., 2008. Overexpression of delta-like 4 induces arterialization and 
attenuates vessel formation in developing mouse embryos. Blood 112, 1720-1729. 
Tygstrup, N., Winkler, K., Mellemgaard, K., Andreassen, M., 1962. DETERMINATION OF THE 
HEPATIC ARTERIAL BLOOD FLOW AND OXYGEN SUPPLY IN MAN BY CLAMPING 
THE HEPATIC ARTERY DURING SURGERY. The Journal of Clinical Investigation 41, 
447-454. 
Vanderpool, C., Sparks, E.E., Huppert, K.A., Gannon, M., Means, A.L., Huppert, S.S., 2012. 
Genetic interactions between hepatocyte nuclear factor-6 and notch signaling regulate 
mouse intrahepatic bile duct development in vivo. Hepatology 55, 233-243. 
Wagenaar, G.T.M., Chamuleau, R.A.F.M., de Haan, J.G., Maas, M.A.W., de Boer, P.A.J., 
Marx, F., Moorman, A.F.M., Frederiks, W.M., Lamers, W.H., 1993. Experimental 
evidence that the physiological position of the liver within the circulation is not a major 
determinant of zonation of gene expression. Hepatology 18, 1144-1153. 
Wagenaar, G.T.M., Chamuleau, R.A.F.M., Maas, M.A.W., De Bruin, K., Korfage, H.A.M., 
Lamers, W.H., 1994. The physiological position of the liver in the circulation is not a 
major determinant of its functional capacity. Hepatology 20, 1532-1540. 
Walter, T.J., Sparks, E.E., Huppert, S.S., 2012. 3-Dimensional Resin Casting and Imaging of 
Mouse Portal Vein or Intrahepatic Bile Duct System. J Vis Exp, e4272. 
Wang, L., Sharma, K., Deng, H.-X., Siddique, T., Grisotti, G., Liu, E., Roos, R.P., 2008. 
Restricted expression of mutant SOD1 in spinal motor neurons and interneurons induces 
motor neuron pathology. Neurobiology of Disease 29, 400-408. 
Wang, L., Wang, X., Xie, G., Wang, L., Hill, C.K., DeLeve, L.D., 2012. Liver sinusoidal 
endothelial cell progenitor cells promote liver regeneration in rats. The Journal of Clinical 
Investigation 122, 1567-1573. 
Wang, M., Tan, Y., Costa, R.H., Holterman, A.-X.L., 2004. In vivo regulation of murine CYP7A1 
by HNF-6: A novel mechanism for diminished CYP7A1 expression in biliary obstruction. 
Hepatology 40, 600-608. 
248 
Wang, M., Xue, L., Cao, Q., Lin, Y., Ding, Y., Yang, P., Che, L., 2009. Expression of Notch1, 
Jagged1 and "-catenin and their clinicopathological significance in hepatocellular 
carcinoma. Neoplasma 56, 533-541. 
Wang, X., Foster, M., Al-Dhalimy, M., Lagasse, E., Finegold, M., Grompe, M., 2003. The origin 
and liver repopulating capacity of murine oval cells. Proceedings of the National 
Academy of Sciences of the United States of America 100, 11881-11888. 
Watt, A.J., Zhao, R., Li, J., Duncan, S.A., 2007. Development of the mammalian liver and 
ventral pancreas is dependent on GATA4. BMC Developmental Biology 7. 
Williams, J.M., Oh, S.-H., Jorgensen, M., Steiger, N., Darwiche, H., Shupe, T., Petersen, B.E., 
2010. The Role of the Wnt Family of Secreted Proteins in Rat Oval “Stem” Cell-Based 
Liver Regeneration: Wnt1 Drives Differentiation. The American journal of pathology 176, 
2732-2742. 
Wisse, E., De Zanger, R., Charels, K., Van Der Smissen, P., McCuskey, R., 1985. The liver 
sieve: considerations concerning the structure and function of endothelial fenestrae, the 
sinusoidal wall and the space of Disse. Hepatology 5, 683-692. 
WÖLfle, D., Jungermann, K., 1985. Long-term effects of physiological oxygen concentrations 
on glycolysis and gluconeogenesis in hepatocyte cultures. European Journal of 
Biochemistry 151, 299-303. 
Yamamoto, C., Yagi, S., Hori, T., Iida, T., Taniguchi, K., Isaji, S., Uemoto, S., 2010. 
Significance of Portal Venous VEGF During Liver Regeneration After Hepatectomy. The 
Journal of surgical research 159, e37-e43. 
Yamane, A., Seetharam, L., Yamaguchi, S., Gotoh, N., Takahashi, T., Neufeld, G., Shibuya, 
M., 1994. A new communication system between hepatocytes and sinusoidal endothelial 
cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor 
family (Flt-1 and KDR/Flk-1). Oncogene 9, 2683. 
Yang, L., Jung, Y., Omenetti, A., Witek, R.P., Choi, S., Vandongen, H.M., Huang, J., Alpini, 
G.D., Diehl, A.M., 2008. Fate-Mapping Evidence That Hepatic Stellate Cells Are 
Epithelial Progenitors in Adult Mouse Livers. STEM CELLS 26, 2104-2113. 
Yanger, K., Zong, Y., Maggs, L.R., Shapira, S.N., Maddipati, R., Aiello, N.M., Thung, S.N., 
Wells, R.G., Greenbaum, L.E., Stanger, B.Z., 2013. Robust cellular reprogramming 
occurs spontaneously during liver regeneration. Genes & Development. 
Yao, Z., Mishra, L., 2009. Cancer stem cells and hepatocellular carcinoma. Cancer Biology & 
Therapy 8, 1691-1698. 
Yokomori, H., Oda, M., Yoshimura, K., Nagai, T., Ogi, M., Nomura, M., Ishii, H., 2003. Vascular 
endothelial growth factor increases fenestral permeability in hepatic sinusoidal 
endothelial cells. Liver International 23, 467-475. 
Zeng, G., Awan, F., Otruba, W., Muller, P., Apte, U., Tan, X., Gandhi, C., Demetris, A.J., 
Monga, S.P.S., 2007. Wnt'er in liver: Expression of Wnt and frizzled genes in mouse. 
Hepatology 45, 195-204. 
249 
Zhang, C., Yang, F., Cornelia, R., Tang, W., Swisher, S., Kim, H., 2011. Hypoxia-inducible 
factor-1 is a positive regulator of Sox9 activity in femoral head osteonecrosis. Bone 48, 
507-513. 
Zhang, H., Ables, E.T., Pope, C.F., Washington, M.K., Hipkens, S., Means, A.L., Path, G., 
Seufert, J., Costa, R.H., Leiter, A.B., Magnuson, M.A., Gannon, M., 2009. Multiple, 
temporal-specific roles for HNF6 in pancreatic endocrine and ductal differentiation. 
Mechanisms of Development 126, 958-973. 
Zhao, R., Watt, A.J., Li, J., Luebke-Wheeler, J., Morrisey, E.E., Duncan, S.A., 2005. GATA6 Is 
Essential for Embryonic Development of the Liver but Dispensable for Early Heart 
Formation. Molecular and Cellular Biology 25, 2622-2631. 
Zhou, L., Zhang, N., Song, W., You, N., Li, Q., Sun, W., Zhang, Y., Wang, D., Dou, K., 2013. 
The Significance of Notch1 Compared with Notch3 in High Metastasis and Poor Overall 
Survival in Hepatocellular Carcinoma. PLoS ONE 8, e57382. 
Zong, Y., Panikkar, A., Xu, J., Antoniou, A., Raynaud, P., Lemaigre, F., Stanger, B.Z., 2009. 
Notch signaling controls liver development by regulating biliary differentiation. 
Development 136, 1727-1739. 
 
 
